Implant-based O
reconstruction O
is O
performed O
in O
the O
majority O
of O
women O
offered O
primary O
reconstruction O
for O
breast O
cancer O
. O

Two O
different O
expander O
implants O
were O
compared O
prospectively O
. O

The O
primary O
endpoint O
was O
the O
number O
of O
operations O
needed O
in O
each O
group O
to O
obtain O
patient O
satisfaction O
. O

Secondary O
endpoints O
were O
evaluation O
of O
breast O
volume O
and O
shape O
and O
aspects O
of O
quality O
of O
life O
. O

Seventy O
consecutive O
breast O
cancer O
patients O
were O
randomized O
to O
either O
a O
one-stage O
reconstruction O
with O
a O
round O
permanent O
expander O
implant O
( O
Becker O
25 O
; O
n=35 O
) O
or O
a O
two-stage O
reconstruction O
with O
a O
crescent-shaped O
expander O
( O
LV O
133 O
; O
n=35 O
) O
, O
later O
replaced O
by O
a O
form-stable O
anatomical O
implant O
. O

Thirty O
patients O
had O
to O
be O
excluded O
and O
40 O
patients O
, O
20 O
in O
each O
group O
, O
were O
evaluated O
. O

The O
median O
follow-up O
for O
both O
groups O
was O
3.5 O
years O
( O
range O
, O
1.5 O
to O
5 O
years O
) O
. O

Plastic O
cups O
, O
plastic O
casts O
, O
and O
two O
-and O
three-dimensional O
scanning O
techniques O
were O
used O
for O
objective O
assessment O
of O
breast O
volume O
and O
shape O
. O

The O
aesthetic O
outcome O
was O
evaluated O
by O
a O
panel O
of O
experts O
and O
lay O
people O
, O
and O
by O
the O
patients O
. O

Quality O
of O
life O
was O
evaluated O
with O
a O
validated O
questionnaire O
( O
36-Item O
Short O
Form O
Health O
Survey O
) O
. O

Of B-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
one-stage I-Premise
group I-Premise
, I-Premise
70 I-Premise
percent I-Premise
had I-Premise
revision I-Premise
surgery I-Premise
, I-Premise
mostly I-Premise
because I-Premise
of I-Premise
upper I-Premise
pole I-Premise
fullness I-Premise
and I-Premise
poor I-Premise
ptosis I-Premise
. I-Premise

These O
findings O
agreed O
with O
the O
data O
from O
the O
two-dimensional O
scanning O
and O
from O
the O
expert O
panel O
and O
the O
patients O
' O
subjective O
judgment O
. O

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

The B-Claim
permanent I-Claim
expander I-Claim
method I-Claim
failed I-Claim
significantly I-Claim
as I-Claim
a I-Claim
one-stage I-Claim
procedure I-Claim
. I-Claim

The B-Claim
crescent I-Claim
two-stage I-Claim
method I-Claim
gave I-Claim
the I-Claim
most I-Claim
acceptable I-Claim
results I-Claim
both I-Claim
objectively I-Claim
and I-Claim
subjectively I-Claim
. I-Claim

To O
analyze O
the O
clinical O
course O
, O
treatment O
, O
complications O
, O
outcome O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
perineal/perianal O
rhabdomyosarcoma O
( O
PRMS O
) O
treated O
within O
the O
CWS-86 O
, O
-91 O
, O
-96 O
, O
and O
-2002P O
trials O
. O

Although O
multiple O
international O
study O
trials O
exist O
for O
the O
treatment O
of O
rhabdomyosarcoma O
, O
only O
very O
limited O
information O
is O
given O
on O
treatment O
, O
outcome O
, O
and O
QOL O
in O
PRMS O
. O

A O
total O
of O
35 O
patients O
suffering O
from O
PRMS O
were O
treated O
with O
neoadjuvant O
chemotherapy O
. O

Local O
therapy O
with O
radiation O
and/or O
surgery O
was O
performed O
, O
followed O
by O
adjuvant O
chemotherapy O
. O

Functional O
long-term O
follow-up O
was O
evaluated O
by O
a O
gastrointestinal/QOL O
survey O
. O

Thirty-two O
patients O
were O
evaluated O
( O
exclusion O
n O
= O
3 O
) O
. O

Eight O
patients O
had O
embryonal O
histology O
, O
and O
24 O
patients O
had O
alveolar O
histology O
. O

The O
median O
age O
was O
108 O
months O
( O
median O
follow-up O
: O
5.8 O
years O
) O
. O

The O
5-year O
overall O
survival O
was O
47 O
% O
( O
95 O
% O
confidence O
interval O
: O
29-64 O
) O
. O

Sixteen O
IRS O
( O
Intergroup O
Rhabdomyosarcoma O
Study O
) O
III O
and O
IV O
patients O
had O
locoregional O
lymph O
node O
involvement O
at O
diagnosis O
. O

Seven O
patients O
were O
treated O
with O
chemotherapy/surgery O
alone O
[ O
5-year O
event-free O
survival O
( O
EFS O
) O
: O
85.7 O
% O
] O
. O

Eleven O
patients O
received O
only O
radiochemotherapy O
( O
5-year O
EFS O
: O
27.3 O
% O
) O
. O

Combined O
radiochemotherapy/surgery O
was O
used O
in O
12 O
patients O
( O
5-year O
EFS O
: O
63.6 O
% O
) O
. O

Two O
patients O
were O
treated O
only O
with O
chemotherapy O
and O
they O
died O
. O

Patients B-Premise
with I-Premise
embryonal I-Premise
histology I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
5-year I-Premise
EFS I-Premise
( I-Premise
87.5 I-Premise
% I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
alveolar I-Premise
histology I-Premise
( I-Premise
39.1 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

Some B-Premise
patients I-Premise
reported I-Premise
symptoms I-Premise
of I-Premise
fecal I-Premise
incontinence I-Premise
. I-Premise

The B-Premise
median I-Premise
Wexner I-Premise
fecal I-Premise
incontinence I-Premise
score I-Premise
was I-Premise
9 I-Premise
( I-Premise
possible I-Premise
range I-Premise
: I-Premise
0-20 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
median I-Premise
QOL I-Premise
score I-Premise
was I-Premise
90.5 I-Premise
( I-Premise
applicable I-Premise
range I-Premise
: I-Premise
0-144 I-Premise
) I-Premise
. I-Premise

The B-Claim
outcome I-Claim
of I-Claim
these I-Claim
patients I-Claim
remains I-Claim
unsatisfactory I-Claim
. I-Claim

Prognostic B-Premise
factors I-Premise
for I-Premise
a I-Premise
favorable I-Premise
outcome I-Premise
are I-Premise
tumor I-Premise
size I-Premise
of I-Premise
smaller I-Premise
than I-Premise
5 I-Premise
cm I-Premise
, I-Premise
negative I-Premise
locoregional I-Premise
lymph I-Premise
nodes I-Premise
, I-Premise
age I-Premise
less I-Premise
than I-Premise
10 I-Premise
years I-Premise
, I-Premise
low I-Premise
IRS I-Premise
group I-Premise
, I-Premise
and I-Premise
embryonal I-Premise
histology I-Premise
. I-Premise

Fecal B-Claim
incontinence I-Claim
seems I-Claim
to I-Claim
be I-Claim
a I-Claim
problem I-Claim
. I-Claim

Phase B-Claim
II I-Claim
and I-Claim
III I-Claim
studies I-Claim
have I-Claim
shown I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
interleukin-2 I-Claim
( I-Claim
IL-2 I-Claim
) I-Claim
and I-Claim
interferon I-Claim
alpha-2b I-Claim
( I-Claim
IFN I-Claim
alpha-2b I-Claim
) I-Claim
in I-Claim
multiagent I-Claim
chemotherapy I-Claim
( I-Claim
CT I-Claim
) I-Claim
for I-Claim
advanced I-Claim
melanoma I-Claim
increases I-Claim
overall I-Claim
response I-Claim
( I-Claim
OR I-Claim
) I-Claim
, I-Claim
albeit I-Claim
without I-Claim
clear I-Claim
evidence I-Claim
of I-Claim
an I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
survival I-Claim
( I-Claim
OS I-Claim
) I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
high-dose I-Claim
IL-2 I-Claim
can I-Claim
cause I-Claim
severe I-Claim
toxicity I-Claim
and I-Claim
is I-Claim
normally I-Claim
administered I-Claim
in I-Claim
an I-Claim
inpatient I-Claim
setting I-Claim
. I-Claim

We O
conducted O
a O
multicenter O
prospective O
randomized O
clinical O
trial O
in O
outpatients O
with O
metastatic O
melanoma O
to O
compare O
CT O
with O
biochemotherapy O
( O
bioCT O
) O
using O
immunomodulant O
doses O
of O
IL-2 O
and O
IFN O
alpha-2b O
. O

One O
hundred O
seventy-six O
eligible O
patients O
with O
advanced O
melanoma O
were O
randomized O
to O
receive O
CT O
( O
cisplatin O
and O
dacarbazine O
with O
or O
without O
carmustine O
every O
21 O
days O
) O
or O
bioCT O
comprising O
the O
same O
CT O
regimen O
followed O
by O
low-dose O
subcutaneous O
IL-2 O
for O
8 O
days O
and O
IFN O
alpha-2b O
three O
times O
a O
week O
, O
both O
for O
six O
cycles O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
18 I-Premise
( I-Premise
CT I-Premise
) I-Premise
and I-Premise
16 I-Premise
( I-Premise
bioCT I-Premise
) I-Premise
months I-Premise
, I-Premise
median I-Premise
OS I-Premise
was I-Premise
9.5 I-Premise
versus I-Premise
11.0 I-Premise
months I-Premise
( I-Premise
P I-Premise
=.51 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
89 I-Premise
CT-arm I-Premise
patients I-Premise
, I-Premise
18 I-Premise
ORs I-Premise
( I-Premise
20.2 I-Premise
% I-Premise
) I-Premise
( I-Premise
three I-Premise
complete I-Premise
responders I-Premise
[ I-Premise
CRs I-Premise
] I-Premise
and I-Premise
15 I-Premise
partial I-Premise
responders I-Premise
[ I-Premise
PRs I-Premise
] I-Premise
) I-Premise
were I-Premise
observed I-Premise
according I-Premise
to I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
criteria I-Premise
. I-Premise

In B-Premise
the I-Premise
87 I-Premise
bioCT-arm I-Premise
patients I-Premise
, I-Premise
22 I-Premise
ORs I-Premise
( I-Premise
25.3 I-Premise
% I-Premise
) I-Premise
( I-Premise
three I-Premise
CRs I-Premise
and I-Premise
19 I-Premise
PRs I-Premise
) I-Premise
( I-Premise
P I-Premise
=.70 I-Premise
) I-Premise
were I-Premise
recorded I-Premise
. I-Premise

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
fairly I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
low-dose I-Claim
immunotherapy I-Claim
did I-Claim
not I-Claim
produce I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
advantage I-Claim
in I-Claim
OS I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
or I-Claim
OR I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
11-month I-Claim
median I-Claim
OS I-Claim
in I-Claim
the I-Claim
bioCT I-Claim
arm I-Claim
does I-Claim
not I-Claim
differ I-Claim
greatly I-Claim
from I-Claim
the I-Claim
best I-Claim
results I-Claim
with I-Claim
high-dose I-Claim
IL-2-containing I-Claim
regimens I-Claim
reported I-Claim
in I-Claim
the I-Claim
literature I-Claim
. I-Claim

Furthermore O
, O
our B-Claim
treatment I-Claim
schedule I-Claim
was I-Claim
carried I-Claim
out I-Claim
on I-Claim
outpatients I-Claim
and I-Claim
had I-Claim
an I-Claim
acceptable I-Claim
level I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

SIR-Spheres O
are O
radioactive O
yttrium90 O
microspheres O
( O
SIR-Spheres O
, O
Sirtex O
Medical O
Limited O
, O
Australia O
) O
used O
to O
selectively O
target O
high O
levels O
of O
ionising O
radiation O
to O
tumors O
within O
the O
liver O
. O

This O
trial O
was O
designed O
to O
measure O
any O
increased O
patient O
benefit O
by O
adding O
a O
single O
administration O
of O
SIR-Spheres O
to O
a O
regimen O
of O
regional O
hepatic O
artery O
chemotherapy O
( O
HAC O
) O
administered O
as O
a O
12 O
day O
infusion O
of O
floxuridine O
and O
repeated O
at O
monthly O
intervals O
, O
vs. O
the O
same O
chemotherapy O
alone O
. O

A O
phase O
III O
randomised O
clinical O
trial O
entering O
74 O
patients O
was O
undertaken O
on O
patients O
with O
bi-lobar O
non-resectable O
liver O
metastases O
from O
primary O
adenocarcinoma O
of O
the O
large O
bowel O
. O

Patient O
benefit O
criteria O
assessed O
in O
the O
trial O
were O
tumor O
response O
, O
time O
to O
disease O
progression O
in O
the O
liver O
, O
overall O
survival O
, O
quality O
of O
life O
, O
and O
treatment O
related O
toxicity O
. O

Tumor O
response O
was O
measured O
by O
serial O
changes O
in O
both O
cross-sectional O
tumor O
areas O
and O
total O
tumor O
volumes O
, O
provided O
any O
response O
lasted O
not O
less O
than O
three O
months O
as O
well O
as O
changes O
in O
serum O
carcino-embryonic O
antigen O
( O
CEA O
) O
. O

The B-Premise
partial I-Premise
and I-Premise
complete I-Premise
response I-Premise
rate I-Premise
( I-Premise
PR I-Premise
+ I-Premise
CR I-Premise
) I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
SIR-Spheres I-Premise
when I-Premise
measured I-Premise
by I-Premise
tumor I-Premise
areas I-Premise
( I-Premise
44 I-Premise
% I-Premise
) I-Premise
vs. I-Premise
17.6 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
tumor I-Premise
volumes I-Premise
( I-Premise
50 I-Premise
% I-Premise
vs. I-Premise
24 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
and I-Premise
CEA I-Premise
( I-Premise
72 I-Premise
% I-Premise
vs. I-Premise
47 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
in I-Premise
the I-Premise
liver I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
SIR-Spheres I-Premise
in I-Premise
comparison I-Premise
to I-Premise
patients I-Premise
receiving I-Premise
HAC I-Premise
alone I-Premise
when I-Premise
measured I-Premise
by I-Premise
either I-Premise
tumor I-Premise
areas I-Premise
( I-Premise
9.7 I-Premise
vs. I-Premise
15.9 I-Premise
months I-Premise
, I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
tumor I-Premise
volumes I-Premise
( I-Premise
7.6 I-Premise
vs. I-Premise
12.0 I-Premise
months I-Premise
, I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
or I-Premise
CEA I-Premise
( I-Premise
5.7 I-Premise
vs. I-Premise
6.7 I-Premise
months I-Premise
, I-Premise
P I-Premise
= I-Premise
0.06 I-Premise
) I-Premise
. I-Premise

The B-Premise
one I-Premise
, I-Premise
two I-Premise
, I-Premise
three I-Premise
and I-Premise
five-year I-Premise
survival I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
SIR-Spheres I-Premise
was I-Premise
72 I-Premise
% I-Premise
, I-Premise
39 I-Premise
% I-Premise
, I-Premise
17 I-Premise
% I-Premise
and I-Premise
3.5 I-Premise
% I-Premise
, I-Premise
compared I-Premise
to I-Premise
68 I-Premise
% I-Premise
, I-Premise
29 I-Premise
% I-Premise
, I-Premise
6.5 I-Premise
% I-Premise
and I-Premise
0 I-Premise
% I-Premise
for I-Premise
HAC I-Premise
alone I-Premise
. I-Premise

Cox B-Premise
regression I-Premise
analysis I-Premise
suggests I-Premise
an I-Premise
improvement I-Premise
in I-Premise
survival I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
SIR-Spheres I-Premise
who I-Premise
survive I-Premise
more I-Premise
than I-Premise
15 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.06 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
increase I-Premise
in I-Premise
grade I-Premise
3-4 I-Premise
treatment I-Premise
related I-Premise
toxicity I-Premise
and I-Premise
no I-Premise
loss I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
SIR-Spheres I-Premise
in I-Premise
comparison I-Premise
to I-Premise
patients I-Premise
receiving I-Premise
HAC I-Premise
alone I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
a I-Claim
single I-Claim
injection I-Claim
of I-Claim
SIR-Spheres I-Claim
plus I-Claim
HAC I-Claim
is I-Claim
substantially I-Claim
more I-Claim
effective I-Claim
in I-Claim
increasing I-Claim
tumor I-Claim
responses I-Claim
and I-Claim
progression I-Claim
free I-Claim
survival I-Claim
than I-Claim
the I-Claim
same I-Claim
regimen I-Claim
of I-Claim
HAC I-Claim
alone I-Claim
. I-Claim

The O
purpose O
of O
the O
study O
was O
to O
assess O
response O
rate O
, O
clinical O
outcome O
, O
organ/function O
preservation O
and O
toxicity O
in O
head O
and O
neck O
cancer O
patients O
treated O
with O
induction O
chemotherapy O
followed O
by O
concomitant O
chemoradiotherapy O
and O
, O
when O
necessary O
, O
limited O
surgery O
. O

The O
study O
design O
was O
a O
phase O
II O
non-randomized O
trial O
in O
hospitalized O
patients O
setting O
. O

The O
treatment O
plan O
consisted O
of O
3 O
cycles O
of O
induction O
chemotherapy O
with O
cisplatin O
, O
fluorouracil O
( O
5-FU O
) O
, O
l-leucovorin O
and O
interferon O
alpha2b O
( O
PFL-IFN O
) O
followed O
by O
7 O
cycles O
of O
5-FU O
, O
hydroxyurea O
and O
concomitant O
radiation O
for O
5 O
days O
( O
FHX O
) O
for O
a O
total O
radiation O
dose O
of O
70 O
Gy O
. O

13 O
Cis-retinoic O
acid O
was O
added O
to O
treatment O
regimen O
for O
chemoprevention O
and O
a O
systematic O
prophylaxis O
of O
mucositis O
was O
administered O
to O
all O
patients O
during O
FHX O
. O

Conservative O
surgical O
resection O
was O
reserved O
to O
patients O
with O
no O
optimal O
response O
( O
PR O
> O
or O
70 O
% O
) O
, O
whereas O
radical O
surgery O
was O
performed O
as O
salvage O
treatment O
. O

Twenty-six O
patients O
were O
treated O
at O
one O
institution O
: O
more O
than O
90 O
% O
had O
stage O
IV O
disease O
and O
only O
19.2 O
% O
had O
laryngeal O
cancer O
. O

Eighty-one O
percent O
of O
patients O
had O
performance O
status O
0 O
and O
23.1 O
% O
of O
patients O
had O
> O
5 O
% O
weight O
loss O
at O
the O
start O
of O
treatment O
. O

Nineteen O
patients O
were O
analyzed O
for O
response O
to O
PFL-IFN O
: O
3/19 O
( O
15.8 O
% O
) O
patients O
achieved O
a O
CR O
and O
7/19 O
( O
36.8 O
% O
) O
achieved O
a O
PR O
for O
an O
ORR O
of O
52.6 O
% O
. O

FHX O
was O
administered O
on O
protocol O
to O
12 O
patients O
: O
6 O
patients O
( O
50 O
% O
) O
had O
CR O
, O
1 O
patient O
( O
8.3 O
% O
) O
had O
PR O
for O
an O
ORR O
of O
58.3 O
% O
, O
2 O
patients O
( O
16.7 O
% O
) O
had O
SD O
and O
3 O
patients O
( O
25 O
% O
) O
had O
PD O
. O

At O
the O
completion O
of O
FHX O
, O
no O
patient O
underwent O
local O
therapy O
according O
to O
treatment O
plan O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
13.5 I-Premise
months I-Premise
( I-Premise
range I-Premise
1-28+ I-Premise
) I-Premise
at I-Premise
June I-Premise
2001 I-Premise
, I-Premise
among I-Premise
26 I-Premise
patients I-Premise
enrolled I-Premise
12 I-Premise
( I-Premise
46.1 I-Premise
% I-Premise
) I-Premise
were I-Premise
still I-Premise
alive I-Premise
and I-Premise
9 I-Premise
( I-Premise
75 I-Premise
% I-Premise
) I-Premise
of I-Premise
them I-Premise
were I-Premise
progression-free I-Premise
. I-Premise

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
9 I-Premise
months I-Premise
( I-Premise
range I-Premise
0-25+ I-Premise
) I-Premise
, I-Premise
the I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
10.5 I-Premise
months I-Premise
( I-Premise
range I-Premise
0-28+ I-Premise
) I-Premise
, I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
was I-Premise
9 I-Premise
months I-Premise
( I-Premise
range I-Premise
1-22 I-Premise
) I-Premise
. I-Premise

The B-Premise
toxicity I-Premise
was I-Premise
significant I-Premise
and I-Premise
consisted I-Premise
mainly I-Premise
of I-Premise
mucositis I-Premise
and I-Premise
, I-Premise
to I-Premise
a I-Premise
lesser I-Premise
extent I-Premise
, I-Premise
neutropenia/thrombocytopenia I-Premise
. I-Premise

In O
the O
present O
study O
, O
the B-Claim
low I-Claim
serum I-Claim
levels I-Claim
of I-Claim
leptin I-Claim
and I-Claim
the I-Claim
high I-Claim
serum I-Claim
levels I-Claim
of I-Claim
proinflammatory I-Claim
cytokines I-Claim
in I-Claim
advanced I-Claim
stage I-Claim
cancer I-Claim
patients I-Claim
were I-Claim
confirmed I-Claim
. I-Claim

In O
conclusion O
, O
this B-Claim
sequential I-Claim
induction I-Claim
chemotherapy I-Claim
and I-Claim
chemoradiotherapy I-Claim
program I-Claim
has I-Claim
been I-Claim
found I-Claim
moderately I-Claim
active I-Claim
and I-Claim
significantly I-Claim
toxic I-Claim
; I-Claim
moreover O
, O
the O
long O
overall O
treatment O
duration O
must O
be O
taken O
into O
consideration O
. O

For O
these O
reasons O
, O
this B-Claim
regimen I-Claim
could I-Claim
not I-Claim
be I-Claim
recommended I-Claim
for I-Claim
a I-Claim
phase I-Claim
III I-Claim
randomized I-Claim
study I-Claim
. I-Claim

Intermittent O
dosing O
may O
reduce O
the O
adverse O
events O
( O
AEs O
) O
of O
androgen-deprivation O
therapy O
( O
ADT O
) O
. O

To O
compare O
intermittent O
androgen O
deprivation O
( O
IAD O
) O
and O
continuous O
androgen O
deprivation O
( O
CAD O
) O
with O
regard O
to O
health-related O
quality O
of O
life O
( O
QoL O
) O
. O

A O
total O
of O
852 O
men O
with O
advanced O
prostate O
cancer O
( O
PCa O
) O
were O
enrolled O
to O
receive O
goserelin O
acetate O
3.6 O
mg O
every O
28 O
d O
for O
24 O
wk O
. O

A O
total O
of O
554 O
patients O
whose O
prostate-specific O
antigen O
( O
PSA O
) O
decreased O
to O
< O
10 O
ng/ml O
or O
by O
≥50 O
% O
( O
< O
20 O
ng/ml O
at O
baseline O
) O
were O
randomised O
to O
IAD O
or O
CAD O
. O

In O
the O
IAD O
arm O
, O
ADT O
was O
resumed O
for O
at O
least O
24 O
wk O
whenever O
PSA O
increased O
> O
20 O
ng/ml O
or O
above O
baseline O
. O

QoL O
was O
monitored O
with O
a O
validated O
Cleary O
30-item O
questionnaire O
and O
analysed O
by O
the O
Mann-Whitney O
U O
test O
, O
0.5 O
standard O
deviation O
rule O
, O
and O
repeated O
measures O
analysis O
of O
variance O
. O

AEs O
and O
adverse O
drug O
reactions O
( O
ADRs O
) O
were O
analysed O
by O
the O
chi-square O
test O
. O

Median O
follow-up O
was O
65 O
mo O
. O

Significant B-Premise
differences I-Premise
in I-Premise
QoL I-Premise
emerged I-Premise
in I-Premise
activity I-Premise
limitation I-Premise
, I-Premise
physical I-Premise
capacity I-Premise
, I-Premise
and I-Premise
sexual I-Premise
functioning I-Premise
, I-Premise
favouring I-Premise
IAD I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
emerged I-Premise
in I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
AEs I-Premise
: I-Premise
87 I-Premise
patients I-Premise
in I-Premise
the I-Premise
IAD I-Premise
arm I-Premise
( I-Premise
31.8 I-Premise
% I-Premise
) I-Premise
and I-Premise
95 I-Premise
in I-Premise
the I-Premise
CAD I-Premise
arm I-Premise
( I-Premise
33.9 I-Premise
% I-Premise
) I-Premise
had I-Premise
cardiovascular I-Premise
( I-Premise
CV I-Premise
) I-Premise
AEs I-Premise
( I-Premise
p=0.59 I-Premise
) I-Premise
, I-Premise
with I-Premise
25 I-Premise
( I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
and I-Premise
29 I-Premise
( I-Premise
10.4 I-Premise
% I-Premise
) I-Premise
withdrawn I-Premise
( I-Premise
p=0.62 I-Premise
) I-Premise
, I-Premise
and I-Premise
21 I-Premise
( I-Premise
7.7 I-Premise
% I-Premise
) I-Premise
and I-Premise
24 I-Premise
( I-Premise
8.6 I-Premise
% I-Premise
) I-Premise
dying I-Premise
because I-Premise
of I-Premise
a I-Premise
CV I-Premise
event I-Premise
( I-Premise
p=0.70 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
; I-Premise
bone B-Premise
fractures I-Premise
occurred I-Premise
in I-Premise
19 I-Premise
( I-Premise
6.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
15 I-Premise
( I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
patients I-Premise
( I-Premise
p=0.44 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Hot B-Premise
flushes I-Premise
or I-Premise
night I-Premise
sweats I-Premise
were I-Premise
the I-Premise
most I-Premise
common I-Premise
ADRs I-Premise
( I-Premise
47.1 I-Premise
% I-Premise
vs I-Premise
50.4 I-Premise
% I-Premise
; I-Premise
p=0.44 I-Premise
) I-Premise
. I-Premise

Erectile B-Premise
dysfunction I-Premise
( I-Premise
15.7 I-Premise
% I-Premise
vs I-Premise
7.9 I-Premise
% I-Premise
; I-Premise
p=0.042 I-Premise
) I-Premise
and I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
2.2 I-Premise
vs I-Premise
0 I-Premise
% I-Premise
; I-Premise
p=0.032 I-Premise
) I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
IAD I-Premise
arm I-Premise
. I-Premise

IAD B-Claim
showed I-Claim
benefits I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
PCa I-Claim
with I-Claim
respect I-Claim
to I-Claim
QoL I-Claim
. I-Claim

The B-Claim
prevalence I-Claim
of I-Claim
AEs I-Claim
was I-Claim
not I-Claim
significantly I-Claim
lower I-Claim
with I-Claim
IAD I-Claim
. I-Claim

Quality O
of O
life O
( O
QoL O
) O
after O
breast O
cancer O
is O
nowadays O
a O
major O
challenge O
. O

Complementary O
interventions O
are O
necessary O
because O
of O
frequent O
depression O
symptoms O
after O
treatment O
and O
also O
to O
favour O
return O
to O
activity O
. O

Besides O
, O
radio-chemotherapy O
has O
side-effects O
like O
weight O
gain O
and O
fatigue O
. O

Several O
strategies O
including O
group O
behavioural-educational O
interventions O
, O
physical O
training O
and/or O
dietary O
education O
, O
have O
been O
tested O
to O
answer O
these O
difficulties O
with O
moderate O
success O
in O
the O
long O
run O
. O

Two O
hundred O
and O
fifty-one O
non-metastatic O
patients O
were O
accrued O
after O
chemotherapy O
in O
a O
prospective O
randomised O
multicenter O
trial O
between O
2008 O
and O
2010 O
, O
testing O
a O
2-week O
intervention O
in O
SPA O
centres O
. O

Intervention O
comprised O
group O
physical O
training O
, O
dietary O
education O
and O
physiotherapy O
. O

Selected O
patients O
were O
in O
complete O
remission O
. O

QoL O
was O
evaluated O
with O
SF36 O
questionnaire O
, O
anxiety O
and O
depression O
with O
the O
hospital O
anxiety O
and O
depression O
( O
HAD O
) O
one O
. O

Anthropometric O
measures O
and O
QoL O
evaluations O
were O
obtained O
before O
randomisation O
and O
every O
6 O
months O
during O
3 O
years O
. O

Two O
hundred O
and O
twenty O
patients O
were O
evaluable O
at O
1 O
year O
. O

Intervention B-Premise
increased I-Premise
SF36 I-Premise
score I-Premise
by I-Premise
9.5 I-Premise
points I-Premise
( I-Premise
p=0.000006 I-Premise
) I-Premise
, I-Premise
4.6 I-Premise
( I-Premise
p=0.032 I-Premise
) I-Premise
and I-Premise
6.2 I-Premise
( I-Premise
p=0.028 I-Premise
) I-Premise
respectively I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
. I-Premise

Effect B-Premise
size I-Premise
( I-Premise
ES I-Premise
) I-Premise
was I-Premise
0.63 I-Premise
[ I-Premise
0.37 I-Premise
; I-Premise
0.90 I-Premise
] I-Premise
, I-Premise
0.29 I-Premise
[ I-Premise
0.03 I-Premise
; I-Premise
0.55 I-Premise
] I-Premise
and I-Premise
0.41 I-Premise
[ I-Premise
0.04 I-Premise
; I-Premise
0.78 I-Premise
] I-Premise
. I-Premise

Anxiety B-Premise
score I-Premise
was I-Premise
shortly I-Premise
minored I-Premise
by I-Premise
intervention I-Premise
( I-Premise
6-month I-Premise
ES=-0.24 I-Premise
[ I-Premise
-0.42 I-Premise
; I-Premise
-0.05 I-Premise
] I-Premise
) I-Premise
and I-Premise
depression I-Premise
score I-Premise
more I-Premise
durably I-Premise
: I-Premise
ES=-0.45 I-Premise
[ I-Premise
-0.72 I-Premise
; I-Premise
-0.18 I-Premise
] I-Premise
, I-Premise
-0.34 I-Premise
[ I-Premise
-61 I-Premise
; I-Premise
-0.08 I-Premise
] I-Premise
, I-Premise
and I-Premise
-0.26 I-Premise
[ I-Premise
-0.63 I-Premise
; I-Premise
0.11 I-Premise
] I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
. I-Premise

This B-Claim
2-week I-Claim
group I-Claim
intervention I-Claim
seemed I-Claim
to I-Claim
durably I-Claim
influence I-Claim
QoL I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
by I-Claim
chemotherapy I-Claim
. I-Claim

Differences B-Claim
, I-Claim
smaller I-Claim
at I-Claim
12 I-Claim
months I-Claim
than I-Claim
at I-Claim
six I-Claim
, I-Claim
suggest I-Claim
that I-Claim
a I-Claim
second I-Claim
but I-Claim
shorter I-Claim
intervention I-Claim
could I-Claim
help I-Claim
maintain I-Claim
the I-Claim
6-month I-Claim
benefits I-Claim
. I-Claim

To O
assess O
toxicities O
, O
functional O
outcomes O
, O
and O
health-related O
quality O
of O
life O
associated O
with O
concurrent O
chemoradiation O
therapy O
( O
CRT O
) O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

Prospective O
and O
retrospective O
outcomes O
study O
. O

Tertiary O
care O
institution O
. O

Participants O
in O
the O
longitudinal O
Outcomes O
Assessment O
Project O
whose O
head O
and O
neck O
cancer O
was O
treated O
with O
CRT O
between O
February O
1 O
, O
2000 O
, O
and O
March O
1 O
, O
2007 O
( O
n O
= O
104 O
) O
. O

Patients O
prospectively O
provided O
functional O
and O
health-related O
quality O
of O
life O
information O
, O
including O
data O
from O
the O
1-year O
and O
most O
current O
follow-up O
visits O
. O

Medical O
records O
were O
reviewed O
to O
determine O
toxicity O
and O
survival O
rates O
. O

Well-defined O
acute O
and O
late O
toxicities O
; O
functional O
outcomes O
( O
diet O
, O
dentition O
, O
tracheostomies O
) O
; O
head O
and O
neck O
cancer-specific O
, O
general O
health O
, O
and O
depression O
outcomes O
; O
and O
survival O
rates O
. O

Most O
patients O
had O
oropharyngeal O
or O
laryngeal O
tumors O
( O
87.5 O
% O
) O
and O
advanced-stage O
disease O
( O
75.0 O
% O
) O
. O

Approximately B-Premise
one-half I-Premise
had I-Premise
hematologic I-Premise
toxicities I-Premise
and I-Premise
toxicity-related I-Premise
treatment I-Premise
delays I-Premise
. I-Premise

Approximately B-Premise
one-quarter I-Premise
had I-Premise
neurotoxicities I-Premise
and/or I-Premise
ototoxicites I-Premise
, I-Premise
moist I-Premise
desquamation I-Premise
, I-Premise
pneumonia I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
requiring I-Premise
hospitalization I-Premise
or I-Premise
intravenous I-Premise
fluids I-Premise
, I-Premise
dehydration I-Premise
or I-Premise
malnutrition I-Premise
requiring I-Premise
hospitalization I-Premise
, I-Premise
and I-Premise
mild I-Premise
or I-Premise
moderate I-Premise
fever I-Premise
. I-Premise

Although B-Premise
patients I-Premise
receiving I-Premise
the I-Premise
current I-Premise
intensity-modulated I-Premise
radiation I-Premise
therapy I-Premise
( I-Premise
IMRT I-Premise
) I-Premise
protocol I-Premise
using I-Premise
the I-Premise
Pinnacle I-Premise
( I-Premise
3 I-Premise
) I-Premise
planning I-Premise
system I-Premise
had I-Premise
more I-Premise
toxicity-related I-Premise
treatment I-Premise
delays I-Premise
, I-Premise
they B-Premise
had I-Premise
fewer I-Premise
toxicities I-Premise
and I-Premise
better I-Premise
functional I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
outcomes I-Premise
compared I-Premise
with I-Premise
those I-Premise
receiving I-Premise
conventional I-Premise
lateral I-Premise
opposing-field I-Premise
radiation I-Premise
or I-Premise
the I-Premise
initial I-Premise
IMRT I-Premise
protocol I-Premise
using I-Premise
the I-Premise
Best I-Premise
nomos I-Premise
PEACOCK I-Premise
planning I-Premise
system I-Premise
. I-Premise

Patients B-Claim
receiving I-Claim
CRT I-Claim
experience I-Claim
a I-Claim
substantial I-Claim
number I-Claim
of I-Claim
treatment-related I-Claim
adverse I-Claim
events I-Claim
, I-Claim
primarily I-Claim
affecting I-Claim
oropharyngeal I-Claim
and I-Claim
laryngeal I-Claim
function I-Claim
, I-Claim
with I-Claim
improvement I-Claim
noted I-Claim
for I-Claim
the I-Claim
current I-Claim
IMRT I-Claim
protocol I-Claim
. I-Claim

Improving O
dental O
prosthetic O
rehabilitation O
and O
including O
evaluations O
with O
speech O
and O
swallowing O
pathologists O
before O
and O
during O
treatment O
may O
enhance O
patient O
outcomes O
. O

To O
evaluate O
the O
combination O
of O
the O
gastrin O
antagonist O
Z-360 O
and O
gemcitabine O
for O
advanced O
pancreatic O
cancer O
. O

Previously O
untreated O
patients O
with O
PC O
were O
randomly O
allocated O
to O
Z-360 O
120 O
mg O
, O
240 O
mg O
or O
placebo O
. O

Z-360/placebo O
was O
given O
on O
day O
-3 O
and O
gemcitabine O
1000 O
mg/m O
( O
2 O
) O
commenced O
on O
day O
1 O
followed O
by O
Z-360 O
on O
day O
2 O
. O

Thereafter O
Z-360/placebo O
was O
given O
twice O
daily O
concurrently O
with O
standard O
dose O
of O
gemcitabine O
. O

Pharmacokinetics O
for O
both O
drugs O
was O
measured O
alone O
and O
in O
combination O
. O

Toxicity O
, O
response O
and O
quality O
of O
life O
were O
also O
recorded O
. O

Thirty-three O
patients O
with O
a O
median O
age O
of O
62 O
years O
were O
randomised O
of O
which O
six O
had O
locally O
advanced O
disease O
and O
26 O
had O
metastatic O
disease O
. O

Analysis O
of O
the O
area O
under O
the O
plasma O
concentration O
versus O
time O
curve O
( O
AUC O
) O
, O
the O
maximum O
observed O
concentration O
( O
Cmax O
( O
obs O
) O
) O
and O
the O
time O
of O
the O
maximum O
observed O
concentration O
( O
Tmax O
( O
obs O
) O
) O
for O
Z-360 O
, O
gemcitabine O
and O
2,2-difluorodeoxyuridine O
( O
dFdU O
) O
, O
could O
not O
exclude O
an O
effect O
on O
the O
systemic O
exposure O
to O
Z-360 O
, O
gemcitabine O
and O
dFdU O
when O
co-administration O
of O
Z-360 O
and O
gemcitabine O
was O
compared O
with O
single O
agent O
administration O
. O

The B-Premise
most I-Premise
commonly I-Premise
reported I-Premise
adverse I-Premise
events I-Premise
were I-Premise
nausea I-Premise
, I-Premise
abdominal I-Premise
pain I-Premise
, I-Premise
vomiting I-Premise
and I-Premise
fatigue I-Premise
. I-Premise

At B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
62.5 I-Premise
% I-Premise
, I-Premise
25 I-Premise
% I-Premise
and I-Premise
60 I-Premise
% I-Premise
had I-Premise
stable I-Premise
disease I-Premise
in I-Premise
the I-Premise
120 I-Premise
mg I-Premise
, I-Premise
240 I-Premise
mg I-Premise
and I-Premise
placebo I-Premise
group I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
higher I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
in I-Premise
Z-360 I-Premise
groups I-Premise
reported I-Premise
improvement I-Premise
in I-Premise
pain I-Premise
. I-Premise

Z-360 B-Claim
is I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
when I-Claim
combined I-Claim
with I-Claim
gemcitabine I-Claim
. I-Claim

A O
Phase O
III O
trial O
is O
needed O
to O
determine O
whether O
the O
combination O
of O
Z-360 O
and O
gemcitabine O
is O
superior O
to O
gemcitabine O
alone O
in O
advanced O
PC O
. O

Oral O
etoposide O
is O
an O
active O
single O
agent O
in O
small-cell O
lung O
cancer O
( O
SCLC O
) O
and O
is O
widely O
prescribed O
as O
first-line O
treatment O
as O
an O
alternative O
to O
intravenous O
combination O
chemotherapy O
in O
patients O
with O
extensive O
disease O
. O

The O
intention O
of O
this O
study O
was O
to O
determine O
if O
the O
effects O
of O
oral O
etoposide O
therapy O
on O
survival O
and O
quality O
of O
life O
are O
equivalent O
to O
those O
of O
intravenous O
chemotherapy O
. O

In O
a O
randomized O
trial O
of O
palliative O
treatment O
in O
advanced O
SCLC O
, O
oral O
etoposide O
( O
100 O
mg O
given O
twice O
daily O
for O
5 O
days O
) O
was O
compared O
with O
intravenous O
chemotherapy O
consisting O
of O
alternating O
cycles O
of O
cisplatin O
and O
etoposide O
( O
PE O
) O
and O
cyclophosphamide O
, O
doxorubicin O
, O
and O
vincristine O
( O
CAV O
) O
. O

Six O
cycles O
of O
chemotherapy O
were O
administered O
every O
21 O
days O
in O
both O
regimens O
. O

Symptom O
control O
and O
quality O
of O
life O
were O
measured O
with O
the O
Rotterdam O
Symptom O
Checklist O
and O
a O
daily O
diary O
card O
. O

In O
January O
1996 O
, O
after O
155 O
patients O
had O
been O
randomly O
assigned O
from O
a O
projected O
intake O
of O
365 O
patients O
, O
an O
independent O
Data O
Monitoring O
Committee O
examined O
the O
interim O
results O
. O

Survival O
was O
determined O
by O
the O
Kaplan-Meier O
method O
, O
and O
the O
logrank O
test O
was O
used O
to O
compare O
treatments O
. O

For O
quality-of-life O
comparisons O
, O
average O
scores O
were O
calculated O
for O
each O
time O
point O
. O

The O
Mann-Whitney O
U O
test O
was O
used O
to O
determine O
any O
significant O
overall O
differences O
between O
treatments O
. O

For O
the O
Rotterdam O
Symptom O
Checklist O
, O
separate O
analyses O
were O
done O
for O
each O
subset O
( O
psychological O
well-being O
, O
physical O
symptoms O
, O
lung O
cancer O
symptoms O
, O
treatment O
symptoms O
, O
activity O
, O
and O
quality O
of O
life O
) O
. O

Response O
rates O
and O
toxicity O
scores O
were O
compared O
by O
using O
chi2 O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Survival B-Premise
was I-Premise
inferior I-Premise
at I-Premise
1 I-Premise
year I-Premise
in I-Premise
the I-Premise
oral I-Premise
etoposide I-Premise
group I-Premise
compared I-Premise
with I-Premise
intravenous I-Premise
therapy I-Premise
( I-Premise
9.8 I-Premise
% I-Premise
for I-Premise
oral I-Premise
versus I-Premise
19.3 I-Premise
% I-Premise
for I-Premise
intravenous I-Premise
; I-Premise
difference I-Premise
= I-Premise
9.5 I-Premise
% I-Premise
; I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
of I-Premise
difference I-Premise
= I-Premise
0.3 I-Premise
% I-Premise
-18.7 I-Premise
% I-Premise
; I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
there I-Premise
was I-Premise
a I-Premise
trend I-Premise
toward I-Premise
inferior I-Premise
overall I-Premise
survival I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
4.8 I-Premise
months I-Premise
for I-Premise
oral I-Premise
treatment I-Premise
and I-Premise
5.9 I-Premise
months I-Premise
for I-Premise
intravenous I-Premise
therapy I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
was I-Premise
worse I-Premise
in I-Premise
the I-Premise
oral I-Premise
etoposide I-Premise
arm I-Premise
( I-Premise
median I-Premise
= I-Premise
3.6 I-Premise
months I-Premise
versus I-Premise
5.6 I-Premise
months I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
overall I-Premise
response I-Premise
rate I-Premise
( I-Premise
32.9 I-Premise
% I-Premise
versus I-Premise
46.3 I-Premise
% I-Premise
; I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

With B-Premise
the I-Premise
exception I-Premise
of I-Premise
acute I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
associated I-Premise
with I-Premise
intravenous I-Premise
chemotherapy I-Premise
, I-Premise
all B-Premise
aspects I-Premise
of I-Premise
symptom I-Premise
control I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
either I-Premise
the I-Premise
same I-Premise
or I-Premise
worse I-Premise
in I-Premise
the I-Premise
oral I-Premise
etoposide I-Premise
group I-Premise
. I-Premise

Study O
closure O
was O
recommended O
. O

These B-Claim
interim I-Claim
results I-Claim
show I-Claim
that I-Claim
this I-Claim
schedule I-Claim
of I-Claim
oral I-Claim
etoposide I-Claim
is I-Claim
inferior I-Claim
to I-Claim
intravenous I-Claim
chemotherapy I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
SCLC I-Claim
and I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
as I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
this I-Claim
disease I-Claim
. I-Claim

To O
evaluate O
the O
effects O
of O
the O
Chinese O
medicine O
( O
CM O
) O
five-element O
music O
on O
quality O
of O
life O
for O
senior O
and O
non-senior O
advanced O
cancer O
patients O
. O

With O
a O
randomized O
controlled O
trial O
, O
170 O
advanced O
cancer O
patients O
were O
randomly O
assigned O
to O
three O
groups O
: O
the O
CM O
five-element O
music O
group O
( O
68 O
patients O
) O
, O
the O
Western O
music O
therapy O
group O
( O
68 O
cases O
) O
, O
and O
the O
no O
music O
therapy O
group O
( O
34 O
cases O
) O
. O

All O
patients O
of O
70 O
years O
old O
or O
older O
were O
considered O
seniors O
and O
the O
remaining O
patients O
younger O
than O
70 O
years O
were O
considered O
nonseniors O
. O

Patients O
in O
the O
CM O
five-element O
music O
group O
listened O
to O
CM O
five-element O
music O
, O
the O
patients O
in O
the O
Western O
music O
group O
listened O
to O
Western O
music O
, O
and O
the O
patients O
in O
the O
no O
music O
group O
did O
not O
listen O
to O
music O
. O

A O
course O
of O
treatment O
was O
3 O
weeks O
, O
with O
30 O
min O
each O
day O
, O
5 O
days O
a O
week O
. O

The O
Hospice O
Quality O
of O
Life O
Index-Revised O
( O
HQOLI-R O
) O
and O
Karnofsky O
performance O
score O
( O
KPS O
) O
were O
measured O
in O
the O
three O
groups O
before O
and O
after O
treatment O
. O

The O
symptom O
diary O
score O
was O
measured O
in O
the O
three O
groups O
every O
3 O
days O
, O
7 O
times O
in O
total O
. O

CM B-Premise
five-element I-Premise
music I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
difference I-Premise
of I-Premise
HQOLI-R I-Premise
, I-Premise
KPS I-Premise
and I-Premise
symptom I-Premise
diary I-Premise
score I-Premise
with I-Premise
other I-Premise
groups I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
significant I-Premise
differences I-Premise
of I-Premise
HQOLI-R I-Premise
, I-Premise
symptom I-Premise
diary I-Premise
score I-Premise
, I-Premise
and I-Premise
KPS I-Premise
after I-Premise
treatment I-Premise
in I-Premise
CM I-Premise
five-element I-Premise
music I-Premise
group I-Premise
and I-Premise
other I-Premise
groups I-Premise
in I-Premise
the I-Premise
non-senior I-Premise
subgroup I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Additionally O
, O
there B-Premise
were I-Premise
significant I-Premise
differences I-Premise
in I-Premise
HQOLI-R I-Premise
and I-Premise
KPS I-Premise
after I-Premise
treatment I-Premise
among I-Premise
the I-Premise
three I-Premise
groups I-Premise
in I-Premise
the I-Premise
senior I-Premise
subgroup I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

CM B-Claim
five-element I-Claim
music I-Claim
therapy I-Claim
could I-Claim
improve I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
KPS I-Claim
for I-Claim
senior I-Claim
and I-Claim
non I-Claim
senior I-Claim
advanced I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
improve I-Claim
subjective I-Claim
symptoms I-Claim
for I-Claim
non-senior I-Claim
advanced I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Bacillus B-Claim
Calmette-Guérin I-Claim
and I-Claim
intravesical I-Claim
chemotherapy I-Claim
represent I-Claim
viable I-Claim
adjuvant I-Claim
options I-Claim
for I-Claim
intermediate I-Claim
risk I-Claim
nonmuscle I-Claim
invasive I-Claim
bladder I-Claim
cancer I-Claim
. I-Claim

Although O
bacillus O
Calmette-Guérin O
is O
perceived O
as O
less O
tolerable O
than O
intravesical O
chemotherapy O
, O
to O
our O
knowledge O
no O
comparative O
studies O
have O
addressed O
quality O
of O
life O
issues O
. O

We O
compared O
the O
quality O
of O
life O
of O
patients O
with O
nonmuscle O
invasive O
bladder O
cancer O
who O
received O
adjuvant O
intravesical O
gemcitabine O
or O
1/3 O
dose O
bacillus O
Calmette-Guérin O
. O

Our O
multicenter O
, O
prospective O
, O
randomized O
, O
phase O
II O
study O
included O
120 O
patients O
with O
intermediate O
risk O
nonmuscle O
invasive O
bladder O
cancer O
. O

Of O
these O
patients O
88 O
remained O
assessable O
at O
1-year O
followup O
. O

Only O
1 O
patient O
was O
withdrawn O
because O
of O
adverse O
events O
. O

Overall O
61 O
patients O
received O
2,000 O
mg/50 O
cc O
gemcitabine O
weekly O
for O
6 O
weeks O
( O
maintenance O
monthly O
for O
1 O
year O
) O
while O
59 O
received O
1/3 O
dose O
bacillus O
Calmette-Guérin O
Connaught O
weekly O
for O
6 O
weeks O
( O
maintenance O
3 O
weekly O
instillations O
at O
3 O
, O
6 O
and O
12 O
months O
) O
. O

Quality O
of O
life O
was O
measured O
by O
the O
EORTC O
QLQ-C30 O
( O
European O
Organization O
for O
the O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Core O
30 O
version O
3.0 O
) O
and O
QLQ-BLS24 O
( O
Quality O
of O
Life O
Superficial O
Bladder O
Cancer-Specific O
24 O
) O
questionnaires O
. O

Group O
differences O
were O
calculated O
using O
ANOVA O
( O
ANOVA/MANOVA O
) O
. O

Treatment B-Premise
was I-Premise
well I-Premise
tolerated I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
although B-Premise
local I-Premise
and I-Premise
systemic I-Premise
side I-Premise
effects I-Premise
were I-Premise
more I-Premise
frequently I-Premise
reported I-Premise
in I-Premise
the I-Premise
bacillus I-Premise
Calmette-Guérin I-Premise
arm I-Premise
. I-Premise

Multivariate B-Premise
analyses I-Premise
showed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
2 I-Premise
groups I-Premise
in I-Premise
all I-Premise
quality I-Premise
of I-Premise
life I-Premise
dimensions I-Premise
. I-Premise

No B-Premise
significant I-Premise
changes I-Premise
over I-Premise
time I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
domains I-Premise
were I-Premise
detected I-Premise
for I-Premise
patients I-Premise
on I-Premise
bacillus I-Premise
Calmette-Guérin I-Premise
and I-Premise
gemcitabine I-Premise
except I-Premise
for I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
which I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
( I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
detected I-Premise
in I-Premise
terms I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
progression I-Premise
between I-Premise
the I-Premise
2 I-Premise
groups I-Premise
at I-Premise
1-year I-Premise
followup I-Premise
. I-Premise

While O
a B-Claim
higher I-Claim
rate I-Claim
of I-Claim
side I-Claim
effects I-Claim
, I-Claim
albeit I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
, I-Claim
was I-Claim
detected I-Claim
with I-Claim
1/3 I-Claim
dose I-Claim
bacillus I-Claim
Calmette-Guérin I-Claim
compared I-Claim
to I-Claim
gemcitabine I-Claim
, I-Claim
our B-Claim
study I-Claim
failed I-Claim
to I-Claim
show I-Claim
significant I-Claim
differences I-Claim
between I-Claim
the I-Claim
2 I-Claim
drugs I-Claim
in I-Claim
terms I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
and O
safety O
of O
first-line O
, O
single-agent O
trastuzumab O
in O
women O
with O
HER2-overexpressing O
metastatic O
breast O
cancer O
. O

One O
hundred O
fourteen O
women O
with O
HER2-overexpressing O
metastatic O
breast O
cancer O
were O
randomized O
to O
receive O
first-line O
treatment O
with O
trastuzumab O
4 O
mg/kg O
loading O
dose O
, O
followed O
by O
2 O
mg/kg O
weekly O
, O
or O
a O
higher O
8 O
mg/kg O
loading O
dose O
, O
followed O
by O
4 O
mg/kg O
weekly O
. O

The B-Premise
objective I-Premise
response I-Premise
rate I-Premise
was I-Premise
26 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
18.2 I-Premise
% I-Premise
to I-Premise
34.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
with I-Premise
seven I-Premise
complete I-Premise
and I-Premise
23 I-Premise
partial I-Premise
responses I-Premise
. I-Premise

Response B-Premise
rates I-Premise
in I-Premise
111 I-Premise
assessable I-Premise
patients I-Premise
with I-Premise
3 I-Premise
and I-Premise
2 I-Premise
HER2 I-Premise
overexpression I-Premise
by I-Premise
immunohistochemistry I-Premise
( I-Premise
IHC I-Premise
) I-Premise
were I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
24.4 I-Premise
% I-Premise
to I-Premise
44.7 I-Premise
% I-Premise
) I-Premise
and I-Premise
none I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
% I-Premise
to I-Premise
15.5 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
clinical I-Premise
benefit I-Premise
rates I-Premise
in I-Premise
assessable I-Premise
patients I-Premise
with I-Premise
3 I-Premise
and I-Premise
2 I-Premise
HER2 I-Premise
overexpression I-Premise
were I-Premise
48 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
response I-Premise
rates I-Premise
in I-Premise
108 I-Premise
assessable I-Premise
patients I-Premise
with I-Premise
and I-Premise
without I-Premise
HER2 I-Premise
gene I-Premise
amplification I-Premise
by I-Premise
fluorescence I-Premise
in I-Premise
situ I-Premise
hybridization I-Premise
( I-Premise
FISH I-Premise
) I-Premise
analysis I-Premise
were I-Premise
34 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
23.9 I-Premise
% I-Premise
to I-Premise
45.7 I-Premise
% I-Premise
) I-Premise
and I-Premise
7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.8 I-Premise
% I-Premise
to I-Premise
22.8 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Seventeen B-Premise
( I-Premise
57 I-Premise
% I-Premise
) I-Premise
of I-Premise
30 I-Premise
patients I-Premise
with I-Premise
an I-Premise
objective I-Premise
response I-Premise
and I-Premise
22 I-Premise
( I-Premise
51 I-Premise
% I-Premise
) I-Premise
of I-Premise
43 I-Premise
patients I-Premise
with I-Premise
clinical I-Premise
benefit I-Premise
had I-Premise
not I-Premise
experienced I-Premise
disease I-Premise
progression I-Premise
at I-Premise
follow-up I-Premise
at I-Premise
12 I-Premise
months I-Premise
or I-Premise
later I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
chills I-Premise
( I-Premise
25 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
, I-Premise
asthenia I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
, I-Premise
fever I-Premise
( I-Premise
22 I-Premise
% I-Premise
) I-Premise
, I-Premise
pain I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
nausea I-Premise
( I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Cardiac B-Premise
dysfunction I-Premise
occurred I-Premise
in I-Premise
two I-Premise
patients I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
; I-Premise
both I-Premise
had I-Premise
histories I-Premise
of I-Premise
cardiac I-Premise
disease I-Premise
and I-Premise
did I-Premise
not I-Premise
require I-Premise
additional I-Premise
intervention I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
trastuzumab I-Premise
. I-Premise

There B-Claim
was I-Claim
no I-Claim
clear I-Claim
evidence I-Claim
of I-Claim
a I-Claim
dose-response I-Claim
relationship I-Claim
for I-Claim
response I-Claim
, I-Claim
survival I-Claim
, I-Claim
or I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Single-agent B-Claim
trastuzumab I-Claim
is I-Claim
active I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
as I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
women I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
with I-Claim
HER2 I-Claim
3 I-Claim
overexpression I-Claim
by I-Claim
IHC I-Claim
or I-Claim
gene I-Claim
amplification I-Claim
by I-Claim
FISH I-Claim
. I-Claim

We O
investigated O
the O
influence O
of O
bladder O
neck O
preservation O
on O
urinary O
continence O
, O
quality O
of O
life O
and O
surgical O
margins O
after O
radical O
prostatectomy O
. O

A O
total O
of O
208 O
men O
who O
presented O
for O
radical O
prostatectomy O
were O
randomized O
to O
complete O
bladder O
neck O
preservation O
with O
subsequent O
urethro-urethral O
anastomosis O
or O
to O
no O
preservation O
as O
controls O
. O

Patients O
with O
failed O
bladder O
neck O
preservation O
were O
not O
included O
in O
study O
. O

We O
documented O
objective O
continence O
by O
the O
24-hour O
pad O
test O
, O
social O
continence O
by O
the O
number O
of O
pads O
per O
day O
and O
quality O
of O
life O
outcomes O
by O
the O
validated O
Incontinence O
Quality O
of O
Life O
questionnaire O
in O
a O
single O
blind O
setting O
. O

Cancer O
resection O
was O
assessed O
by O
surgical O
margin O
status O
. O

At B-Premise
0 I-Premise
, I-Premise
3 I-Premise
, I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
mean I-Premise
urine I-Premise
loss I-Premise
in I-Premise
the I-Premise
control I-Premise
vs I-Premise
the I-Premise
bladder I-Premise
neck I-Premise
preservation I-Premise
group I-Premise
was I-Premise
713.3 I-Premise
vs I-Premise
237.0 I-Premise
, I-Premise
49.6 I-Premise
vs I-Premise
15.6 I-Premise
, I-Premise
44.4 I-Premise
vs I-Premise
5.5 I-Premise
and I-Premise
25.4 I-Premise
vs I-Premise
3.1 I-Premise
gm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
each I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
, I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
control I-Premise
vs I-Premise
the I-Premise
preservation I-Premise
group I-Premise
the I-Premise
social I-Premise
continence I-Premise
rate I-Premise
was I-Premise
55.3 I-Premise
% I-Premise
vs I-Premise
84.2 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
74.8 I-Premise
% I-Premise
vs I-Premise
89.5 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
81.4 I-Premise
% I-Premise
vs I-Premise
94.7 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
0.027 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
80.4 I-Premise
vs I-Premise
90.3 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
85.4 I-Premise
vs I-Premise
91.7 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.016 I-Premise
) I-Premise
and I-Premise
86.0 I-Premise
vs I-Premise
93.8 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

We B-Premise
noted I-Premise
significantly I-Premise
less I-Premise
urine I-Premise
loss I-Premise
, I-Premise
higher I-Premise
objective I-Premise
and I-Premise
social I-Premise
continence I-Premise
rates I-Premise
, I-Premise
and I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
after I-Premise
complete I-Premise
bladder I-Premise
neck I-Premise
preservation I-Premise
at I-Premise
all I-Premise
followup I-Premise
points I-Premise
. I-Premise

On O
multiple O
logistic O
regression O
analysis O
complete O
bladder O
neck O
preservation O
was O
an O
independent O
positive O
predictor O
of O
continence O
. O

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
in I-Premise
surgical I-Premise
margin I-Premise
status I-Premise
between I-Premise
the I-Premise
control I-Premise
and I-Premise
bladder I-Premise
neck I-Premise
preservation I-Premise
groups I-Premise
( I-Premise
12.5 I-Premise
% I-Premise
vs I-Premise
14.7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0.65 I-Premise
) I-Premise
. I-Premise

In B-Claim
what I-Claim
is I-Claim
to I-Claim
our I-Claim
knowledge I-Claim
the I-Claim
first I-Claim
prospective I-Claim
, I-Claim
randomized I-Claim
, I-Claim
controlled I-Claim
, I-Claim
single I-Claim
blind I-Claim
trial I-Claim
complete I-Claim
bladder I-Claim
neck I-Claim
preservation I-Claim
during I-Claim
radical I-Claim
prostatectomy I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
significantly I-Claim
higher I-Claim
urinary I-Claim
continence I-Claim
rate I-Claim
and I-Claim
increased I-Claim
patient I-Claim
satisfaction I-Claim
without I-Claim
compromising I-Claim
resection I-Claim
margins I-Claim
. I-Claim

Docetaxel O
administered O
every O
3 O
weeks O
is O
a O
standard O
treatment O
for O
castration-resistant O
advanced O
prostate O
cancer O
. O

We O
hypothesised O
that O
2-weekly O
administration O
of O
docetaxel O
would O
be O
better O
tolerated O
than O
3-weekly O
docetaxel O
in O
patients O
with O
castration-resistant O
advanced O
prostate O
cancer O
, O
and O
did O
a O
prospective O
, O
multicentre O
, O
randomised O
, O
phase O
3 O
study O
to O
compare O
efficacy O
and O
safety O
. O

Eligible O
patients O
had O
advanced O
prostate O
cancer O
( O
metastasis O
, O
a O
prostate-specific-antigen O
test O
result O
of O
more O
than O
10·0 O
ng/mL O
, O
and O
WHO O
performance O
status O
score O
of O
0-2 O
) O
, O
had O
received O
no O
chemotherapy O
( O
except O
with O
estramustine O
) O
, O
had O
undergone O
surgical O
or O
chemical O
castration O
, O
and O
had O
been O
referred O
to O
a O
treatment O
centre O
in O
Finland O
, O
Ireland O
, O
or O
Sweden O
. O

Enrolment O
and O
treatment O
were O
done O
between O
March O
1 O
, O
2004 O
, O
and O
May O
31 O
, O
2009 O
. O

Randomisation O
was O
done O
centrally O
and O
stratified O
by O
centre O
and O
WHO O
performance O
status O
score O
of O
0-1 O
vs O
2 O
. O

Patients O
were O
assigned O
75 O
mg/m O
( O
2 O
) O
docetaxel O
intravenously O
on O
day O
1 O
of O
a O
3-week O
cycle O
, O
or O
50 O
mg/m O
( O
2 O
) O
docetaxel O
intravenously O
on O
days O
1 O
and O
15 O
of O
a O
4-week O
cycle O
. O

10 O
mg O
oral O
prednisolone O
was O
administered O
daily O
to O
all O
patients O
. O

The O
primary O
endpoint O
was O
time O
to O
treatment O
failure O
( O
TTTF O
) O
. O

We O
assessed O
data O
in O
the O
per-protocol O
population O
. O

177 O
patients O
were O
randomly O
assigned O
to O
the O
2-weekly O
docetaxel O
group O
and O
184 O
to O
the O
3-weekly O
group O
. O

170 O
patients O
in O
the O
2-weekly O
group O
and O
176 O
in O
the O
3-weekly O
group O
were O
included O
in O
the O
analysis O
. O

The B-Premise
2-weekly I-Premise
administration I-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
longer I-Premise
TTTF I-Premise
than I-Premise
was I-Premise
3-weekly I-Premise
administration I-Premise
( I-Premise
5·6 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5·0-6·2 I-Premise
vs I-Premise
4·9 I-Premise
months I-Premise
, I-Premise
4·5-5·4 I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
1·3 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1·1-1·6 I-Premise
, I-Premise
p=0·014 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3-4 I-Premise
adverse I-Premise
events I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
3-weekly I-Premise
than I-Premise
in I-Premise
the I-Premise
2-weekly I-Premise
administration I-Premise
group I-Premise
, I-Premise
including I-Premise
neutropenia I-Premise
( I-Premise
93 I-Premise
[ I-Premise
53 I-Premise
% I-Premise
] I-Premise
vs I-Premise
61 I-Premise
[ I-Premise
36 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
( I-Premise
51 I-Premise
[ I-Premise
29 I-Premise
% I-Premise
] I-Premise
vs I-Premise
22 I-Premise
[ I-Premise
13 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
25 I-Premise
[ I-Premise
14 I-Premise
% I-Premise
] I-Premise
vs I-Premise
six I-Premise
[ I-Premise
4 I-Premise
% I-Premise
] I-Premise
) I-Premise
. I-Premise

Neutropenic B-Premise
infections I-Premise
were I-Premise
reported I-Premise
more I-Premise
frequently I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
docetaxel I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
43 I-Premise
[ I-Premise
24 I-Premise
% I-Premise
] I-Premise
vs I-Premise
11 I-Premise
[ I-Premise
6 I-Premise
% I-Premise
] I-Premise
, I-Premise
p=0·002 I-Premise
) I-Premise
. I-Premise

Administration B-Claim
of I-Claim
docetaxel I-Claim
every I-Claim
2 I-Claim
weeks I-Claim
seems I-Claim
to I-Claim
be I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
patients I-Claim
with I-Claim
castration-resistant I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
and I-Claim
could I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
when I-Claim
3-weekly I-Claim
single-dose I-Claim
administration I-Claim
is I-Claim
unlikely I-Claim
to I-Claim
be I-Claim
tolerated I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
cancer I-Claim
( I-Claim
AGGEC I-Claim
) I-Claim
providing I-Claim
clinical I-Claim
benefit I-Claim
with I-Claim
improved I-Claim
palliation I-Claim
is I-Claim
highly I-Claim
desirable I-Claim
. I-Claim

However O
, O
a O
prospective O
evaluation O
of O
clinical O
benefit O
in O
AGGEC O
patients O
has O
never O
before O
been O
reported O
in O
a O
phase O
III O
setting O
. O

In O
a O
multinational O
trial O
( O
V325 O
) O
, O
445 O
patients O
were O
randomly O
assigned O
and O
treated O
with O
either O
docetaxel O
plus O
cisplatin O
and O
fluorouracil O
( O
DCF O
) O
or O
cisplatin O
and O
fluorouracil O
( O
CF O
) O
. O

Clinical O
benefit O
was O
prospectively O
evaluated O
in O
this O
trial O
as O
a O
secondary O
end O
point O
. O

The O
primary O
measure O
for O
clinical O
benefit O
analysis O
was O
time O
to O
definitive O
worsening O
by O
one O
or O
more O
categories O
of O
Karnofsky O
performance O
status O
( O
KPS O
) O
. O

Secondary O
clinical O
benefit O
end O
points O
included O
time O
to O
5 O
% O
definitive O
weight O
loss O
, O
time O
to O
definitive O
worsening O
of O
appetite O
by O
one O
grade O
, O
pain-free O
survival O
( O
defined O
as O
time O
to O
first O
appearance O
of O
pain O
) O
, O
and O
time O
to O
first O
cancer O
pain-related O
opioid O
intake O
. O

Clinical O
benefit O
assessments O
were O
recorded O
at O
each O
clinic O
visit O
. O

Clinical O
benefit O
assessments O
were O
performed O
in O
more O
than O
75 O
% O
of O
patients O
throughout O
V325 O
. O

DCF B-Premise
significantly I-Premise
prolonged I-Premise
time I-Premise
to I-Premise
definitive I-Premise
worsening I-Premise
of I-Premise
KPS I-Premise
compared I-Premise
with I-Premise
CF I-Premise
( I-Premise
median I-Premise
, I-Premise
6.1 I-Premise
v I-Premise
4.8 I-Premise
months I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.38 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.08 I-Premise
to I-Premise
1.76 I-Premise
; I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
. I-Premise

Although B-Premise
time I-Premise
to I-Premise
definitive I-Premise
weight I-Premise
loss I-Premise
and I-Premise
time I-Premise
to I-Premise
definitive I-Premise
worsening I-Premise
of I-Premise
appetite I-Premise
favored I-Premise
DCF I-Premise
, I-Premise
the B-Premise
results I-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Pain-free B-Premise
survival I-Premise
and I-Premise
time I-Premise
to I-Premise
first I-Premise
cancer I-Premise
pain-related I-Premise
opioid I-Premise
intake I-Premise
were I-Premise
comparable I-Premise
. I-Premise

To O
our O
knowledge O
, O
V325 O
is O
the O
first O
phase O
III O
trial O
to O
report O
clinical O
benefit O
in O
AGGEC O
patients O
. O

Clinical O
benefit O
was O
assessed O
beyond O
protocol-specific O
chemotherapy O
. O

The B-Claim
addition I-Claim
of I-Claim
D I-Claim
to I-Claim
CF I-Claim
not I-Claim
only I-Claim
significantly I-Claim
improved I-Claim
clinical I-Claim
benefit I-Claim
but I-Claim
also I-Claim
improved I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
and I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
CF I-Claim
. I-Claim

The O
addition O
of O
mTOR O
inhibitor O
everolimus O
( O
EVE O
) O
to O
exemestane O
( O
EXE O
) O
was O
evaluated O
in O
an O
international O
, O
phase O
3 O
study O
( O
BOLERO-2 O
) O
in O
patients O
with O
hormone-receptor-positive O
( O
HR O
( O
+ O
) O
) O
breast O
cancer O
refractory O
to O
letrozole O
or O
anastrozole O
. O

The O
safety O
and O
efficacy O
of O
anticancer O
treatments O
may O
be O
influenced O
by O
ethnicity O
( O
Sekine O
et O
al O
. O

in O
Br O
J O
Cancer O
99:1757-62 O
, O
2008 O
) O
. O

Safety O
and O
efficacy O
results O
from O
Asian O
versus O
non-Asian O
patients O
in O
BOLERO-2 O
are O
reported O
. O

Patients O
were O
randomized O
( O
2:1 O
) O
to O
10 O
mg/day O
EVE O
+ O
EXE O
or O
placebo O
( O
PBO O
) O
+ O
EXE O
. O

Primary O
endpoint O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Secondary O
endpoints O
included O
overall O
survival O
, O
response O
rate O
, O
clinical O
benefit O
rate O
, O
and O
safety O
. O

Of O
143 O
Asian O
patients O
, O
98 O
received O
EVE O
+ O
EXE O
and O
45 O
received O
PBO O
+ O
EXE O
. O

Treatment B-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
significantly I-Premise
improved I-Premise
median I-Premise
PFS I-Premise
versus I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
among I-Premise
Asian I-Premise
patients I-Premise
by I-Premise
38 I-Premise
% I-Premise
( I-Premise
HR I-Premise
= I-Premise
0.62 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.41-0.94 I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
also I-Premise
improved I-Premise
among I-Premise
non-Asian I-Premise
patients I-Premise
by I-Premise
59 I-Premise
% I-Premise
( I-Premise
HR I-Premise
= I-Premise
0.41 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.33-0.50 I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
duration I-Premise
among I-Premise
EVE-treated I-Premise
Asian I-Premise
patients I-Premise
was I-Premise
8.48 I-Premise
versus I-Premise
4.14 I-Premise
months I-Premise
for I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
, I-Premise
and I-Premise
7.33 I-Premise
versus I-Premise
2.83 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
non-Asian I-Premise
patients I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3/4 I-Premise
adverse I-Premise
events I-Premise
( I-Premise
stomatitis I-Premise
, I-Premise
anemia I-Premise
, I-Premise
elevated I-Premise
liver I-Premise
enzymes I-Premise
, I-Premise
hyperglycemia I-Premise
, I-Premise
and I-Premise
dyspnea I-Premise
) I-Premise
occurred I-Premise
at I-Premise
similar I-Premise
frequencies I-Premise
in I-Premise
Asian I-Premise
and I-Premise
non-Asian I-Premise
patients I-Premise
. I-Premise

Grade B-Premise
1/2 I-Premise
interstitial I-Premise
lung I-Premise
disease I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
Asian I-Premise
patients I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
Asian I-Premise
patients I-Premise
. I-Premise

Adding B-Claim
EVE I-Claim
to I-Claim
EXE I-Claim
provided I-Claim
substantial I-Claim
clinical I-Claim
benefit I-Claim
in I-Claim
both I-Claim
Asian I-Claim
and I-Claim
non-Asian I-Claim
patients I-Claim
with I-Claim
similar I-Claim
safety I-Claim
profiles I-Claim
. I-Claim

This B-Claim
combination I-Claim
represents I-Claim
an I-Claim
improvement I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
HR I-Claim
( I-Claim
+ I-Claim
) I-Claim
/HER2 I-Claim
( I-Claim
- I-Claim
) I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
progressing I-Claim
on I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
regardless I-Claim
of I-Claim
ethnicity I-Claim
. I-Claim

Older B-Claim
patients I-Claim
, I-Claim
even I-Claim
if I-Claim
fit I-Claim
, I-Claim
are I-Claim
often I-Claim
considered I-Claim
incapable I-Claim
of I-Claim
tolerating I-Claim
platinum-based I-Claim
systemic I-Claim
therapy I-Claim
. I-Claim

We O
performed O
a O
retrospective O
analysis O
of O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
5592 O
, O
a O
phase O
III O
randomized O
trial O
of O
platinum-based O
chemotherapy O
regimens O
for O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
, O
and O
compared O
outcomes O
in O
enrollees O
70 O
years O
of O
age O
and O
older O
with O
those O
in O
younger O
patients O
. O

ECOG O
carried O
out O
a O
randomized O
phase O
III O
trial O
of O
cisplatin O
plus O
either O
etoposide O
or O
paclitaxel O
in O
chemotherapy-naïve O
NSCLC O
patients O
with O
stages O
III O
( O
B O
) O
or O
IV O
disease O
. O

Toxic O
effects O
, O
response O
rates O
, O
and O
survival O
rates O
were O
compared O
between O
age O
groups O
. O

All O
P O
values O
were O
two-sided O
. O

A O
total O
of O
574 O
patients O
enrolled O
from O
August O
1993 O
through O
December O
1994 O
were O
evaluable O
. O

Eighty-six O
( O
15 O
% O
) O
were O
70 O
years O
old O
or O
older O
. O

Older B-Premise
patients I-Premise
had I-Premise
a I-Premise
higher I-Premise
incidence I-Premise
of I-Premise
cardiovascular I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
and I-Premise
respiratory I-Premise
( I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
comorbidities I-Premise
and I-Premise
nonanalgesic I-Premise
medication I-Premise
use I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
. I-Premise

Leukopenia B-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
neuropsychiatric I-Premise
toxicity I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
elderly I-Premise
men I-Premise
than I-Premise
in I-Premise
younger I-Premise
men I-Premise
. I-Premise

Elderly B-Premise
women I-Premise
lost I-Premise
more I-Premise
weight I-Premise
than I-Premise
younger I-Premise
women I-Premise
( I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
. I-Premise

Other B-Premise
toxic I-Premise
effects I-Premise
were I-Premise
similar I-Premise
in I-Premise
older I-Premise
and I-Premise
younger I-Premise
patients I-Premise
. I-Premise

The B-Premise
proportions I-Premise
with I-Premise
clinical I-Premise
partial I-Premise
or I-Premise
complete I-Premise
response I-Premise
( I-Premise
21.5 I-Premise
% I-Premise
versus I-Premise
23.3 I-Premise
% I-Premise
; I-Premise
Fisher I-Premise
's I-Premise
exact I-Premise
test I-Premise
, I-Premise
P I-Premise
=.66 I-Premise
) I-Premise
, I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
4.37 I-Premise
versus I-Premise
4.30 I-Premise
months I-Premise
; I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
=.29 I-Premise
) I-Premise
, I-Premise
and I-Premise
survival I-Premise
distribution I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
=.29 I-Premise
; I-Premise
median I-Premise
survival I-Premise
, I-Premise
9.05 I-Premise
versus I-Premise
8.53 I-Premise
months I-Premise
; I-Premise
1-year I-Premise
survival I-Premise
, I-Premise
38 I-Premise
% I-Premise
versus I-Premise
29 I-Premise
% I-Premise
; I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
, I-Premise
14 I-Premise
% I-Premise
versus I-Premise
12 I-Premise
% I-Premise
) I-Premise
were I-Premise
similar I-Premise
in I-Premise
patients I-Premise
younger I-Premise
than I-Premise
70 I-Premise
years I-Premise
and I-Premise
70 I-Premise
years I-Premise
old I-Premise
or I-Premise
older I-Premise
. I-Premise

Baseline B-Premise
quality-of-life I-Premise
and I-Premise
treatment-outcome I-Premise
indices I-Premise
were I-Premise
similar I-Premise
. I-Premise

Equivalent B-Premise
declines I-Premise
over I-Premise
time I-Premise
in I-Premise
functional I-Premise
well-being I-Premise
occurred I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Response B-Claim
rate I-Claim
, I-Claim
toxicity I-Claim
, I-Claim
and I-Claim
survival I-Claim
in I-Claim
fit I-Claim
, I-Claim
elderly I-Claim
NSCLC I-Claim
patients I-Claim
receiving I-Claim
platinum-based I-Claim
treatment I-Claim
appear I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
those I-Claim
in I-Claim
younger I-Claim
patients I-Claim
, I-Claim
although B-Claim
patients I-Claim
70 I-Claim
years I-Claim
old I-Claim
or I-Claim
older I-Claim
have I-Claim
more I-Claim
comorbidities I-Claim
and I-Claim
can I-Claim
expect I-Claim
more I-Claim
leukopenia I-Claim
and I-Claim
neuropsychiatric I-Claim
toxicity I-Claim
. I-Claim

Advanced B-Claim
age I-Claim
alone I-Claim
should I-Claim
not I-Claim
preclude I-Claim
appropriate I-Claim
NSCLC I-Claim
treatment I-Claim
. I-Claim

To O
investigate O
the O
effect O
of O
two O
doses O
of O
megestrol O
acetate O
( O
MA O
) O
compared O
with O
placebo O
on O
quality O
of O
life O
( O
QoL O
) O
and O
nutritional O
status O
( O
NS O
) O
in O
patients O
with O
advanced O
endocrine-insensitive O
cancer O
. O

Two O
hundred O
forty O
patients O
were O
randomised O
to O
double-blind O
MA O
480 O
mg/day O
, O
MA O
160 O
mg/day O
, O
or O
matching O
placebo O
for O
12 O
weeks O
. O

Nutritional O
status O
( O
including O
weight O
, O
skinfold O
thickness O
and O
midarm O
circumference O
) O
and O
QoL O
( O
using O
6 O
linear O
analogue O
self-assessment O
( O
LASA O
) O
scales O
) O
were O
assessed O
at O
randomisation O
and O
after O
four O
, O
eight O
and O
12 O
weeks O
. O

A O
QoL O
ranking O
incorporating O
QoL O
and O
death O
was O
also O
used O
ranging O
from O
1 O
= O
dead O
to O
5 O
= O
much O
better O
QoL O
. O

One O
hundred O
seventy-four O
patients O
were O
assessable O
at O
week O
four O
, O
136 O
at O
week O
eight O
and O
103 O
patients O
at O
week O
12 O
. O

Patients B-Premise
receiving I-Premise
MA I-Premise
reported I-Premise
substantially I-Premise
better I-Premise
appetite I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
possibly I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
than I-Premise
patients I-Premise
receiving I-Premise
placebo I-Premise
, I-Premise
based I-Premise
on I-Premise
a I-Premise
test I-Premise
for I-Premise
trend I-Premise
. I-Premise

A B-Premise
larger I-Premise
benefit I-Premise
was I-Premise
seen I-Premise
with I-Premise
the I-Premise
higher I-Premise
dose I-Premise
which I-Premise
( I-Premise
unlike I-Premise
the I-Premise
lower I-Premise
dose I-Premise
) I-Premise
was I-Premise
significantly I-Premise
better I-Premise
in I-Premise
pairwise I-Premise
comparisons I-Premise
with I-Premise
placebo I-Premise
for I-Premise
appetite I-Premise
, I-Premise
mood I-Premise
and I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
each I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Despite B-Premise
some I-Premise
missing I-Premise
data I-Premise
on I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
QoL I-Premise
ranking I-Premise
was I-Premise
available I-Premise
on I-Premise
227 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
of I-Premise
patients I-Premise
with I-Premise
significantly I-Premise
higher I-Premise
QoL I-Premise
ranking I-Premise
associated I-Premise
with I-Premise
MA I-Premise
( I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
QoL I-Premise
occurred I-Premise
early I-Premise
within I-Premise
four I-Premise
weeks I-Premise
and I-Premise
were I-Premise
sustained I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
NS I-Premise
measurements I-Premise
, I-Premise
including I-Premise
weight I-Premise
( I-Premise
P I-Premise
= I-Premise
0.29 I-Premise
) I-Premise
. I-Premise

Side B-Premise
effects I-Premise
of I-Premise
therapy I-Premise
were I-Premise
minor I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
across I-Premise
treatments I-Premise
. I-Premise

Megestrol B-Claim
acetate I-Claim
given I-Claim
at I-Claim
480 I-Claim
mg/day I-Claim
is I-Claim
useful I-Claim
palliation I-Claim
in I-Claim
patients I-Claim
with I-Claim
endocrine-insensitive I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

It B-Claim
improves I-Claim
appetite I-Claim
, I-Claim
mood I-Claim
and I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
these I-Claim
patients I-Claim
, I-Claim
although B-Claim
not I-Claim
through I-Claim
a I-Claim
direct I-Claim
effect I-Claim
on I-Claim
nutritional I-Claim
status I-Claim
. I-Claim

Suramin B-Claim
is I-Claim
a I-Claim
novel I-Claim
agent I-Claim
that I-Claim
has I-Claim
demonstrated I-Claim
preliminary I-Claim
evidence I-Claim
of I-Claim
antitumor I-Claim
activity I-Claim
in I-Claim
hormone-refractory I-Claim
prostate I-Claim
cancer I-Claim
( I-Claim
HRPC I-Claim
) I-Claim
. I-Claim

A O
prospective O
randomized O
clinical O
trial O
was O
designed O
to O
evaluate O
pain O
and O
opioid O
analgesic O
intake O
as O
surrogates O
for O
antitumor O
response O
in O
HRPC O
patients O
with O
significant O
, O
opioid O
analgesic-dependent O
pain O
. O

A O
double-blind O
, O
placebo-controlled O
trial O
randomized O
patients O
to O
receive O
a O
78-day O
, O
outpatient O
regimen O
of O
either O
suramin O
plus O
hydrocortisone O
( O
HC O
, O
40 O
mg/d O
) O
or O
placebo O
plus O
HC O
. O

Treatment O
assignment O
was O
unblinded O
when O
either O
disease O
progression O
or O
dose-limiting O
toxicity O
occurred O
; O
placebo O
patients O
were O
allowed O
to O
cross-over O
to O
open-label O
suramin O
plus O
HC O
. O

In O
addition O
to O
pain O
and O
opioid O
analgesic O
intake O
, O
prostate-specific O
antigen O
( O
PSA O
) O
response O
, O
time O
to O
disease O
progression O
, O
quality O
of O
life O
, O
performance O
status O
, O
and O
survival O
were O
compared O
. O

Overall B-Premise
mean I-Premise
reductions I-Premise
in I-Premise
combined I-Premise
pain I-Premise
and I-Premise
opioid I-Premise
analgesic I-Premise
intake I-Premise
were I-Premise
greater I-Premise
for I-Premise
suramin I-Premise
plus I-Premise
HC I-Premise
( I-Premise
rank I-Premise
sum I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

Pain B-Premise
response I-Premise
was I-Premise
achieved I-Premise
in I-Premise
a I-Premise
higher I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
suramin I-Premise
than I-Premise
placebo I-Premise
( I-Premise
43 I-Premise
% I-Premise
v I-Premise
28 I-Premise
% I-Premise
; I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
, I-Premise
and O
duration B-Premise
of I-Premise
response I-Premise
was I-Premise
longer I-Premise
for I-Premise
suramin I-Premise
responders I-Premise
( I-Premise
median I-Premise
, I-Premise
240 I-Premise
v I-Premise
69 I-Premise
days I-Premise
; I-Premise
P I-Premise
=.0027 I-Premise
) I-Premise
. I-Premise

Time B-Premise
to I-Premise
disease I-Premise
progression I-Premise
was I-Premise
longer I-Premise
( I-Premise
relative I-Premise
risk I-Premise
= I-Premise
1.5 I-Premise
; I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.2 I-Premise
to I-Premise
1.9 I-Premise
) I-Premise
and O
the B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
with I-Premise
a I-Premise
greater I-Premise
than I-Premise
50 I-Premise
% I-Premise
decline I-Premise
in I-Premise
PSA I-Premise
was I-Premise
higher I-Premise
( I-Premise
33 I-Premise
% I-Premise
v I-Premise
16 I-Premise
% I-Premise
; I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
suramin I-Premise
. I-Premise

Neither B-Premise
quality I-Premise
of I-Premise
life I-Premise
nor I-Premise
performance I-Premise
status I-Premise
was I-Premise
decreased I-Premise
by I-Premise
suramin I-Premise
treatment I-Premise
, I-Premise
and O
overall B-Premise
survival I-Premise
was I-Premise
similar I-Premise
. I-Premise

Most B-Premise
adverse I-Premise
events I-Premise
were I-Premise
of I-Premise
mild I-Premise
or I-Premise
moderate I-Premise
intensity I-Premise
and I-Premise
were I-Premise
easily I-Premise
managed I-Premise
medically I-Premise
. I-Premise

Outpatient B-Claim
treatment I-Claim
with I-Claim
suramin I-Claim
plus I-Claim
HC I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
provides I-Claim
moderate I-Claim
palliative I-Claim
benefit I-Claim
and I-Claim
delay I-Claim
in I-Claim
disease I-Claim
progression I-Claim
for I-Claim
patients I-Claim
with I-Claim
symptomatic I-Claim
HRPC I-Claim
. I-Claim

To O
compare O
vinflunine O
( O
VFL O
) O
to O
docetaxel O
in O
patients O
with O
stage O
IIIB/IV O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
who O
have O
experienced O
treatment O
failure O
with O
first-line O
platinum-based O
chemotherapy O
. O

Randomized O
, O
multicenter O
, O
phase O
III O
study O
, O
551 O
patients O
received O
either O
vinflunine O
320 O
mg/m O
( O
2 O
) O
or O
docetaxel O
75 O
mg/m O
( O
2 O
) O
every O
21 O
days O
until O
disease O
progression O
or O
serious O
toxicity O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

The O
noninferiority O
analysis O
was O
based O
on O
a O
10 O
% O
difference O
( O
types O
I/II O
error O
rates O
: O
5 O
% O
/20 O
% O
) O
. O

Secondary O
end O
points O
included O
response O
rate O
( O
ORR O
) O
, O
response O
duration O
, O
overall O
survival O
( O
OS O
) O
, O
clinical O
benefit O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
safety O
. O

Median B-Premise
PFS I-Premise
was I-Premise
2.3 I-Premise
months I-Premise
for I-Premise
each I-Premise
arm I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.004 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.841 I-Premise
to I-Premise
1.199 I-Premise
) I-Premise
. I-Premise

ORR B-Premise
, I-Premise
stable I-Premise
disease I-Premise
, I-Premise
median I-Premise
OS I-Premise
, I-Premise
were I-Premise
4.4 I-Premise
% I-Premise
versus I-Premise
5.5 I-Premise
% I-Premise
, I-Premise
36.0 I-Premise
% I-Premise
versus I-Premise
39.6 I-Premise
% I-Premise
, I-Premise
6.7 I-Premise
versus I-Premise
7.2 I-Premise
months I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.973 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.805 I-Premise
to I-Premise
1.176 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
patient I-Premise
benefit I-Premise
and I-Premise
QOL I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Lung I-Premise
) I-Premise
. I-Premise

No B-Premise
unexpected I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
. I-Premise

Grade B-Premise
higher I-Premise
than I-Premise
0 I-Premise
( I-Premise
vinflunine I-Premise
v I-Premise
docetaxel I-Premise
) I-Premise
anemia I-Premise
( I-Premise
82.1 I-Premise
% I-Premise
v I-Premise
79.8 I-Premise
% I-Premise
) I-Premise
, I-Premise
neutropenia I-Premise
( I-Premise
49.3 I-Premise
v I-Premise
39.02 I-Premise
% I-Premise
) I-Premise
, I-Premise
thrombocytopenia I-Premise
( I-Premise
30.6 I-Premise
% I-Premise
v I-Premise
14.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3.3 I-Premise
% I-Premise
v I-Premise
4.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
39.2 I-Premise
% I-Premise
v I-Premise
11.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
36.6 I-Premise
% I-Premise
v I-Premise
33.9 I-Premise
% I-Premise
) I-Premise
, I-Premise
injection I-Premise
site I-Premise
reaction I-Premise
( I-Premise
31.9 I-Premise
% I-Premise
v I-Premise
0.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
nausea I-Premise
( I-Premise
26.7 I-Premise
% I-Premise
v I-Premise
23.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
23.8 I-Premise
% I-Premise
v I-Premise
14.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
alopecia I-Premise
( I-Premise
19.8 I-Premise
% I-Premise
v I-Premise
35.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatis I-Premise
( I-Premise
19.4 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
abdominal I-Premise
pain I-Premise
( I-Premise
20.1 I-Premise
% I-Premise
v I-Premise
3.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
myalgia I-Premise
( I-Premise
14.7 I-Premise
% I-Premise
v I-Premise
6.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
peripheral I-Premise
neuropathy I-Premise
( I-Premise
10.7 I-Premise
% I-Premise
v I-Premise
15.0 I-Premise
% I-Premise
) I-Premise
, I-Premise
arthralgia I-Premise
( I-Premise
7.0 I-Premise
% I-Premise
v I-Premise
7.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
6.2 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
edema I-Premise
( I-Premise
1.5 I-Premise
% I-Premise
v I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
nail I-Premise
disorders I-Premise
( I-Premise
1.1 I-Premise
% I-Premise
v I-Premise
5 I-Premise
; I-Premise
1 I-Premise
% I-Premise
) I-Premise
were I-Premise
observed I-Premise
. I-Premise

This B-Claim
noninferiority I-Claim
phase I-Claim
III I-Claim
study I-Claim
showed I-Claim
similar I-Claim
efficacy I-Claim
end I-Claim
points I-Claim
for I-Claim
vinflunine I-Claim
and I-Claim
docetaxel I-Claim
. I-Claim

Despite B-Claim
higher I-Claim
rates I-Claim
of I-Claim
some I-Claim
adverse I-Claim
effects I-Claim
( I-Claim
anemia I-Claim
, I-Claim
abdominal I-Claim
pain I-Claim
, I-Claim
constipation I-Claim
, I-Claim
fatigue I-Claim
) I-Claim
the B-Claim
overall I-Claim
toxicity I-Claim
profile I-Claim
of I-Claim
vinflunine I-Claim
was I-Claim
manageable I-Claim
. I-Claim

Therefore O
, O
VFL B-Claim
may I-Claim
be I-Claim
another I-Claim
option I-Claim
in I-Claim
the I-Claim
second-line I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

This O
randomised O
, O
placebo-controlled O
single-blind O
trial O
investigated O
the O
safety O
and O
efficacy O
of O
SAMITAL® O
, O
a O
formulation O
of O
highly O
standardised O
botanical O
extracts O
, O
in O
the O
treatment O
of O
chemo/radiotherapy-induced O
oral O
mucositis O
( O
OM O
) O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

Patients O
received O
SAMITAL® O
or O
placebo O
four O
times O
daily O
for O
up O
to O
50 O
days O
during O
scheduled O
chemo/radiotherapy O
. O

Severity O
of O
OM O
was O
monitored O
according O
to O
a O
modified O
WHO O
severity O
scale O
, O
and O
pain O
and O
quality-of-life O
assessments O
were O
based O
on O
the O
effect O
of O
symptoms O
of O
OM O
on O
relevant O
daily O
activities O
, O
according O
to O
a O
visual O
analogue O
scale O
. O

Mean B-Premise
scores I-Premise
for I-Premise
the I-Premise
severity I-Premise
of I-Premise
OM I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
versus I-Premise
baseline I-Premise
) I-Premise
reduced I-Premise
from I-Premise
day I-Premise
31 I-Premise
until I-Premise
the I-Premise
end I-Premise
of I-Premise
treatment I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
SAMITAL® I-Premise
( I-Premise
n I-Premise
= I-Premise
20 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
10 I-Premise
) I-Premise
. I-Premise

Pain B-Premise
reduction I-Premise
was I-Premise
significant I-Premise
from I-Premise
day I-Premise
4 I-Premise
till I-Premise
end I-Premise
of I-Premise
treatment I-Premise
with I-Premise
SAMITAL® I-Premise
and I-Premise
from I-Premise
days I-Premise
7 I-Premise
to I-Premise
21 I-Premise
in I-Premise
placebo I-Premise
patients I-Premise
. I-Premise

SAMITAL® B-Premise
also I-Premise
significantly I-Premise
improved I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
as I-Premise
shown I-Premise
by I-Premise
improvements I-Premise
in I-Premise
scores I-Premise
for I-Premise
relevant I-Premise
daily I-Premise
activities I-Premise
including I-Premise
eating I-Premise
, I-Premise
drinking I-Premise
and I-Premise
sleeping I-Premise
. I-Premise

All O
SAMITAL® O
patients O
completed O
the O
treatment O
period O
, O
but O
no O
placebo O
recipients O
completed O
treatment O
. O

No B-Premise
severe I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
with I-Premise
SAMITAL® I-Premise
, I-Premise
and I-Premise
systemic I-Premise
absorption I-Premise
of I-Premise
relevant I-Premise
active I-Premise
ingredients I-Premise
was I-Premise
undetectable I-Premise
. I-Premise

SAMITAL® B-Claim
significantly I-Claim
decreased I-Claim
the I-Claim
severity I-Claim
of I-Claim
chemo/radiotherapy-induced I-Claim
OM I-Claim
in I-Claim
patients I-Claim
with I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
, I-Claim
with I-Claim
no I-Claim
treatment-related I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Pain B-Claim
relief I-Claim
lasted I-Claim
through I-Claim
the I-Claim
treatment I-Claim
period I-Claim
, I-Claim
and I-Claim
improvements I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
were I-Claim
reflected I-Claim
by I-Claim
the I-Claim
significant I-Claim
benefits I-Claim
of I-Claim
SAMITAL® I-Claim
on I-Claim
activities I-Claim
like I-Claim
drinking I-Claim
, I-Claim
eating I-Claim
and I-Claim
speaking I-Claim
. I-Claim

Patients O
who O
develop O
castration-resistant O
prostate O
cancer O
( O
CRPCa O
) O
typically O
continue O
on O
androgen O
deprivation O
therapy O
( O
ADT O
) O
. O

Whether O
these O
patients O
need O
to O
remain O
on O
ADT O
has O
not O
been O
well O
studied O
. O

We O
conducted O
a O
multicenter O
randomized O
trial O
to O
compare O
an O
intermittent O
versus O
continuous O
approach O
to O
ADT O
in O
CRPCa O
patients O
. O

Overall O
survival O
, O
health-related O
quality O
of O
life O
( O
QOL O
) O
, O
and O
cost O
were O
the O
main O
endpoints O
. O

CRPCa O
patients O
were O
randomized O
2:1 O
to O
intermittent O
or O
continuous O
luteinizing O
hormone-releasing O
hormone O
agonists O
( O
LHRHa O
) O
. O

Patients O
were O
followed O
with O
clinical O
assessments O
, O
laboratory O
investigations O
, O
and O
QOL O
questionnaires O
( O
EORTC O
QLQ-C30 O
or O
PROSQOLI O
) O
every O
2 O
months O
. O

If O
the O
serum O
testosterone O
rose O
above O
castrate O
levels O
( O
1.75 O
nmol/L O
) O
, O
LHRHa O
were O
reinitiated O
. O

The O
study O
was O
designed O
to O
close O
if O
> O
50 O
% O
of O
patients O
needed O
to O
restart O
ADT O
in O
the O
intermittent O
arm O
. O

Thirty-one O
patients O
were O
followed O
with O
a O
median O
follow-up O
of O
26.8 O
months-18 O
in O
the O
intermittent O
arm O
and O
13 O
in O
the O
continuous O
. O

Twelve O
of O
18 O
patients O
on O
the O
intermittent O
arm O
were O
reinitiated O
on O
LHRHa O
at O
a O
median O
time O
of O
17.9 O
months O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
or I-Premise
cancer-specific I-Premise
survival I-Premise
between I-Premise
the I-Premise
2 I-Premise
arms I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
between I-Premise
the I-Premise
2 I-Premise
arms I-Premise
at I-Premise
0 I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

The B-Premise
total I-Premise
mean I-Premise
costs I-Premise
at I-Premise
24 I-Premise
months I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
intermittent I-Premise
arm I-Premise
( I-Premise
$ I-Premise
3135 I-Premise
vs. I-Premise
$ I-Premise
8253 I-Premise
Canadian I-Premise
dollars I-Premise
, I-Premise
P=0.0167 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
continuous I-Premise
. I-Premise

The B-Premise
main I-Premise
limitation I-Premise
of I-Premise
this I-Premise
study I-Premise
is I-Premise
the I-Premise
small I-Premise
sample I-Premise
size I-Premise
. I-Premise

We B-Claim
have I-Claim
observed I-Claim
that I-Claim
intermittent I-Claim
ADT I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPCa I-Claim
, I-Claim
using I-Claim
a I-Claim
testosterone I-Claim
of I-Claim
> I-Claim
1.75 I-Claim
ngmol/L I-Claim
as I-Claim
a I-Claim
trigger I-Claim
to I-Claim
reinitiate I-Claim
LHRHa I-Claim
, I-Claim
results I-Claim
in I-Claim
a I-Claim
substantial I-Claim
cost I-Claim
savings I-Claim
with I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
oncologic I-Claim
and I-Claim
QOL I-Claim
outcomes I-Claim
. I-Claim

Menopausal O
hormone O
therapy O
continues O
in O
clinical O
use O
but O
questions O
remain O
regarding O
its O
risks O
and O
benefits O
for O
chronic O
disease O
prevention O
. O

To O
report O
a O
comprehensive O
, O
integrated O
overview O
of O
findings O
from O
the O
2 O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
hormone O
therapy O
trials O
with O
extended O
postintervention O
follow-up O
. O

A O
total O
of O
27,347 O
postmenopausal O
women O
aged O
50 O
to O
79 O
years O
were O
enrolled O
at O
40 O
US O
centers O
. O

Women O
with O
an O
intact O
uterus O
received O
conjugated O
equine O
estrogens O
( O
CEE O
; O
0.625 O
mg/d O
) O
plus O
medroxyprogesterone O
acetate O
( O
MPA O
; O
2.5 O
mg/d O
) O
( O
n O
= O
8506 O
) O
or O
placebo O
( O
n O
= O
8102 O
) O
. O

Women O
with O
prior O
hysterectomy O
received O
CEE O
alone O
( O
0.625 O
mg/d O
) O
( O
n O
= O
5310 O
) O
or O
placebo O
( O
n O
= O
5429 O
) O
. O

The O
intervention O
lasted O
a O
median O
of O
5.6 O
years O
in O
CEE O
plus O
MPA O
trial O
and O
7.2 O
years O
in O
CEE O
alone O
trial O
with O
13 O
years O
of O
cumulative O
follow-up O
until O
September O
30 O
, O
2010 O
. O

Primary O
efficacy O
and O
safety O
outcomes O
were O
coronary O
heart O
disease O
( O
CHD O
) O
and O
invasive O
breast O
cancer O
, O
respectively O
. O

A O
global O
index O
also O
included O
stroke O
, O
pulmonary O
embolism O
, O
colorectal O
cancer O
, O
endometrial O
cancer O
, O
hip O
fracture O
, O
and O
death O
. O

During B-Premise
the I-Premise
CEE I-Premise
plus I-Premise
MPA I-Premise
intervention I-Premise
phase I-Premise
, I-Premise
the I-Premise
numbers I-Premise
of I-Premise
CHD I-Premise
cases I-Premise
were I-Premise
196 I-Premise
for I-Premise
CEE I-Premise
plus I-Premise
MPA I-Premise
vs I-Premise
159 I-Premise
for I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.95-1.45 I-Premise
) I-Premise
and I-Premise
206 I-Premise
vs I-Premise
155 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.24 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.01-1.53 I-Premise
) I-Premise
. I-Premise

Other B-Premise
risks I-Premise
included I-Premise
increased I-Premise
stroke I-Premise
, I-Premise
pulmonary I-Premise
embolism I-Premise
, I-Premise
dementia I-Premise
( I-Premise
in I-Premise
women I-Premise
aged I-Premise
≥65 I-Premise
years I-Premise
) I-Premise
, I-Premise
gallbladder I-Premise
disease I-Premise
, I-Premise
and I-Premise
urinary I-Premise
incontinence I-Premise
; I-Premise
benefits I-Premise
included I-Premise
decreased I-Premise
hip I-Premise
fractures I-Premise
, I-Premise
diabetes I-Premise
, I-Premise
and I-Premise
vasomotor I-Premise
symptoms I-Premise
. I-Premise

Most B-Premise
risks I-Premise
and I-Premise
benefits I-Premise
dissipated I-Premise
postintervention I-Premise
, I-Premise
although B-Premise
some I-Premise
elevation I-Premise
in I-Premise
breast I-Premise
cancer I-Premise
risk I-Premise
persisted I-Premise
during I-Premise
cumulative I-Premise
follow-up I-Premise
( I-Premise
434 I-Premise
cases I-Premise
for I-Premise
CEE I-Premise
plus I-Premise
MPA I-Premise
vs I-Premise
323 I-Premise
for I-Premise
placebo I-Premise
; I-Premise
HR I-Premise
, I-Premise
1.28 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.11-1.48 I-Premise
] I-Premise
) I-Premise
. I-Premise

The B-Premise
risks I-Premise
and I-Premise
benefits I-Premise
were I-Premise
more I-Premise
balanced I-Premise
during I-Premise
the I-Premise
CEE I-Premise
alone I-Premise
intervention I-Premise
with I-Premise
204 I-Premise
CHD I-Premise
cases I-Premise
for I-Premise
CEE I-Premise
alone I-Premise
vs I-Premise
222 I-Premise
cases I-Premise
for I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.94 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.78-1.14 I-Premise
) I-Premise
and I-Premise
104 I-Premise
vs I-Premise
135 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.79 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.61-1.02 I-Premise
) I-Premise
; I-Premise
cumulatively I-Premise
, I-Premise
there I-Premise
were I-Premise
168 I-Premise
vs I-Premise
216 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
cases I-Premise
of I-Premise
breast I-Premise
cancer I-Premise
diagnosed I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.79 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.65-0.97 I-Premise
) I-Premise
. I-Premise

Results O
for O
other O
outcomes O
were O
similar O
to O
CEE O
plus O
MPA O
. O

Neither O
regimen O
affected O
all-cause O
mortality O
. O

For B-Premise
CEE I-Premise
alone I-Premise
, I-Premise
younger I-Premise
women I-Premise
( I-Premise
aged I-Premise
50-59 I-Premise
years I-Premise
) I-Premise
had I-Premise
more I-Premise
favorable I-Premise
results I-Premise
for I-Premise
all-cause I-Premise
mortality I-Premise
, I-Premise
myocardial I-Premise
infarction I-Premise
, I-Premise
and I-Premise
the I-Premise
global I-Premise
index I-Premise
( I-Premise
nominal I-Premise
P I-Premise
< I-Premise
.05 I-Premise
for I-Premise
trend I-Premise
by I-Premise
age I-Premise
) I-Premise
. I-Premise

Absolute B-Premise
risks I-Premise
of I-Premise
adverse I-Premise
events I-Premise
( I-Premise
measured I-Premise
by I-Premise
the I-Premise
global I-Premise
index I-Premise
) I-Premise
per I-Premise
10,000 I-Premise
women I-Premise
annually I-Premise
taking I-Premise
CEE I-Premise
plus I-Premise
MPA I-Premise
ranged I-Premise
from I-Premise
12 I-Premise
excess I-Premise
cases I-Premise
for I-Premise
ages I-Premise
of I-Premise
50-59 I-Premise
years I-Premise
to I-Premise
38 I-Premise
for I-Premise
ages I-Premise
of I-Premise
70-79 I-Premise
years I-Premise
; I-Premise
for I-Premise
women I-Premise
taking I-Premise
CEE I-Premise
alone I-Premise
, I-Premise
from I-Premise
19 I-Premise
fewer I-Premise
cases I-Premise
for I-Premise
ages I-Premise
of I-Premise
50-59 I-Premise
years I-Premise
to I-Premise
51 I-Premise
excess I-Premise
cases I-Premise
for I-Premise
ages I-Premise
of I-Premise
70-79 I-Premise
years I-Premise
. I-Premise

Quality-of-life O
outcomes O
had O
mixed O
results O
in O
both O
trials O
. O

Menopausal B-Claim
hormone I-Claim
therapy I-Claim
has I-Claim
a I-Claim
complex I-Claim
pattern I-Claim
of I-Claim
risks I-Claim
and I-Claim
benefits I-Claim
. I-Claim

Findings B-Claim
from I-Claim
the I-Claim
intervention I-Claim
and I-Claim
extended I-Claim
postintervention I-Claim
follow-up I-Claim
of I-Claim
the I-Claim
2 I-Claim
WHI I-Claim
hormone I-Claim
therapy I-Claim
trials I-Claim
do I-Claim
not I-Claim
support I-Claim
use I-Claim
of I-Claim
this I-Claim
therapy I-Claim
for I-Claim
chronic I-Claim
disease I-Claim
prevention I-Claim
, I-Claim
although B-Claim
it I-Claim
is I-Claim
appropriate I-Claim
for I-Claim
symptom I-Claim
management I-Claim
in I-Claim
some I-Claim
women I-Claim
. I-Claim

Colorectal O
cancer O
survivors O
are O
at O
risk O
for O
poor O
health O
outcomes O
because O
of O
unhealthy O
lifestyles O
, O
but O
few O
studies O
have O
developed O
translatable O
health O
behavior O
change O
interventions O
. O

This O
study O
aimed O
to O
determine O
the O
effects O
of O
a O
telephone-delivered O
multiple O
health O
behavior O
change O
intervention O
( O
CanChange O
) O
on O
health O
and O
behavioral O
outcomes O
among O
colorectal O
cancer O
survivors O
. O

In O
this O
two-group O
randomized O
controlled O
trial O
, O
410 O
colorectal O
cancer O
survivors O
were O
randomly O
assigned O
to O
the O
health O
coaching O
intervention O
( O
11 O
theory-based O
telephone-delivered O
health O
coaching O
sessions O
delivered O
over O
6 O
months O
focusing O
on O
physical O
activity O
, O
weight O
management O
, O
dietary O
habits O
, O
alcohol O
, O
and O
smoking O
) O
or O
usual O
care O
. O

Assessment O
of O
primary O
( O
ie O
, O
physical O
activity O
[ O
Godin O
Leisure O
Time O
Index O
] O
, O
health-related O
quality O
of O
life O
[ O
HRQoL O
; O
Short O
Form-36 O
] O
, O
and O
cancer-related O
fatigue O
[ O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Fatigue O
Scale O
] O
) O
and O
secondary O
outcomes O
( O
ie O
, O
body O
mass O
index O
[ O
kg/m O
( O
2 O
) O
] O
, O
diet O
and O
alcohol O
intake O
[ O
Food O
Frequency O
Questionnaire O
] O
, O
and O
smoking O
) O
were O
conducted O
at O
baseline O
and O
6 O
and O
12 O
months O
. O

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
significant I-Premise
intervention I-Premise
effects I-Premise
were I-Premise
observed I-Premise
for I-Premise
moderate I-Premise
physical I-Premise
activity I-Premise
( I-Premise
28.5 I-Premise
minutes I-Premise
; I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
-0.9 I-Premise
kg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
; I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
energy I-Premise
from I-Premise
total I-Premise
fat I-Premise
( I-Premise
-7.0 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
, I-Premise
and I-Premise
energy I-Premise
from I-Premise
saturated I-Premise
fat I-Premise
( I-Premise
-2.8 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
.016 I-Premise
) I-Premise
. I-Premise

A B-Premise
significant I-Premise
intervention I-Premise
effect I-Premise
was I-Premise
reported I-Premise
for I-Premise
vegetable I-Premise
intake I-Premise
( I-Premise
0.4 I-Premise
servings I-Premise
per I-Premise
day I-Premise
; I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise

No B-Premise
significant I-Premise
group I-Premise
differences I-Premise
were I-Premise
found I-Premise
at I-Premise
6 I-Premise
or I-Premise
12 I-Premise
months I-Premise
for I-Premise
HRQoL I-Premise
, I-Premise
cancer-related I-Premise
fatigue I-Premise
, I-Premise
fruit I-Premise
, I-Premise
fiber I-Premise
, I-Premise
or I-Premise
alcohol I-Premise
intake I-Premise
, I-Premise
or I-Premise
smoking I-Premise
. I-Premise

The B-Claim
CanChange I-Claim
intervention I-Claim
was I-Claim
effective I-Claim
for I-Claim
improving I-Claim
physical I-Claim
activity I-Claim
, I-Claim
dietary I-Claim
habits I-Claim
, I-Claim
and I-Claim
body I-Claim
mass I-Claim
index I-Claim
in I-Claim
colorectal I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

The O
intervention O
is O
translatable O
through O
existing O
telephone O
cancer O
support O
and O
information O
services O
in O
Australia O
and O
other O
countries O
. O

Evaluation O
of O
health-related O
quality-of-life O
( O
HRQoL O
) O
and O
symptom O
improvement O
were O
preplanned O
secondary O
objectives O
for O
the O
overall O
population O
and O
posthoc O
analyses O
for O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
mutation-positive/negative O
subgroups O
in O
IPASS O
. O

HRQoL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
( O
FACT-L O
) O
and O
Trial O
Outcome O
Index O
( O
TOI O
) O
; O
symptom O
improvement O
by O
the O
Lung O
Cancer O
Subscale O
( O
LCS O
) O
. O

Improvements O
defined O
as O
: O
6 O
or O
more O
( O
FACT-L O
; O
TOI O
) O
, O
2 O
or O
more O
( O
LCS O
) O
points O
increase O
maintained O
for O
21 O
or O
more O
days O
. O

Overall O
( O
n O
= O
1151/1217 O
evaluable O
) O
, O
HRQoL O
improvement O
rates O
were O
significantly O
greater O
with O
gefitinib O
versus O
carboplatin/paclitaxel O
; O
symptom O
improvement O
rates O
were O
similar O
for O
both O
treatments O
. O

Significantly B-Premise
more I-Premise
patients I-Premise
recorded I-Premise
improvements I-Premise
in I-Premise
HRQoL I-Premise
and I-Premise
symptoms I-Premise
with I-Premise
gefitinib I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
mutation-positive I-Premise
subgroup I-Premise
( I-Premise
n I-Premise
= I-Premise
259 I-Premise
; I-Premise
FACT-L I-Premise
70.2 I-Premise
% I-Premise
versus I-Premise
44.5 I-Premise
% I-Premise
; I-Premise
odds I-Premise
ratio I-Premise
, I-Premise
3.01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.79-5.07 I-Premise
] I-Premise
; I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
; I-Premise
TOI I-Premise
70.2 I-Premise
% I-Premise
versus I-Premise
38.3 I-Premise
% I-Premise
; I-Premise
3.96 I-Premise
[ I-Premise
2.33-6.71 I-Premise
] I-Premise
; I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
; I-Premise
LCS I-Premise
75.6 I-Premise
% I-Premise
versus I-Premise
53.9 I-Premise
% I-Premise
; I-Premise
2.70 I-Premise
[ I-Premise
1.58-4.62 I-Premise
] I-Premise
; I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
with I-Premise
carboplatin/paclitaxel I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
mutation-negative I-Premise
subgroup I-Premise
( I-Premise
n I-Premise
= I-Premise
169 I-Premise
; I-Premise
FACT-L I-Premise
14.6 I-Premise
% I-Premise
versus I-Premise
36.3 I-Premise
% I-Premise
; I-Premise
odds I-Premise
ratio I-Premise
, I-Premise
0.31 I-Premise
[ I-Premise
0.15-0.65 I-Premise
] I-Premise
; I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
; I-Premise
TOI I-Premise
12.4 I-Premise
% I-Premise
versus I-Premise
28.8 I-Premise
% I-Premise
; I-Premise
0.35 I-Premise
[ I-Premise
0.16-0.79 I-Premise
] I-Premise
; I-Premise
p I-Premise
= I-Premise
0.011 I-Premise
; I-Premise
LCS I-Premise
20.2 I-Premise
% I-Premise
versus I-Premise
47.5 I-Premise
% I-Premise
; I-Premise
0.28 I-Premise
[ I-Premise
0.14-0.55 I-Premise
] I-Premise
; I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time-to-worsening I-Premise
( I-Premise
months I-Premise
) I-Premise
FACT-L I-Premise
score I-Premise
was I-Premise
longer I-Premise
with I-Premise
gefitinib I-Premise
versus I-Premise
carboplatin/paclitaxel I-Premise
for I-Premise
the I-Premise
overall I-Premise
population I-Premise
( I-Premise
8.3 I-Premise
versus I-Premise
2.5 I-Premise
) I-Premise
and I-Premise
EGFR I-Premise
mutation-positive I-Premise
subgroup I-Premise
( I-Premise
15.6 I-Premise
versus I-Premise
3.0 I-Premise
) I-Premise
, I-Premise
and I-Premise
similar I-Premise
for I-Premise
both I-Premise
treatments I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
mutation-negative I-Premise
subgroup I-Premise
( I-Premise
1.4 I-Premise
versus I-Premise
1.4 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time-to-improvement I-Premise
with I-Premise
gefitinib I-Premise
was I-Premise
8 I-Premise
days I-Premise
in I-Premise
patients I-Premise
with I-Premise
EGFR I-Premise
mutation-positive I-Premise
tumors I-Premise
who I-Premise
improved I-Premise
. I-Premise

HRQoL B-Claim
and I-Claim
symptom I-Claim
endpoints I-Claim
were I-Claim
consistent I-Claim
with I-Claim
efficacy I-Claim
outcomes I-Claim
in I-Claim
IPASS I-Claim
and I-Claim
favored I-Claim
gefitinib I-Claim
in I-Claim
patients I-Claim
with I-Claim
EGFR I-Claim
mutation-positive I-Claim
tumors I-Claim
and I-Claim
carboplatin/paclitaxel I-Claim
in I-Claim
patients I-Claim
with I-Claim
EGFR I-Claim
mutation-negative I-Claim
tumors I-Claim
. I-Claim

In B-Claim
a I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
infusion I-Claim
with I-Claim
adenosine I-Claim
5'-triphosphate I-Claim
( I-Claim
ATP I-Claim
) I-Claim
inhibited I-Claim
loss I-Claim
of I-Claim
body I-Claim
weight I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

In O
the O
present O
article O
, O
the O
effects O
of O
ATP O
on O
body O
composition O
, O
energy O
intake O
, O
and O
energy O
expenditure O
as O
secondary O
outcome O
measures O
in O
the O
same O
patients O
are O
reported O
. O

Patients O
with O
NSCLC O
, O
stage O
IIIB O
or O
IV O
, O
were O
randomized O
to O
receive O
either O
10 O
intravenous O
, O
30-hour O
ATP O
infusions O
every O
2 O
to O
4 O
weeks O
or O
no O
ATP O
. O

Fat O
mass O
( O
FM O
) O
, O
fat-free O
mass O
( O
FFM O
) O
, O
and O
arm O
muscle O
area O
were O
assessed O
at O
4-week O
intervals O
for O
28 O
weeks O
. O

Food O
intake O
, O
body O
cell O
mass O
( O
BCM O
) O
, O
and O
resting O
energy O
expenditure O
( O
REE O
) O
were O
assessed O
at O
8-week O
intervals O
for O
16 O
weeks O
. O

Between-group O
differences O
were O
tested O
for O
statistical O
significance O
by O
repeated-measures O
analysis O
of O
covariance O
. O

Fifty-eight O
patients O
were O
randomized O
( O
28 O
ATP O
, O
30 O
control O
) O
. O

No B-Premise
change I-Premise
in I-Premise
body I-Premise
composition I-Premise
over I-Premise
the I-Premise
28-week I-Premise
follow-up I-Premise
period I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
, I-Premise
whereas I-Premise
, I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
, I-Premise
the I-Premise
control I-Premise
group I-Premise
lost I-Premise
0.6 I-Premise
kg I-Premise
of I-Premise
FM I-Premise
( I-Premise
P I-Premise
=.004 I-Premise
) I-Premise
, I-Premise
0.5 I-Premise
kg I-Premise
of I-Premise
FFM I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
, I-Premise
1.8 I-Premise
% I-Premise
of I-Premise
arm I-Premise
muscle I-Premise
area I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
0.6 I-Premise
% I-Premise
of I-Premise
BCM/kg I-Premise
body I-Premise
weight I-Premise
( I-Premise
P I-Premise
=.054 I-Premise
) I-Premise
and I-Premise
decreased I-Premise
568 I-Premise
KJ/d I-Premise
in I-Premise
energy I-Premise
intake I-Premise
( I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

Appetite B-Premise
also I-Premise
remained I-Premise
stable I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
but I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
=.0004 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
in I-Premise
REE I-Premise
between I-Premise
the I-Premise
ATP I-Premise
and I-Premise
control I-Premise
groups I-Premise
were I-Premise
observed I-Premise
. I-Premise

The B-Claim
inhibition I-Claim
of I-Claim
weight I-Claim
loss I-Claim
by I-Claim
ATP I-Claim
infusions I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
is I-Claim
attributed I-Claim
to I-Claim
counteracting I-Claim
the I-Claim
loss I-Claim
of I-Claim
both I-Claim
metabolically I-Claim
active I-Claim
and I-Claim
inactive I-Claim
tissues I-Claim
. I-Claim

These B-Premise
effects I-Premise
are I-Premise
partly I-Premise
ascribed I-Premise
to I-Premise
maintenance I-Premise
of I-Premise
energy I-Premise
intake I-Premise
. I-Premise

To O
evaluate O
whether O
treatment O
with O
single-agent O
docetaxel O
would O
result O
in O
longer O
survival O
than O
would O
best O
supportive O
care O
in O
patients O
with O
non-small-cell O
lung O
cancer O
who O
had O
previously O
been O
treated O
with O
platinum-based O
chemotherapy O
. O

Secondary O
end O
points O
included O
assessment O
of O
response O
( O
docetaxel O
arm O
only O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Patients O
with O
performance O
statuses O
of O
0 O
to O
2 O
and O
stage O
IIIB/IV O
non-small-cell O
lung O
cancer O
with O
either O
measurable O
or O
evaluable O
lesions O
were O
eligible O
for O
entry O
onto O
the O
study O
if O
they O
had O
undergone O
one O
or O
more O
platinum-based O
chemotherapy O
regimens O
and O
if O
they O
had O
adequate O
hematology O
and O
biochemistry O
parameters O
. O

They O
were O
excluded O
if O
they O
had O
symptomatic O
brain O
metastases O
or O
if O
they O
had O
previously O
been O
treated O
with O
paclitaxel O
. O

Patients O
were O
stratified O
by O
performance O
status O
and O
best O
response O
to O
cisplatin O
chemotherapy O
and O
were O
then O
randomized O
to O
treatment O
with O
docetaxel O
100 O
mg/m O
( O
2 O
) O
( O
49 O
patients O
) O
or O
75 O
mg/m O
( O
2 O
) O
( O
55 O
patients O
) O
or O
best O
supportive O
care O
. O

Patients O
in O
both O
arms O
were O
assessed O
every O
3 O
weeks O
. O

One O
hundred O
four O
patients O
( O
103 O
of O
whom O
were O
eligible O
for O
entry O
onto O
the O
study O
) O
were O
well O
balanced O
for O
prognostic O
factors O
. O

Of O
84 O
patients O
with O
measurable O
lesions O
, O
six O
( O
7 O
. O

1 O
% O
) O
achieved O
partial O
responses O
( O
three O
patients O
at O
each O
dose O
level O
) O
. O

Time B-Premise
to I-Premise
progression I-Premise
was I-Premise
longer I-Premise
for I-Premise
docetaxel I-Premise
patients I-Premise
than I-Premise
for I-Premise
best I-Premise
supportive I-Premise
care I-Premise
patients I-Premise
( I-Premise
10.6 I-Premise
v I-Premise
6.7 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
survival I-Premise
( I-Premise
7.0 I-Premise
v I-Premise
4.6 I-Premise
months I-Premise
; I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
=.047 I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
was I-Premise
more I-Premise
significant I-Premise
for I-Premise
docetaxel I-Premise
75 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
patients I-Premise
, I-Premise
compared I-Premise
with I-Premise
corresponding I-Premise
best I-Premise
supportive I-Premise
care I-Premise
patients I-Premise
( I-Premise
7.5 I-Premise
v I-Premise
4.6 I-Premise
months I-Premise
; I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
=.010 I-Premise
; I-Premise
1-year I-Premise
survival I-Premise
, I-Premise
37 I-Premise
% I-Premise
v I-Premise
11 I-Premise
% I-Premise
; I-Premise
chi I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
, I-Premise
P I-Premise
=.003 I-Premise
) I-Premise
. I-Premise

Febrile B-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
11 I-Premise
patients I-Premise
treated I-Premise
with I-Premise
docetaxel I-Premise
100 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
, I-Premise
three I-Premise
of I-Premise
whom I-Premise
died I-Premise
, I-Premise
and I-Premise
in I-Premise
one I-Premise
patient I-Premise
treated I-Premise
with I-Premise
docetaxel I-Premise
75 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
nonhematologic I-Premise
toxicity I-Premise
, I-Premise
with I-Premise
the I-Premise
exception I-Premise
of I-Premise
diarrhea I-Premise
, I-Premise
occurred I-Premise
at I-Premise
a I-Premise
similar I-Premise
rate I-Premise
in I-Premise
both I-Premise
the I-Premise
docetaxel I-Premise
and I-Premise
best I-Premise
supportive I-Premise
care I-Premise
groups I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
docetaxel I-Claim
is I-Claim
associated I-Claim
with I-Claim
significant I-Claim
prolongation I-Claim
of I-Claim
survival I-Claim
, I-Claim
and O
at B-Claim
a I-Claim
dose I-Claim
of I-Claim
75 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
the I-Claim
benefits I-Claim
of I-Claim
docetaxel I-Claim
therapy I-Claim
outweigh I-Claim
the I-Claim
risks I-Claim
. I-Claim

Enhanced O
recovery O
programmes O
( O
ERPs O
) O
have O
been O
shown O
to O
reduce O
length O
of O
hospital O
stay O
( O
LOS O
) O
and O
complications O
in O
colorectal O
surgery O
. O

Whether O
ERPs O
have O
the O
same O
benefits O
in O
open O
liver O
resection O
surgery O
is O
unclear O
, O
and O
randomized O
clinical O
trials O
are O
lacking O
. O

Consecutive O
patients O
scheduled O
for O
open O
liver O
resection O
were O
randomized O
to O
an O
ERP O
group O
or O
standard O
care O
. O

Primary O
endpoints O
were O
time O
until O
medically O
fit O
for O
discharge O
( O
MFD O
) O
and O
LOS O
. O

Secondary O
endpoints O
were O
postoperative O
morbidity O
, O
pain O
scores O
, O
readmission O
rate O
, O
mortality O
, O
quality O
of O
life O
( O
QoL O
) O
and O
patient O
satisfaction O
. O

ERP O
elements O
included O
greater O
preoperative O
education O
, O
preoperative O
oral O
carbohydrate O
loading O
, O
postoperative O
goal-directed O
fluid O
therapy O
, O
early O
mobilization O
and O
physiotherapy O
. O

Both O
groups O
received O
standardized O
anaesthesia O
with O
epidural O
analgesia O
. O

The O
analysis O
included O
46 O
patients O
in O
the O
ERP O
group O
and O
45 O
in O
the O
standard O
care O
group O
. O

Median B-Premise
MFD I-Premise
time I-Premise
was I-Premise
reduced I-Premise
in I-Premise
the I-Premise
ERP I-Premise
group I-Premise
( I-Premise
3 I-Premise
days I-Premise
versus I-Premise
6 I-Premise
days I-Premise
with I-Premise
standard I-Premise
care I-Premise
; I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
LOS I-Premise
( I-Premise
4 I-Premise
days I-Premise
versus I-Premise
7 I-Premise
days I-Premise
; I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

The B-Premise
ERP I-Premise
significantly I-Premise
reduced I-Premise
the I-Premise
rate I-Premise
of I-Premise
medical I-Premise
complications I-Premise
( I-Premise
7 I-Premise
versus I-Premise
27 I-Premise
per I-Premise
cent I-Premise
; I-Premise
P I-Premise
= I-Premise
0·020 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
surgical I-Premise
complications I-Premise
( I-Premise
15 I-Premise
versus I-Premise
11 I-Premise
per I-Premise
cent I-Premise
; I-Premise
P I-Premise
= I-Premise
0·612 I-Premise
) I-Premise
, I-Premise
readmissions I-Premise
( I-Premise
4 I-Premise
versus I-Premise
0 I-Premise
per I-Premise
cent I-Premise
; I-Premise
P I-Premise
= I-Premise
0·153 I-Premise
) I-Premise
or I-Premise
mortality I-Premise
( I-Premise
both I-Premise
2 I-Premise
per I-Premise
cent I-Premise
; I-Premise
P I-Premise
= I-Premise
0·987 I-Premise
) I-Premise
. I-Premise

QoL B-Premise
over I-Premise
28 I-Premise
days I-Premise
was I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
ERP I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0·002 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
patient I-Premise
satisfaction I-Premise
. I-Premise

ERPs B-Claim
for I-Claim
open I-Claim
liver I-Claim
resection I-Claim
surgery I-Claim
are I-Claim
safe I-Claim
and I-Claim
effective I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
in I-Claim
the I-Claim
ERP I-Claim
recovered I-Claim
faster I-Claim
, I-Claim
were I-Claim
discharged I-Claim
sooner I-Claim
, I-Claim
and I-Claim
had I-Claim
fewer I-Claim
medical-related I-Claim
complications I-Claim
and I-Claim
improved I-Claim
QoL I-Claim
. I-Claim

Although O
chemotherapy-induced O
cognitive O
impairment O
is O
common O
among O
breast O
cancer O
patients O
, O
evidence O
for O
effective O
interventions O
addressing O
cognitive O
deficits O
is O
limited O
. O

This O
randomized O
controlled O
trial O
examined O
the O
feasibility O
and O
preliminary O
efficacy O
of O
a O
Tibetan O
Sound O
Meditation O
( O
TSM O
) O
program O
to O
improve O
cognitive O
function O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
. O

Forty-seven O
breast O
cancer O
patients O
( O
mean O
age O
56.3 O
years O
) O
, O
who O
were O
staged O
I-III O
at O
diagnosis O
, O
6-60 O
months O
post-chemotherapy O
, O
and O
reported O
cognitive O
impairment O
at O
study O
entry O
were O
recruited O
. O

Participants O
were O
randomized O
to O
either O
two O
weekly O
TSM O
sessions O
for O
6 O
weeks O
or O
a O
wait O
list O
control O
group O
. O

Neuropsychological O
assessments O
were O
completed O
at O
baseline O
and O
1 O
month O
post-treatment O
. O

Self-report O
measures O
of O
cognitive O
function O
( O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
-Cog O
) O
, O
quality O
of O
life O
( O
SF-36 O
) O
, O
depressive O
symptoms O
( O
Center O
for O
Epidemiologic O
Studies O
Depression O
Scale O
) O
, O
sleep O
disturbance O
( O
Pittsburgh O
Sleep O
Quality O
Index O
) O
, O
fatigue O
( O
Brief O
Fatigue O
Inventory O
) O
, O
and O
spirituality O
( O
FACT-Sp O
) O
were O
completed O
at O
baseline O
, O
the O
end O
of O
treatment O
, O
and O
1 O
month O
later O
. O

Relative B-Premise
to I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
women I-Premise
in I-Premise
the I-Premise
TSM I-Premise
group I-Premise
performed I-Premise
better I-Premise
on I-Premise
the I-Premise
verbal I-Premise
memory I-Premise
test I-Premise
( I-Premise
Rey I-Premise
Auditory I-Premise
Verbal I-Premise
Learning I-Premise
Test I-Premise
trial I-Premise
1 I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.06 I-Premise
) I-Premise
and I-Premise
the I-Premise
short-term I-Premise
memory I-Premise
and I-Premise
processing I-Premise
speed I-Premise
task I-Premise
( I-Premise
Digit I-Premise
Symbol I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.09 I-Premise
) I-Premise
and I-Premise
reported I-Premise
improved I-Premise
cognitive I-Premise
function I-Premise
( I-Premise
p I-Premise
= I-Premise
0.06 I-Premise
) I-Premise
, I-Premise
cognitive I-Premise
abilities I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
, I-Premise
mental I-Premise
health I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
spirituality I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
treatment I-Premise
but I-Premise
not I-Premise
1 I-Premise
month I-Premise
later I-Premise
. I-Premise

This B-Claim
randomized I-Claim
controlled I-Claim
trial I-Claim
revealed I-Claim
that I-Claim
TSM I-Claim
program I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
feasible I-Claim
and I-Claim
acceptable I-Claim
intervention I-Claim
and I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
short-term I-Claim
improvements I-Claim
in I-Claim
objective I-Claim
and I-Claim
subjective I-Claim
cognitive I-Claim
function I-Claim
as I-Claim
well I-Claim
as I-Claim
mental I-Claim
health I-Claim
and I-Claim
spirituality I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
choice I-Claim
of I-Claim
reconstruction I-Claim
after I-Claim
gastrectomy I-Claim
and I-Claim
the I-Claim
significance I-Claim
of I-Claim
remaining I-Claim
reservoir I-Claim
function I-Claim
is I-Claim
a I-Claim
matter I-Claim
of I-Claim
controversy I-Claim
. I-Claim

To O
broaden O
the O
criteria O
for O
choice O
of O
treatment O
, O
we O
conducted O
a O
prospective O
randomized O
clinical O
trial O
to O
determine O
the O
impact O
of O
various O
gastrectomy O
procedures O
on O
quality O
of O
life O
. O

Consecutive O
patients O
( O
n O
= O
64 O
) O
eligible O
for O
curative O
gastric O
cancer O
surgery O
were O
randomized O
to O
have O
either O
a O
total O
( O
n O
= O
31 O
) O
or O
subtotal O
( O
n O
= O
13 O
) O
gastrectomy O
or O
a O
jejunal O
S-shaped O
pouch O
( O
n O
= O
20 O
) O
implanted O
as O
a O
gastric O
substitute O
. O

The O
quality-of-life O
evaluation O
was O
based O
on O
a O
battery O
of O
questionnaires O
covering O
both O
general O
and O
specific O
aspects O
of O
life O
. O

The O
patients O
were O
rated O
by O
one O
of O
two O
psychiatrists O
who O
were O
blinded O
to O
the O
patients O
' O
group O
affiliation O
. O

Assessments O
were O
made O
on O
three O
occasions O
: O
during O
the O
week O
prior O
to O
surgery O
and O
3 O
and O
12 O
months O
after O
the O
surgical O
intervention O
. O

The B-Premise
postoperative I-Premise
complication I-Premise
and I-Premise
mortality I-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
with I-Premise
few I-Premise
serious I-Premise
complications I-Premise
recorded I-Premise
. I-Premise

Irrespective B-Premise
of I-Premise
type I-Premise
of I-Premise
treatment I-Premise
, I-Premise
the I-Premise
patients I-Premise
suffered I-Premise
from I-Premise
alimentary I-Premise
symptoms I-Premise
and I-Premise
functional I-Premise
limitations I-Premise
in I-Premise
everyday I-Premise
life I-Premise
, I-Premise
whereas B-Premise
their I-Premise
mental I-Premise
well-being I-Premise
improved I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Patients B-Premise
who I-Premise
underwent I-Premise
subtotal I-Premise
gastrectomy I-Premise
had I-Premise
the I-Premise
best I-Premise
outcome I-Premise
, I-Premise
especially I-Premise
with I-Premise
respect I-Premise
to I-Premise
complaints I-Premise
of I-Premise
diarrhea I-Premise
. I-Premise

Patients B-Premise
given I-Premise
a I-Premise
gastric I-Premise
substitute I-Premise
after I-Premise
gastrectomy I-Premise
showed I-Premise
no I-Premise
difference I-Premise
from I-Premise
those I-Premise
who I-Premise
had I-Premise
only I-Premise
a I-Premise
total I-Premise
gastrectomy I-Premise
. I-Premise

We B-Claim
conclude I-Claim
that I-Claim
despite I-Claim
significant I-Claim
unfavorable I-Claim
consequences I-Claim
that I-Claim
follow I-Claim
gastrectomy I-Claim
, I-Claim
patients I-Claim
recover I-Claim
with I-Claim
an I-Claim
improved I-Claim
mental I-Claim
status I-Claim
. I-Claim

A B-Claim
pouch I-Claim
reconstruction I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
does I-Claim
not I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
but O
a B-Claim
subtotal I-Claim
gastrectomy I-Claim
has I-Claim
advantages I-Claim
that I-Claim
must I-Claim
be I-Claim
considered I-Claim
when I-Claim
the I-Claim
procedure I-Claim
is I-Claim
clinically I-Claim
feasible I-Claim
. I-Claim

To O
evaluate O
the O
effect O
of O
epoetin O
alfa O
on O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
solid O
tumors O
and O
mild-to-moderate O
anemia O
receiving O
platinum-based O
chemotherapy O
relative O
to O
population O
norms O
. O

In O
the O
original O
study O
, O
patients O
( O
n O
= O
316 O
) O
with O
hemoglobin O
( O
Hb O
) O
levels O
< O
or O
=12.1 O
g/dl O
were O
randomized O
2:1 O
to O
receive O
either O
epoetin O
alfa O
at O
a O
dose O
of O
10,000 O
U O
thrice O
weekly O
s.c. O
or O
best O
supportive O
care O
( O
BSC O
) O
to O
compare O
the O
effects O
on O
transfusion O
use O
, O
hematologic O
response O
, O
and O
QOL O
( O
measured O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
[ O
FACT-An O
] O
and O
Cancer O
Linear O
Analogue O
Scale O
[ O
CLAS O
] O
) O
. O

The O
QOL O
data O
from O
this O
previously O
reported O
trial O
were O
reanalyzed O
here O
relative O
to O
population O
norms O
. O

Mean O
baseline O
QOL O
scores O
were O
similar O
between O
groups O
. O

At O
study O
completion O
, O
mean O
CLAS O
, O
FACT-An O
, O
FACT-An O
Anemia O
subscale O
, O
and O
FACT-An O
Fatigue O
subscale O
scores O
were O
significantly O
higher O
for O
patients O
given O
epoetin O
alfa O
than O
for O
those O
treated O
with O
BSC O
. O

Compared O
with O
population O
norms O
, O
both O
groups O
had O
impaired O
QOL O
at O
baseline O
. O

Differences B-Premise
in I-Premise
mean I-Premise
QOL I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
study I-Premise
end I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
versus I-Premise
BSC I-Premise
were I-Premise
3.17 I-Premise
points I-Premise
for I-Premise
the I-Premise
FACT-General I-Premise
Total I-Premise
, I-Premise
9.90 I-Premise
for I-Premise
the I-Premise
FACT-An I-Premise
Fatigue I-Premise
subscale I-Premise
, I-Premise
and I-Premise
7.30 I-Premise
for I-Premise
the I-Premise
FACT-An I-Premise
Anemia I-Premise
subscale I-Premise
. I-Premise

This B-Premise
was I-Premise
equivalent I-Premise
to I-Premise
corrections I-Premise
in I-Premise
QOL I-Premise
deficits I-Premise
attributable I-Premise
to I-Premise
epoetin I-Premise
alfa I-Premise
of I-Premise
97.3 I-Premise
% I-Premise
, I-Premise
40.7 I-Premise
% I-Premise
, I-Premise
and I-Premise
38.0 I-Premise
% I-Premise
for I-Premise
the I-Premise
FACT-General I-Premise
Total I-Premise
, I-Premise
FACT-An I-Premise
Fatigue I-Premise
, I-Premise
and I-Premise
FACT-An I-Premise
Anemia I-Premise
subscale I-Premise
scores I-Premise
, I-Premise
respectively I-Premise
, I-Premise
versus I-Premise
BSC I-Premise
. I-Premise

A B-Premise
somewhat I-Premise
greater I-Premise
QOL I-Premise
benefit I-Premise
was I-Premise
observed I-Premise
for I-Premise
the I-Premise
FACT-An I-Premise
Fatigue I-Premise
and I-Premise
FACT-An I-Premise
Anemia I-Premise
subscales I-Premise
in I-Premise
the I-Premise
subset I-Premise
of I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
10.5 I-Premise
g/dl I-Premise
. I-Premise

Patients B-Premise
in I-Premise
this I-Premise
study I-Premise
had I-Premise
impaired I-Premise
QOL I-Premise
compared I-Premise
with I-Premise
population I-Premise
norms I-Premise
. I-Premise

Early B-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
to I-Claim
correct I-Claim
anemia I-Claim
improved I-Claim
QOL I-Claim
in I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
way I-Claim
, I-Claim
and I-Claim
improvements I-Claim
were I-Claim
greater I-Claim
in I-Claim
patients I-Claim
with I-Claim
baseline I-Claim
Hb I-Claim
levels I-Claim
> I-Claim
10.5 I-Claim
g/dl I-Claim
. I-Claim

To O
observe O
the O
effect O
of O
Chinese O
medicine O
( O
CM O
) O
comprehensive O
regimen O
as O
the O
maintenance O
therapy O
( O
MT O
) O
on O
time O
to O
progression O
( O
TTP O
) O
and O
quality O
of O
life O
( O
QOL O
) O
of O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
study O
was O
a O
prospective O
, O
randomized O
and O
controlled O
clinical O
trial O
. O

Fifty O
non-progressive O
patients O
with O
advanced O
NSCLC O
who O
responded O
to O
first-line O
therapy O
were O
randomized O
into O
the O
test O
group O
( O
25 O
cases O
, O
treated O
with O
CM O
comprehensive O
regimen O
: O
intravenous O
dripping O
of O
Chinese O
herbal O
preparation O
, O
oral O
administration O
of O
Chinese O
herbal O
decoction O
, O
and O
point O
application O
) O
and O
the O
control O
group O
[ O
25 O
cases O
, O
treated O
with O
one O
of O
three O
single-agent O
maintenance O
chemotherapy O
regimens O
: O
pemetrexed O
( O
500 O
mg/m2 O
, O
day O
1 O
) O
, O
docetaxel O
( O
75 O
mg/m2 O
, O
day O
1 O
) O
, O
and O
gemcitabine O
( O
1000 O
mg/mi O
, O
day O
1 O
and O
day O
8 O
) O
in O
the O
ratio O
of O
1:1 O
] O
. O

Each O
cycle O
consisted O
of O
21 O
days O
. O

Cycles O
were O
repeated O
until O
the O
disease O
progressed O
, O
or O
intolerable O
toxic O
or O
adverse O
reaction O
occurred O
, O
or O
patients O
refused O
to O
continue O
the O
treatment O
. O

The O
primary O
end O
point O
was O
TTP O
and O
the O
secondary O
end O
point O
was O
QOL O
. O

QOL O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
quality-of-life O
questionnaire O
QLQ-LC43 O
( O
EORTC O
QLQ-LC43 O
) O
. O

TTP O
of O
fifty O
patients O
and O
QOL O
of O
43 O
patients O
had O
been O
statistically O
analyzed O
. O

( O
1 O
) O
The B-Premise
TTP I-Premise
in I-Premise
the I-Premise
test I-Premise
group I-Premise
was I-Premise
prolonged I-Premise
for I-Premise
23 I-Premise
days I-Premise
when I-Premise
compared I-Premise
with I-Premise
that I-Premise
of I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
with I-Premise
insignificant I-Premise
difference I-Premise
( I-Premise
87 I-Premise
days I-Premise
vs I-Premise
64 I-Premise
days I-Premise
, I-Premise
P=0.063 I-Premise
) I-Premise
. I-Premise

( O
2 O
) O
The B-Premise
scores I-Premise
of I-Premise
domains I-Premise
in I-Premise
EORTC I-Premise
QLQ-LC43 I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
test I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
except B-Premise
cognitive I-Premise
and I-Premise
social I-Premise
functions I-Premise
, I-Premise
the I-Premise
symptoms I-Premise
of I-Premise
dysphagia I-Premise
and I-Premise
pain I-Premise
in I-Premise
other I-Premise
parts I-Premise
. I-Premise

( O
1 O
) O
The B-Claim
CM I-Claim
comprehensive I-Claim
regimen I-Claim
as I-Claim
MT I-Claim
had I-Claim
equivalent I-Claim
efficacy I-Claim
on I-Claim
TTP I-Claim
when I-Claim
compared I-Claim
with I-Claim
single-agent I-Claim
maintenance I-Claim
chemotherapy I-Claim
regimen I-Claim
. I-Claim

It B-Claim
was I-Claim
advantageous I-Claim
over I-Claim
improving I-Claim
the I-Claim
QOL I-Claim
. I-Claim

( O
2 O
) O
It B-Claim
is I-Claim
necessary I-Claim
to I-Claim
enlarge I-Claim
the I-Claim
sample I-Claim
size I-Claim
to I-Claim
further I-Claim
confirm I-Claim
the I-Claim
therapeutic I-Claim
efficacy I-Claim
of I-Claim
CM I-Claim
comprehensive I-Claim
regimen I-Claim
as I-Claim
MT I-Claim
in I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Restorative O
proctocolectomy O
with O
ileal O
pouch-anal O
anastomosis O
( O
IPAA O
) O
is O
the O
standard O
surgical O
procedure O
for O
ulcerative O
colitis O
( O
UC O
) O
and O
familial O
adenomatous O
polyposis O
( O
FAP O
) O
. O

While O
minimal O
invasive O
techniques O
have O
been O
applied O
increasingly O
, O
clear O
evidence O
of O
superiority O
for O
laparoscopic O
pouch O
procedures O
is O
not O
yet O
available O
. O

The O
aim O
of O
the O
LapConPouch O
Trial O
was O
to O
compare O
the O
effectiveness O
of O
laparoscopic O
( O
LAP O
) O
versus O
conventional O
( O
CON O
) O
ileoanal O
pouch O
procedure O
in O
patients O
undergoing O
elective O
restorative O
proctocolectomy O
. O

The O
trial O
was O
designed O
as O
a O
single-centre O
, O
pre-operatively O
randomized O
, O
controlled O
trial O
using O
a O
two-group O
parallel O
superiority O
design O
. O

Eligible O
for O
participation O
were O
patients O
scheduled O
for O
restorative O
proctocolectomy O
either O
for O
FAP O
or O
for O
UC O
. O

Patients O
and O
outcome O
assessors O
were O
blinded O
to O
group O
assignment O
. O

The O
primary O
endpoint O
was O
defined O
as O
the O
amount O
of O
blood O
loss O
. O

Statistical O
analyses O
were O
explorative O
since O
the O
trial O
had O
to O
be O
stopped O
prematurely O
. O

A O
total O
of O
42 O
patients O
( O
21 O
LAP O
( O
50.0 O
% O
) O
; O
21 O
CON O
( O
50.0 O
% O
) O
) O
were O
randomized O
. O

The B-Premise
trial I-Premise
had I-Premise
to I-Premise
be I-Premise
stopped I-Premise
prematurely I-Premise
due I-Premise
to I-Premise
insufficient I-Premise
patient I-Premise
recruitment I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
amount I-Premise
of I-Premise
blood I-Premise
loss I-Premise
between I-Premise
both I-Premise
groups I-Premise
: I-Premise
LAP I-Premise
261.5 I-Premise
± I-Premise
195.4 I-Premise
ml I-Premise
, I-Premise
CON I-Premise
228.1 I-Premise
± I-Premise
119.5 I-Premise
ml I-Premise
. I-Premise

Secondary O
endpoints O
differ O
in O
both O
groups O
. O

Laparoscopic B-Claim
surgery I-Claim
was I-Claim
superior I-Claim
regarding I-Claim
the I-Claim
length I-Claim
of I-Claim
skin I-Claim
incision I-Claim
; I-Claim
in O
contrast O
, O
the B-Claim
conventional I-Claim
approach I-Claim
was I-Claim
superior I-Claim
in I-Claim
duration I-Claim
of I-Claim
operation I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
discrepancies I-Premise
in I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
postoperative I-Premise
pain I-Premise
, I-Premise
bowel I-Premise
function I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
both I-Premise
approaches I-Premise
. I-Premise

The O
conversion O
rate O
from O
LAP O
to O
CON O
approach O
was O
23.8 O
% O
. O

There B-Claim
was I-Claim
no I-Claim
difference I-Claim
with I-Claim
respect I-Claim
to I-Claim
blood I-Claim
loss I-Claim
between I-Claim
the I-Claim
LAP I-Claim
and I-Claim
the I-Claim
CON I-Claim
group I-Claim
. I-Claim

The B-Claim
LAP I-Claim
approach I-Claim
is I-Claim
feasible I-Claim
for I-Claim
restorative I-Claim
proctocolectomy I-Claim
, I-Claim
and I-Claim
IPAA I-Claim
seems I-Claim
at I-Claim
least I-Claim
as I-Claim
safe I-Claim
as I-Claim
CON I-Claim
surgery I-Claim
. I-Claim

The O
most O
obvious O
advantage O
of O
the O
minimal O
invasive O
technique O
is O
the O
improved O
cosmesis O
. O

This O
analysis O
of O
the O
results O
of O
a O
randomized O
, O
controlled O
trial O
evaluating O
the O
effects O
of O
epoetin O
alfa O
( O
EPO O
) O
therapy O
on O
transfusion O
requirements O
, O
hemoglobin O
( O
Hb O
) O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
cancer O
receiving O
platinum-based O
chemotherapy O
was O
conducted O
to O
evaluate O
the O
effect O
of O
initial O
Hb O
level O
on O
study O
outcomes O
. O

Patients O
with O
Hb O
levels O
< O
or O
=12.1 O
g/dl O
were O
randomized O
2:1 O
to O
receive O
EPO O
, O
10,000 O
U O
three O
times O
weekly O
s.c. O
or O
best O
supportive O
care O
( O
BSC O
) O
until O
4 O
weeks O
after O
their O
last O
chemotherapy O
cycle O
. O

For O
this O
analysis O
, O
patients O
were O
stratified O
by O
baseline O
Hb O
level O
( O
< O
or O
=9.7 O
g/dl O
, O
> O
9.7 O
g/dl O
to O
< O
or O
=10.5 O
g/dl O
, O
> O
10.5 O
g/dl O
to O
< O
or O
=11.3 O
g/dl O
, O
and O
> O
11.3 O
g/dl O
to O
< O
or O
=12.1 O
g/dl O
) O
, O
and O
study O
results O
were O
reanalyzed O
. O

Significantly B-Premise
fewer I-Premise
EPO I-Premise
patients I-Premise
than I-Premise
BSC I-Premise
patients I-Premise
with I-Premise
initial I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
9.7 I-Premise
g/dl I-Premise
to I-Premise
< I-Premise
or I-Premise
=12.1 I-Premise
g/dl I-Premise
required I-Premise
transfusions I-Premise
. I-Premise

EPO B-Premise
maintained I-Premise
Hb I-Premise
levels I-Premise
throughout I-Premise
the I-Premise
study I-Premise
for I-Premise
patients I-Premise
with I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
11.3 I-Premise
g/dl I-Premise
to I-Premise
< I-Premise
or I-Premise
=12.1 I-Premise
g/dl I-Premise
, I-Premise
compared I-Premise
with I-Premise
a I-Premise
decrease I-Premise
with I-Premise
BSC I-Premise
. I-Premise

For B-Premise
patients I-Premise
with I-Premise
baseline I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
10.5 I-Premise
g/dl I-Premise
, I-Premise
for I-Premise
whom I-Premise
the I-Premise
mean I-Premise
changes I-Premise
from I-Premise
baseline I-Premise
to I-Premise
last I-Premise
assessment I-Premise
were I-Premise
measured I-Premise
by I-Premise
the I-Premise
Cancer I-Premise
Linear I-Premise
Analogue I-Premise
Scale I-Premise
assessments I-Premise
of I-Premise
energy I-Premise
and I-Premise
overall I-Premise
QOL I-Premise
as I-Premise
well I-Premise
as I-Premise
by I-Premise
the I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
( I-Premise
FACT I-Premise
) I-Premise
-Fatigue I-Premise
and I-Premise
FACT-An I-Premise
Anemia I-Premise
subscale I-Premise
, I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
with I-Premise
EPO I-Premise
than I-Premise
with I-Premise
BSC I-Premise
. I-Premise

QOL B-Premise
declined I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
BSC I-Premise
, I-Premise
and O
the B-Premise
mean I-Premise
decreases I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
greater I-Premise
for I-Premise
BSC I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
10.5 I-Premise
g/dl I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
overall I-Premise
BSC I-Premise
group I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
receiving I-Claim
platinum-based I-Claim
chemotherapy I-Claim
and I-Claim
with I-Claim
baseline I-Claim
Hb I-Claim
levels I-Claim
> I-Claim
10.5 I-Claim
g/dl I-Claim
, I-Claim
early I-Claim
intervention I-Claim
with I-Claim
EPO I-Claim
reduces I-Claim
transfusions I-Claim
, I-Claim
maintains I-Claim
Hb I-Claim
level I-Claim
, I-Claim
and I-Claim
maintains I-Claim
or I-Claim
improves I-Claim
QOL I-Claim
. I-Claim

This B-Claim
study I-Claim
supports I-Claim
the I-Claim
positive I-Claim
effects I-Claim
of I-Claim
early I-Claim
intervention I-Claim
when I-Claim
analyzed I-Claim
according I-Claim
to I-Claim
initial I-Claim
Hb I-Claim
value I-Claim
. I-Claim

The B-Claim
extent I-Claim
to I-Claim
which I-Claim
chemotherapy I-Claim
may I-Claim
relieve I-Claim
tumour-related I-Claim
symptoms I-Claim
, I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
gastric I-Claim
cancer I-Claim
is I-Claim
not I-Claim
known I-Claim
in I-Claim
spite I-Claim
of I-Claim
the I-Claim
extensive I-Claim
use I-Claim
of I-Claim
this I-Claim
treatment I-Claim
modality I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
estimate O
any O
gain O
in O
the O
quantity O
and O
quality O
of O
life O
produced O
by O
chemotherapy O
in O
these O
patients O
. O

Between O
January O
1991 O
and O
February O
1995 O
, O
61 O
patients O
with O
gastric O
cancer O
were O
randomized O
to O
either O
chemotherapy O
in O
addition O
to O
best O
supportive O
care O
or O
to O
best O
supportive O
care O
. O

Chemotherapy O
was O
allowed O
in O
the O
latter O
group O
if O
the O
supportive O
measures O
did O
not O
lead O
to O
palliation O
. O

Chemotherapy O
was O
the O
ELF-regimen O
consisting O
of O
5-fluorouracil O
, O
leucovorin O
and O
etoposide O
, O
or O
, O
in O
elderly O
patients O
with O
poor O
performance O
, O
a O
5-fluorouracil/leucovorin O
regimen O
( O
FLv O
) O
. O

Quality O
of O
life O
was O
evaluated O
with O
the O
EORTC-QLQ-C30 O
instrument O
. O

More B-Premise
patients I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
( I-Premise
45 I-Premise
% I-Premise
, I-Premise
14/31 I-Premise
) I-Premise
had I-Premise
an I-Premise
improved I-Premise
or I-Premise
prolonged I-Premise
high I-Premise
quality I-Premise
of I-Premise
life I-Premise
for I-Premise
a I-Premise
minimum I-Premise
period I-Premise
of I-Premise
4 I-Premise
months I-Premise
compared I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
best I-Premise
supportive I-Premise
care I-Premise
group I-Premise
( I-Premise
20 I-Premise
% I-Premise
, I-Premise
6/30 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

A B-Premise
similar I-Premise
difference I-Premise
was I-Premise
seen I-Premise
in I-Premise
the I-Premise
treating I-Premise
physician I-Premise
's I-Premise
evaluation I-Premise
of I-Premise
whether I-Premise
the I-Premise
patient I-Premise
was I-Premise
subjectively I-Premise
improved I-Premise
or I-Premise
continued I-Premise
to I-Premise
do I-Premise
well I-Premise
for I-Premise
at I-Premise
least I-Premise
4 I-Premise
months I-Premise
( I-Premise
17/31 I-Premise
, I-Premise
55 I-Premise
% I-Premise
versus I-Premise
6/30 I-Premise
, I-Premise
20 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
( I-Premise
median I-Premise
8 I-Premise
vs. I-Premise
5 I-Premise
months I-Premise
) I-Premise
although B-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.12 I-Premise
) I-Premise
. I-Premise

After B-Premise
corrections I-Premise
for I-Premise
imbalances I-Premise
in I-Premise
pretreatment I-Premise
characteristics I-Premise
, I-Premise
chemotherapy I-Premise
treatment I-Premise
was I-Premise
, I-Premise
however I-Premise
, I-Premise
associated I-Premise
with I-Premise
a I-Premise
survival I-Premise
benefit I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

Also B-Premise
, I-Premise
the I-Premise
quality-adjusted I-Premise
survival I-Premise
time I-Premise
and I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
were I-Premise
longer I-Premise
for I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
chemotherapy I-Premise
( I-Premise
median I-Premise
5 I-Premise
vs. I-Premise
2 I-Premise
months I-Premise
, I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

The B-Claim
results I-Claim
show I-Claim
that I-Claim
chemotherapy I-Claim
can I-Claim
add I-Claim
to I-Claim
both I-Claim
quantity I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim

The B-Claim
number I-Claim
of I-Claim
patients I-Claim
who I-Claim
benefit I-Claim
from I-Claim
treatment I-Claim
is I-Claim
, I-Claim
however I-Claim
, I-Claim
still I-Claim
rather I-Claim
limited I-Claim
. I-Claim

Laparoscopic-assisted B-Claim
colectomy I-Claim
( I-Claim
LAC I-Claim
) I-Claim
has I-Claim
emerged I-Claim
as I-Claim
the I-Claim
preferred I-Claim
minimally I-Claim
invasive I-Claim
surgical I-Claim
strategy I-Claim
for I-Claim
diseases I-Claim
of I-Claim
the I-Claim
colon I-Claim
. I-Claim

The B-Claim
safety I-Claim
and I-Claim
efficacy I-Claim
of I-Claim
LAC I-Claim
for I-Claim
colon I-Claim
cancer I-Claim
are I-Claim
unknown I-Claim
, I-Claim
and O
the B-Claim
nature I-Claim
and I-Claim
magnitude I-Claim
of I-Claim
any I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
benefit I-Claim
resulting I-Claim
from I-Claim
LAC I-Claim
for I-Claim
colon I-Claim
cancer I-Claim
is I-Claim
also I-Claim
unknown I-Claim
. I-Claim

To O
compare O
short-term O
QOL O
outcomes O
after O
LAC O
vs O
open O
colectomy O
for O
colon O
cancer O
. O

Multicenter O
, O
randomized O
controlled O
trial O
( O
Clinical O
Outcomes O
of O
Surgical O
Therapy O
[ O
COST O
] O
) O
. O

Between O
September O
1994 O
and O
February O
1999 O
, O
37 O
of O
48 O
centers O
provided O
data O
for O
the O
QOL O
component O
of O
the O
trial O
for O
449 O
consecutive O
patients O
with O
clinically O
resectable O
colon O
cancer O
. O

Scores O
on O
the O
Symptoms O
Distress O
Scale O
( O
SDS O
) O
, O
Quality O
of O
Life O
Index O
, O
and O
a O
single-item O
global O
rating O
scale O
at O
2 O
days O
, O
2 O
weeks O
, O
and O
2 O
months O
postoperative O
; O
duration O
of O
postoperative O
in-hospital O
analgesic O
use O
; O
and O
length O
of O
stay O
. O

Of O
449 O
patients O
, O
428 O
provided O
QOL O
data O
. O

In B-Premise
an I-Premise
intention-to-treat I-Premise
analysis I-Premise
comparing I-Premise
SDS I-Premise
pain I-Premise
intensity I-Premise
, I-Premise
SDS I-Premise
summary I-Premise
, I-Premise
QOL I-Premise
Index I-Premise
summary I-Premise
, I-Premise
and I-Premise
global I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
at I-Premise
each I-Premise
time I-Premise
point I-Premise
, I-Premise
the I-Premise
only I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
observed I-Premise
between I-Premise
groups I-Premise
was I-Premise
the I-Premise
global I-Premise
rating I-Premise
scale I-Premise
score I-Premise
for I-Premise
2 I-Premise
weeks I-Premise
postsurgery I-Premise
. I-Premise

The B-Premise
mean I-Premise
( I-Premise
median I-Premise
) I-Premise
global I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
2 I-Premise
weeks I-Premise
postsurgery I-Premise
were I-Premise
76.9 I-Premise
( I-Premise
80 I-Premise
) I-Premise
for I-Premise
LAC I-Premise
vs I-Premise
74.4 I-Premise
( I-Premise
75 I-Premise
) I-Premise
for I-Premise
open I-Premise
colectomy I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
. I-Premise

While B-Premise
in I-Premise
the I-Premise
hospital I-Premise
, I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
LAC I-Premise
required I-Premise
fewer I-Premise
days I-Premise
of I-Premise
both I-Premise
parenteral I-Premise
analgesics I-Premise
compared I-Premise
with I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
open I-Premise
colectomy I-Premise
( I-Premise
mean I-Premise
[ I-Premise
median I-Premise
] I-Premise
, I-Premise
3.2 I-Premise
[ I-Premise
3 I-Premise
] I-Premise
vs I-Premise
4.0 I-Premise
[ I-Premise
4 I-Premise
] I-Premise
days I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
oral I-Premise
analgesics I-Premise
( I-Premise
mean I-Premise
[ I-Premise
median I-Premise
] I-Premise
, I-Premise
1.9 I-Premise
[ I-Premise
1 I-Premise
] I-Premise
vs I-Premise
2.2 I-Premise
[ I-Premise
2 I-Premise
] I-Premise
days I-Premise
; I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
. I-Premise

Only B-Claim
minimal I-Claim
short-term I-Claim
QOL I-Claim
benefits I-Claim
were I-Claim
found I-Claim
with I-Claim
LAC I-Claim
for I-Claim
colon I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
standard I-Claim
open I-Claim
colectomy I-Claim
. I-Claim

Until B-Claim
ongoing I-Claim
trials I-Claim
establish I-Claim
that I-Claim
LAC I-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
open I-Claim
colectomy I-Claim
in I-Claim
preventing I-Claim
recurrence I-Claim
and I-Claim
death I-Claim
from I-Claim
colon I-Claim
cancer I-Claim
, I-Claim
this I-Claim
procedure I-Claim
should I-Claim
not I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
colon I-Claim
cancer I-Claim
. I-Claim

The B-Claim
impact I-Claim
of I-Claim
prolonged I-Claim
subclinical I-Claim
hyperthyroidism I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
is I-Claim
unclear I-Claim
. I-Claim

Therefore O
, O
we O
evaluated O
quality O
of O
life O
in O
patients O
with O
differentiated O
thyroid O
carcinoma O
( O
DTC O
) O
on O
TSH-suppressive O
thyroxine O
therapy O
as O
a O
model O
for O
subclinical O
hyperthyroidism O
and O
we O
investigated O
whether O
restoration O
to O
euthyroidism O
affects O
quality O
of O
life O
. O

We O
performed O
a O
prospective O
, O
single-blinded O
, O
placebo-controlled O
, O
randomized O
trial O
of O
6 O
months O
' O
duration O
with O
two O
parallel O
groups O
. O

Twenty-four O
subjects O
with O
a O
history O
of O
differentiated O
thyroid O
carcinoma O
with O
> O
10 O
years O
TSH-suppressive O
therapy O
with O
L-thyroxine O
completed O
the O
study O
. O

L-thyroxine O
dose O
was O
replaced O
by O
study O
medication O
containing O
L-thyroxine O
or O
L-thyroxine O
plus O
placebo O
. O

Medication O
was O
titrated O
to O
establish O
continuation O
of O
TSH O
suppression O
( O
low-TSH O
group O
) O
and O
euthyroidism O
( O
euthyroid O
group O
) O
. O

Both O
groups O
consisted O
of O
12 O
patients O
. O

We O
evaluated O
quality O
of O
life O
using O
five O
validated O
questionnaires O
. O

At O
baseline O
, O
the O
somatic O
disorder O
questionnaire O
( O
SDQ O
) O
indicated O
more O
somatic O
dysfunction O
in O
patients O
as O
compared O
with O
reference O
values O
, O
whereas O
the O
depression O
score O
( O
HADS O
) O
revealed O
a O
better O
score O
than O
the O
reference O
group O
. O

All O
other O
quality O
of O
life O
parameters O
were O
normal O
. O

At O
baseline O
, O
no O
significant O
differences O
between O
the O
low-TSH O
and O
the O
euthyroidism O
groups O
were O
observed O
. O

After B-Premise
6 I-Premise
months I-Premise
, I-Premise
none I-Premise
of I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
parameters I-Premise
in I-Premise
the I-Premise
low-TSH I-Premise
group I-Premise
was I-Premise
different I-Premise
from I-Premise
baseline I-Premise
values I-Premise
. I-Premise

In B-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
motivation I-Premise
was I-Premise
significantly I-Premise
improved I-Premise
( I-Premise
Multidimensional I-Premise
Fatigue I-Premise
Index-20 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
, I-Premise
although B-Premise
this I-Premise
parameter I-Premise
did I-Premise
not I-Premise
differ I-Premise
from I-Premise
the I-Premise
reference I-Premise
group I-Premise
at I-Premise
baseline I-Premise
. I-Premise

A B-Premise
probable I-Premise
worsening I-Premise
in I-Premise
role I-Premise
limitations I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
physical I-Premise
problems I-Premise
( I-Premise
Short I-Premise
Form-36 I-Premise
; I-Premise
P I-Premise
= I-Premise
0.050 I-Premise
) I-Premise
was I-Premise
observed I-Premise
. I-Premise

No B-Premise
improvement I-Premise
in I-Premise
the I-Premise
SDQ I-Premise
score I-Premise
was I-Premise
observed I-Premise
. I-Premise

In B-Claim
summary I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
DTC I-Claim
and I-Claim
long-term I-Claim
subclinical I-Claim
hyperthyroidism I-Claim
in I-Claim
general I-Claim
is I-Claim
preserved I-Claim
. I-Claim

Restoration B-Claim
of I-Claim
euthyroidism I-Claim
in I-Claim
general I-Claim
does I-Claim
not I-Claim
affect I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Most O
patients O
with O
glioblastoma O
are O
older O
than O
60 O
years O
, O
but O
treatment O
guidelines O
are O
based O
on O
trials O
in O
patients O
aged O
only O
up O
to O
70 O
years O
. O

We O
did O
a O
randomised O
trial O
to O
assess O
the O
optimum O
palliative O
treatment O
in O
patients O
aged O
60 O
years O
and O
older O
with O
glioblastoma O
. O

Patients O
with O
newly O
diagnosed O
glioblastoma O
were O
recruited O
from O
Austria O
, O
Denmark O
, O
France O
, O
Norway O
, O
Sweden O
, O
Switzerland O
, O
and O
Turkey O
. O

They O
were O
assigned O
by O
a O
computer-generated O
randomisation O
schedule O
, O
stratified O
by O
centre O
, O
to O
receive O
temozolomide O
( O
200 O
mg/m O
( O
2 O
) O
on O
days O
1-5 O
of O
every O
28 O
days O
for O
up O
to O
six O
cycles O
) O
, O
hypofractionated O
radiotherapy O
( O
34·0 O
Gy O
administered O
in O
3·4 O
Gy O
fractions O
over O
2 O
weeks O
) O
, O
or O
standard O
radiotherapy O
( O
60·0 O
Gy O
administered O
in O
2·0 O
Gy O
fractions O
over O
6 O
weeks O
) O
. O

Patients O
and O
study O
staff O
were O
aware O
of O
treatment O
assignment O
. O

The O
primary O
endpoint O
was O
overall O
survival O
. O

Analyses O
were O
done O
by O
intention O
to O
treat O
. O

This O
trial O
is O
registered O
, O
number O
ISRCTN81470623 O
. O

342 O
patients O
were O
enrolled O
, O
of O
whom O
291 O
were O
randomised O
across O
three O
treatment O
groups O
( O
temozolomide O
n=93 O
, O
hypofractionated O
radiotherapy O
n=98 O
, O
standard O
radiotherapy O
n=100 O
) O
and O
51 O
of O
whom O
were O
randomised O
across O
only O
two O
groups O
( O
temozolomide O
n=26 O
, O
hypofractionated O
radiotherapy O
n=25 O
) O
. O

In B-Premise
the I-Premise
three-group I-Premise
randomisation I-Premise
, I-Premise
in I-Premise
comparison I-Premise
with I-Premise
standard I-Premise
radiotherapy I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
temozolomide I-Premise
( I-Premise
8·3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
7·1-9·5 I-Premise
; I-Premise
n=93 I-Premise
] I-Premise
vs I-Premise
6·0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5·1-6·8 I-Premise
; I-Premise
n=100 I-Premise
] I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0·70 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·52-0·93 I-Premise
, I-Premise
p=0·01 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
hypofractionated I-Premise
radiotherapy I-Premise
( I-Premise
7·5 I-Premise
months I-Premise
[ I-Premise
6·5-8·6 I-Premise
; I-Premise
n=98 I-Premise
] I-Premise
, I-Premise
HR I-Premise
0·85 I-Premise
[ I-Premise
0·64-1·12 I-Premise
] I-Premise
, I-Premise
p=0·24 I-Premise
) I-Premise
. I-Premise

For B-Premise
all I-Premise
patients I-Premise
who I-Premise
received I-Premise
temozolomide I-Premise
or I-Premise
hypofractionated I-Premise
radiotherapy I-Premise
( I-Premise
n=242 I-Premise
) I-Premise
overall I-Premise
survival I-Premise
was I-Premise
similar I-Premise
( I-Premise
8·4 I-Premise
months I-Premise
[ I-Premise
7·3-9·4 I-Premise
; I-Premise
n=119 I-Premise
] I-Premise
vs I-Premise
7·4 I-Premise
months I-Premise
[ I-Premise
6·4-8·4 I-Premise
; I-Premise
n=123 I-Premise
] I-Premise
; I-Premise
HR I-Premise
0·82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·63-1·06 I-Premise
; I-Premise
p=0·12 I-Premise
) I-Premise
. I-Premise

For B-Premise
age I-Premise
older I-Premise
than I-Premise
70 I-Premise
years I-Premise
, I-Premise
survival I-Premise
was I-Premise
better I-Premise
with I-Premise
temozolomide I-Premise
and I-Premise
with I-Premise
hypofractionated I-Premise
radiotherapy I-Premise
than I-Premise
with I-Premise
standard I-Premise
radiotherapy I-Premise
( I-Premise
HR I-Premise
for I-Premise
temozolomide I-Premise
vs I-Premise
standard I-Premise
radiotherapy I-Premise
0·35 I-Premise
[ I-Premise
0·21-0·56 I-Premise
] I-Premise
, I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
; I-Premise
HR I-Premise
for I-Premise
hypofractionated I-Premise
vs I-Premise
standard I-Premise
radiotherapy I-Premise
0·59 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·37-0·93 I-Premise
] I-Premise
, I-Premise
p=0·02 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
temozolomide I-Premise
who I-Premise
had I-Premise
tumour I-Premise
MGMT I-Premise
promoter I-Premise
methylation I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
survival I-Premise
than I-Premise
those I-Premise
without I-Premise
MGMT I-Premise
promoter I-Premise
methylation I-Premise
( I-Premise
9·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
8·0-11·4 I-Premise
] I-Premise
vs I-Premise
6·8 I-Premise
months I-Premise
[ I-Premise
5·9-7·7 I-Premise
] I-Premise
; I-Premise
HR I-Premise
0·56 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·34-0·93 I-Premise
] I-Premise
, I-Premise
p=0·02 I-Premise
) I-Premise
, I-Premise
but I-Premise
no I-Premise
difference I-Premise
was I-Premise
noted I-Premise
between I-Premise
those I-Premise
with I-Premise
methylated I-Premise
and I-Premise
unmethylated I-Premise
MGMT I-Premise
promoter I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
( I-Premise
HR I-Premise
0·97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·69-1·38 I-Premise
] I-Premise
; I-Premise
p=0·81 I-Premise
) I-Premise
. I-Premise

As O
expected O
, O
the B-Premise
most I-Premise
common I-Premise
grade I-Premise
3-4 I-Premise
adverse I-Premise
events I-Premise
in I-Premise
the I-Premise
temozolomide I-Premise
group I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
n=12 I-Premise
) I-Premise
and I-Premise
thrombocytopenia I-Premise
( I-Premise
n=18 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3-5 I-Premise
infections I-Premise
in I-Premise
all I-Premise
randomisation I-Premise
groups I-Premise
were I-Premise
reported I-Premise
in I-Premise
18 I-Premise
patients I-Premise
. I-Premise

Two B-Premise
patients I-Premise
had I-Premise
fatal I-Premise
infections I-Premise
( I-Premise
one I-Premise
in I-Premise
the I-Premise
temozolomide I-Premise
group I-Premise
and I-Premise
one I-Premise
in I-Premise
the I-Premise
standard I-Premise
radiotherapy I-Premise
group I-Premise
) I-Premise
and I-Premise
one I-Premise
in I-Premise
the I-Premise
temozolomide I-Premise
group I-Premise
with I-Premise
grade I-Premise
2 I-Premise
thrombocytopenia I-Premise
died I-Premise
from I-Premise
complications I-Premise
after I-Premise
surgery I-Premise
for I-Premise
a I-Premise
gastrointestinal I-Premise
bleed I-Premise
. I-Premise

Standard B-Claim
radiotherapy I-Claim
was I-Claim
associated I-Claim
with I-Claim
poor I-Claim
outcomes I-Claim
, I-Claim
especially I-Claim
in I-Claim
patients I-Claim
older I-Claim
than I-Claim
70 I-Claim
years I-Claim
. I-Claim

Both B-Claim
temozolomide I-Claim
and I-Claim
hypofractionated I-Claim
radiotherapy I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
standard I-Claim
treatment I-Claim
options I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
glioblastoma I-Claim
. I-Claim

MGMT B-Claim
promoter I-Claim
methylation I-Claim
status I-Claim
might I-Claim
be I-Claim
a I-Claim
useful I-Claim
predictive I-Claim
marker I-Claim
for I-Claim
benefit I-Claim
from I-Claim
temozolomide I-Claim
. I-Claim

To O
evaluate O
the O
difference O
of O
efficacy O
, O
side-effects O
and O
quality O
of O
life O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
patients O
treated O
with O
oxaliplatin O
plus O
vinorelbine O
or O
cisplatin O
plus O
vinorelbine O
. O

Eligible O
patients O
were O
randomly O
assigned O
to O
NL O
( O
oxaliplatin O
+ O
vinorelbine O
) O
group O
and O
NP O
( O
cisplatin O
+ O
vinorelbine O
) O
group O
in O
a O
2:1 O
ratio O
. O

In O
the O
NL O
group O
, O
70 O
evaluable O
cases O
were O
treated O
with O
oxaliplatin O
130 O
mg/m O
( O
2 O
) O
i.v O
. O

on O
day O
2 O
, O
and O
vinorelbine O
25 O
mg/m O
( O
2 O
) O
i.v O
. O

on O
days O
1 O
and O
8 O
in O
21 O
days O
per O
cycle O
. O

In O
the O
NP O
group O
, O
32 O
evaluable O
cases O
were O
treated O
with O
cisplatin O
80 O
mg/m O
( O
2 O
) O
i.v O
. O

divided O
to O
2 O
- O
3 O
days O
dosing O
, O
21 O
days O
per O
cycle O
, O
and O
vinorelbine O
administered O
by O
the O
same O
way O
as O
in O
the O
NL O
group O
. O

The O
response O
rate O
, O
time O
to O
progression O
( O
TTP O
) O
, O
one-year O
survival O
, O
side-effects O
and O
the O
quality O
of O
life O
were O
observed O
. O

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
35.7 I-Premise
% I-Premise
vs. I-Premise
43.8 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.4 I-Premise
) I-Premise
, I-Premise
median I-Premise
TTP I-Premise
was I-Premise
4.7 I-Premise
months I-Premise
vs. I-Premise
5.5 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.6 I-Premise
) I-Premise
, I-Premise
one-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
38.5 I-Premise
% I-Premise
vs. I-Premise
58.6 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.07 I-Premise
) I-Premise
in I-Premise
the I-Premise
NL I-Premise
and I-Premise
NP I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Grade B-Premise
I-II I-Premise
neuro-sensory I-Premise
toxicity I-Premise
occurred I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
in I-Premise
NL I-Premise
group I-Premise
than I-Premise
in I-Premise
NP I-Premise
group I-Premise
( I-Premise
68.4 I-Premise
% I-Premise
vs. I-Premise
36.4 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.0017 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
Grade I-Premise
I-II I-Premise
granulocytopenia I-Premise
was I-Premise
significantly I-Premise
less I-Premise
occurred I-Premise
in I-Premise
NL I-Premise
group I-Premise
than I-Premise
in I-Premise
NP I-Premise
group I-Premise
( I-Premise
49.4 I-Premise
% I-Premise
vs. I-Premise
70.6 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Due B-Claim
to I-Claim
good I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
, I-Claim
the I-Claim
NL I-Claim
regimen I-Claim
offered I-Claim
a I-Claim
new I-Claim
candidate I-Claim
for I-Claim
treating I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Restoring O
sensory O
innervation O
may O
be O
a O
useful O
adjunct O
in O
free O
flap O
head O
and O
neck O
reconstruction O
but O
, O
as O
yet O
, O
has O
not O
been O
shown O
to O
improve O
outcomes O
of O
breast O
reconstruction O
. O

The O
authors O
' O
previous O
study O
demonstrated O
objectively O
improved O
sensation O
in O
a O
group O
of O
innervated O
transverse O
rectus O
abdominis O
musculocutaneous O
( O
TRAM O
) O
flap O
breast O
reconstruction O
patients O
relative O
to O
noninnervated O
flaps O
. O

This O
study O
compared O
patient-rated O
outcomes O
of O
free O
TRAM O
breast O
reconstruction O
in O
innervated O
versus O
noninnervated O
flaps O
. O

Twenty-seven O
women O
were O
randomized O
prospectively O
to O
undergo O
either O
innervated O
or O
noninnervated O
free O
TRAM O
flap O
breast O
reconstruction O
. O

For O
innervated O
flaps O
, O
the O
T10 O
intercostal O
nerve O
was O
harvested O
with O
the O
TRAM O
flap O
and O
neurotized O
to O
the O
T4 O
sensory O
nerve O
at O
the O
recipient O
site O
. O

Three O
validated O
outcome O
tools O
were O
administered O
after O
surgery O
: O
the O
Medical O
Outcomes O
Study O
36-Item O
Short O
Form O
Health O
Survey O
, O
the O
Body O
Image O
after O
Breast O
Cancer O
Questionnaire O
, O
and O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
. O

Results B-Premise
were I-Premise
correlated I-Premise
with I-Premise
previously I-Premise
reported I-Premise
objective I-Premise
sensibility I-Premise
outcomes I-Premise
. I-Premise

Eighteen O
of O
27 O
women O
returned O
their O
questionnaires O
a O
mean O
48 O
months O
after O
free O
TRAM O
flap O
reconstruction O
. O

Demographic O
analysis O
revealed O
no O
significant O
differences O
in O
patient O
age O
, O
height O
, O
smoking O
, O
radiation O
therapy O
, O
and O
nipple-areola O
complex O
reconstruction O
between O
randomized O
patient O
groups O
. O

There B-Premise
was I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
all I-Premise
three I-Premise
measures I-Premise
in I-Premise
patients I-Premise
who I-Premise
were I-Premise
randomized I-Premise
to I-Premise
receive I-Premise
innervated I-Premise
free I-Premise
TRAM I-Premise
flaps I-Premise
compared I-Premise
with I-Premise
those I-Premise
receiving I-Premise
noninnervated I-Premise
flaps I-Premise
. I-Premise

This B-Claim
study I-Claim
demonstrates I-Claim
that I-Claim
innervation I-Claim
of I-Claim
free I-Claim
TRAM I-Claim
flaps I-Claim
used I-Claim
for I-Claim
breast I-Claim
reconstruction I-Claim
not I-Claim
only I-Claim
improves I-Claim
sensibility I-Claim
but I-Claim
also I-Claim
has I-Claim
a I-Claim
positive I-Claim
effect I-Claim
on I-Claim
patient-rated I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Despite O
improvements O
in O
surgical O
techniques O
, O
urinary O
incontinence O
( O
UI O
) O
is O
not O
uncommon O
after O
radical O
prostatectomy O
( O
RP O
) O
, O
and O
it O
may O
dramatically O
worsen O
quality O
of O
life O
( O
QoL O
) O
. O

To O
determine O
the O
benefit O
of O
starting O
pelvic O
floor O
muscle O
exercise O
( O
PFME O
) O
30d O
before O
RP O
and O
of O
continuing O
PFME O
postoperatively O
for O
early O
recovery O
of O
continence O
. O

A O
randomised O
, O
prospective O
study O
was O
designed O
. O

Men O
with O
localised O
prostate O
cancer O
( O
PCa O
) O
who O
underwent O
an O
open O
radical O
retropubic O
prostatectomy O
( O
RRP O
) O
at O
our O
department O
of O
urology O
were O
included O
. O

Patients O
were O
randomised O
to O
start O
PFME O
preoperatively O
and O
continue O
postoperatively O
( O
active O
group O
: O
A O
) O
or O
to O
start O
PFME O
postoperatively O
alone O
( O
control O
group O
: O
B O
) O
. O

The O
primary O
outcome O
measure O
was O
self-reported O
continence O
after O
surgery O
. O

Secondary O
outcome O
measures O
were O
assessed O
by O
degree O
of O
UI O
based O
on O
a O
24-h O
pad O
test O
and O
QoL O
instruments O
( O
International O
Continence O
Society O
[ O
ICS O
] O
male O
short O
form O
[ O
SF O
] O
) O
. O

Of O
143 O
men O
evaluated O
for O
the O
study O
, O
118 O
were O
randomised O
either O
to O
start O
PFME O
preoperatively O
and O
continue O
postoperatively O
( O
group O
A O
; O
n=59 O
) O
or O
to O
start O
postoperative O
PFME O
( O
group O
B O
; O
n=59 O
) O
. O

After B-Premise
1 I-Premise
mo I-Premise
, I-Premise
44.1 I-Premise
% I-Premise
( I-Premise
26 I-Premise
of I-Premise
59 I-Premise
) I-Premise
of I-Premise
patients I-Premise
were I-Premise
continent I-Premise
in I-Premise
group I-Premise
A I-Premise
, I-Premise
while I-Premise
20.3 I-Premise
% I-Premise
( I-Premise
12 I-Premise
of I-Premise
59 I-Premise
) I-Premise
were I-Premise
continent I-Premise
in I-Premise
group I-Premise
B I-Premise
( I-Premise
p=0.018 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
mo I-Premise
, I-Premise
59.3 I-Premise
% I-Premise
( I-Premise
35 I-Premise
of I-Premise
59 I-Premise
) I-Premise
and I-Premise
37.3 I-Premise
% I-Premise
( I-Premise
22 I-Premise
of I-Premise
59 I-Premise
) I-Premise
patients I-Premise
were I-Premise
continent I-Premise
in I-Premise
group I-Premise
A I-Premise
and I-Premise
group I-Premise
B I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p=0.028 I-Premise
) I-Premise
. I-Premise

The B-Premise
ICS I-Premise
male I-Premise
SF I-Premise
mean I-Premise
score I-Premise
showed I-Premise
better I-Premise
results I-Premise
in I-Premise
group I-Premise
A I-Premise
than I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
at I-Premise
both I-Premise
1 I-Premise
mo I-Premise
( I-Premise
14.6 I-Premise
vs I-Premise
18.3 I-Premise
) I-Premise
and I-Premise
3 I-Premise
mo I-Premise
( I-Premise
8.1 I-Premise
vs I-Premise
12.2 I-Premise
) I-Premise
after I-Premise
RP I-Premise
( I-Premise
p=0.002 I-Premise
) I-Premise
. I-Premise

In B-Premise
age-adjusted I-Premise
logistic I-Premise
regression I-Premise
analyses I-Premise
, I-Premise
patients I-Premise
who I-Premise
performed I-Premise
preoperative I-Premise
PFME I-Premise
had I-Premise
a I-Premise
0.41-fold I-Premise
lower I-Premise
risk I-Premise
of I-Premise
being I-Premise
incontinent I-Premise
1 I-Premise
mo I-Premise
after I-Premise
RP I-Premise
and I-Premise
a I-Premise
0.38-fold I-Premise
lower I-Premise
risk I-Premise
of I-Premise
being I-Premise
incontinent I-Premise
3 I-Premise
mo I-Premise
after I-Premise
RP I-Premise
( I-Premise
p≤0.001 I-Premise
) I-Premise
. I-Premise

Preoperative B-Claim
PFME I-Claim
may I-Claim
improve I-Claim
early I-Claim
continence I-Claim
and I-Claim
QoL I-Claim
outcomes I-Claim
after I-Claim
RP I-Claim
. I-Claim

Further B-Claim
studies I-Claim
are I-Claim
needed I-Claim
to I-Claim
corroborate I-Claim
our I-Claim
results I-Claim
. I-Claim

The O
role O
of O
chemotherapy O
for O
advanced O
NSCLC O
patients O
and O
ECOG O
PS2 O
remains O
controversial O
. O

We O
evaluated O
4 O
doses O
of O
3-weekly O
docetaxel O
to O
identify O
a O
less O
toxic O
, O
clinically O
effective O
dose O
. O

Seventy-three O
patients O
with O
stage O
III O
( O
22 O
% O
) O
( O
unsuitable O
for O
radical O
surgery/radiotherapy O
) O
and O
IV O
( O
78 O
% O
) O
NSCLC O
were O
randomized O
to O
receive O
4 O
doses O
of O
3-weekly O
docetaxel O
, O
for O
4 O
cycles O
: O
arm O
( O
A O
) O
40 O
mg/m O
( O
2 O
) O
( O
n=17 O
) O
, O
arm O
( O
B O
) O
50 O
mg/m O
( O
2 O
) O
( O
n=17 O
) O
, O
arm O
( O
C O
) O
60 O
mg/m O
( O
2 O
) O
( O
n=19 O
) O
, O
arm O
( O
D O
) O
50 O
mg/m O
( O
2 O
) O
escalated O
by O
10 O
mg/m O
( O
2 O
) O
to O
a O
maximum O
of O
70 O
mg/m O
( O
2 O
) O
( O
n=19 O
) O
. O

Primary O
endpoints O
: O
maximum O
tolerated O
dose O
, O
RR O
, O
duration O
of O
response O
, O
symptom O
improvement O
, O
toxicity O
and O
QoL O
. O

Secondary O
endpoint O
: O
overall O
survival O
( O
OS O
) O
. O

Patients O
and O
disease O
characteristics O
were O
well O
balanced O
. O

Median O
age O
was O
67 O
( O
range O
45-81 O
) O
, O
there O
were O
32 O
male O
and O
41 O
female O
, O
histology O
subtype O
: O
squamous/adenocarcinoma/mixed/NOS=42 O
% O
/49 O
% O
/4 O
% O
/5 O
% O
. O

Seven O
patients O
did O
not O
receive O
any O
treatment O
because O
of O
deterioration O
in O
PS O
or O
death O
. O

50 O
% O
of O
patients O
in O
arm O
D O
, O
who O
received O
more O
than O
one O
cycle O
, O
received O
dose O
escalation O
. O

There B-Premise
was I-Premise
no I-Premise
statistical I-Premise
difference I-Premise
in I-Premise
the I-Premise
number I-Premise
of I-Premise
cycles I-Premise
administered I-Premise
( I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
and I-Premise
D I-Premise
: I-Premise
median I-Premise
2 I-Premise
cycles I-Premise
and I-Premise
arm I-Premise
C I-Premise
: I-Premise
median I-Premise
3 I-Premise
cycles I-Premise
) I-Premise
and I-Premise
no I-Premise
difference I-Premise
in I-Premise
RR I-Premise
: I-Premise
arm I-Premise
A=6 I-Premise
% I-Premise
, I-Premise
arm I-Premise
B=6 I-Premise
% I-Premise
, I-Premise
arm I-Premise
C=10 I-Premise
% I-Premise
, I-Premise
and I-Premise
arm I-Premise
D=0 I-Premise
% I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
between I-Premise
the I-Premise
four I-Premise
arms I-Premise
. I-Premise

No B-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
hospitalization I-Premise
rate I-Premise
, I-Premise
blood I-Premise
transfusions I-Premise
, I-Premise
antibiotics I-Premise
administration I-Premise
and I-Premise
non-haematological I-Premise
toxicity I-Premise
. I-Premise

QoL O
: O
no O
difference O
in O
total O
scores O
between O
baseline O
and O
cycles O
1-4 O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pain I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
post I-Premise
cycles I-Premise
2 I-Premise
and I-Premise
3 I-Premise
( I-Premise
p=0.025 I-Premise
and I-Premise
p=0.002 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
OS I-Premise
( I-Premise
p=0.992 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
and I-Premise
6-month I-Premise
survival I-Premise
were I-Premise
61 I-Premise
, I-Premise
86 I-Premise
, I-Premise
88 I-Premise
and I-Premise
97 I-Premise
days I-Premise
and I-Premise
29 I-Premise
% I-Premise
, I-Premise
33 I-Premise
% I-Premise
, I-Premise
21 I-Premise
% I-Premise
and I-Premise
26 I-Premise
% I-Premise
for I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
C I-Premise
, I-Premise
and I-Premise
D I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Clinical B-Claim
efficacy I-Claim
of I-Claim
docetaxel I-Claim
was I-Claim
observed I-Claim
at I-Claim
all I-Claim
dose I-Claim
levels I-Claim
. I-Claim

Higher B-Claim
dose I-Claim
levels I-Claim
were I-Claim
not I-Claim
associated I-Claim
with I-Claim
increased I-Claim
toxicities I-Claim
, I-Claim
use I-Claim
of I-Claim
IV I-Claim
antibiotics I-Claim
or I-Claim
hospitalization I-Claim
rates I-Claim
. I-Claim

However O
, O
the B-Premise
median I-Premise
survival I-Premise
observed I-Premise
is I-Premise
shorter I-Premise
than I-Premise
historical I-Premise
data I-Premise
and I-Premise
do I-Premise
not I-Premise
support I-Premise
further I-Premise
evaluation I-Premise
of I-Premise
these I-Premise
doses I-Premise
of I-Premise
single I-Premise
agent I-Premise
docetaxel I-Premise
in I-Premise
this I-Premise
population I-Premise
. I-Premise

Somatostatin O
analogs O
are O
indicated O
for O
symptom O
control O
in O
patients O
with O
gastroenteropancreatic O
neuroendocrine O
tumors O
( O
NETs O
) O
. O

The O
ability O
of O
somatostatin O
analogs O
to O
control O
the O
growth O
of O
well-differentiated O
metastatic O
NETs O
is O
a O
matter O
of O
debate O
. O

We O
performed O
a O
placebo-controlled O
, O
double-blind O
, O
phase O
IIIB O
study O
in O
patients O
with O
well-differentiated O
metastatic O
midgut O
NETs O
. O

The O
hypothesis O
was O
that O
octreotide O
LAR O
prolongs O
time O
to O
tumor O
progression O
and O
survival O
. O

Treatment-naive O
patients O
were O
randomly O
assigned O
to O
either O
placebo O
or O
octreotide O
LAR O
30 O
mg O
intramuscularly O
in O
monthly O
intervals O
until O
tumor O
progression O
or O
death O
. O

The O
primary O
efficacy O
end O
point O
was O
time O
to O
tumor O
progression O
. O

Secondary O
end O
points O
were O
survival O
time O
and O
tumor O
response O
. O

This O
report O
is O
based O
on O
67 O
tumor O
progressions O
and O
16 O
observed O
deaths O
in O
85 O
patients O
at O
the O
time O
of O
the O
planned O
interim O
analysis O
. O

Median B-Premise
time I-Premise
to I-Premise
tumor I-Premise
progression I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
LAR I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
was I-Premise
14.3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.34 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.20 I-Premise
to I-Premise
0.59 I-Premise
; I-Premise
P I-Premise
= I-Premise
.000072 I-Premise
) I-Premise
. I-Premise

After B-Premise
6 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
, I-Premise
stable I-Premise
disease I-Premise
was I-Premise
observed I-Premise
in I-Premise
66.7 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
LAR I-Premise
group I-Premise
and I-Premise
37.2 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Functionally O
active O
and O
inactive O
tumors O
responded O
similarly O
. O

The B-Premise
most I-Premise
favorable I-Premise
effect I-Premise
was I-Premise
observed I-Premise
in I-Premise
patients I-Premise
with I-Premise
low I-Premise
hepatic I-Premise
tumor I-Premise
load I-Premise
and I-Premise
resected I-Premise
primary I-Premise
tumor I-Premise
. I-Premise

Seven B-Premise
and I-Premise
nine I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
LAR I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.81 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.30 I-Premise
to I-Premise
2.18 I-Premise
) I-Premise
. I-Premise

Octreotide B-Claim
LAR I-Claim
significantly I-Claim
lengthens I-Claim
time I-Claim
to I-Claim
tumor I-Claim
progression I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
patients I-Claim
with I-Claim
functionally I-Claim
active I-Claim
and I-Claim
inactive I-Claim
metastatic I-Claim
midgut I-Claim
NETs I-Claim
. I-Claim

Because B-Premise
of I-Premise
the I-Premise
low I-Premise
number I-Premise
of I-Premise
observed I-Premise
deaths I-Premise
, I-Premise
survival I-Premise
analysis I-Premise
was I-Premise
not I-Premise
confirmatory I-Premise
. I-Premise

In B-Claim
the I-Claim
context I-Claim
of I-Claim
chronic I-Claim
physical I-Claim
illness I-Claim
, I-Claim
such I-Claim
as I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
depression I-Claim
is I-Claim
associated I-Claim
with I-Claim
increased I-Claim
morbidity I-Claim
, I-Claim
longer I-Claim
periods I-Claim
of I-Claim
hospitalization I-Claim
, I-Claim
and I-Claim
greater I-Claim
overall I-Claim
disability I-Claim
. I-Claim

Prompt B-Claim
diagnosis I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
is I-Claim
, I-Claim
therefore I-Claim
, I-Claim
essential I-Claim
. I-Claim

Several O
small O
studies O
have O
established O
the O
efficacy O
of O
tricyclic O
antidepressants O
( O
TCAs O
) O
in O
this O
setting O
, O
and O
the O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
would O
appear O
to O
be O
an O
alternative O
therapeutic O
option O
because O
of O
their O
established O
efficacy O
and O
better O
tolerability O
profile O
. O

This O
was O
a O
multicenter O
. O

double-blind O
, O
parallel-group O
study O
in O
which O
179 O
women O
with O
breast O
cancer O
were O
randomized O
to O
treatment O
with O
either O
the O
SSRI O
paroxetine O
( O
20-40 O
mg/day O
) O
, O
or O
the O
TCA O
, O
amitriptyline O
( O
75-150 O
mg/day O
) O
. O

After B-Premise
8-weeks I-Premise
treatment I-Premise
, I-Premise
depressive I-Premise
symptomatology I-Premise
had I-Premise
improved I-Premise
markedly I-Premise
and I-Premise
to I-Premise
a I-Premise
similar I-Premise
extent I-Premise
in I-Premise
both I-Premise
groups I-Premise
on I-Premise
the I-Premise
Montgomery I-Premise
Asberg I-Premise
Depression I-Premise
Rating I-Premise
Scale I-Premise
. I-Premise

Clinical B-Premise
global I-Premise
impression I-Premise
( I-Premise
CGI I-Premise
) I-Premise
Global I-Premise
improvement I-Premise
and I-Premise
Patient I-Premise
global I-Premise
evaluation I-Premise
scales I-Premise
indicated I-Premise
that I-Premise
patients I-Premise
were I-Premise
minimally I-Premise
to I-Premise
much I-Premise
improved I-Premise
at I-Premise
study I-Premise
endpoint I-Premise
: I-Premise
a I-Premise
change I-Premise
from I-Premise
moderately/mildly I-Premise
ill I-Premise
to I-Premise
borderline I-Premise
ill I-Premise
on I-Premise
the I-Premise
CGI I-Premise
severity I-Premise
of I-Premise
Illness I-Premise
scale I-Premise
. I-Premise

A B-Claim
steady I-Claim
improvement I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
also I-Claim
observed I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
clinically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

In B-Premise
total I-Premise
, I-Premise
47 I-Premise
( I-Premise
53.4 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
paroxetine I-Premise
group I-Premise
and I-Premise
53 I-Premise
( I-Premise
59.6 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
amitriptyline I-Premise
group I-Premise
had I-Premise
adverse I-Premise
experiences I-Premise
, I-Premise
the I-Premise
most I-Premise
common I-Premise
of I-Premise
which I-Premise
were I-Premise
the I-Premise
well-recognized I-Premise
side-effects I-Premise
of I-Premise
the I-Premise
antidepressant I-Premise
medications I-Premise
or I-Premise
chemotherapy I-Premise
. I-Premise

Anticholinergic B-Premise
effects I-Premise
were I-Premise
almost I-Premise
twice I-Premise
as I-Premise
frequent I-Premise
in I-Premise
the I-Premise
amitriptyline I-Premise
group I-Premise
( I-Premise
19.1 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
paroxetine I-Premise
( I-Premise
11.4 I-Premise
% I-Premise
) I-Premise
. I-Premise

This O
study O
has O
demonstrated O
that O
paroxetine B-Claim
is I-Claim
a I-Claim
suitable I-Claim
alternative I-Claim
to I-Claim
amitriptyline I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
depression I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

In O
anorectal O
cancer O
patients O
, O
an O
acute O
side O
effect O
of O
chemoradiotherapy O
is O
gastrointestinal O
toxicity O
, O
which O
often O
impedes O
treatment O
delivery O
. O

Based O
on O
previous O
trials O
, O
octreotide O
acetate O
is O
widely O
recommended O
for O
the O
control O
of O
chemotherapy-induced O
diarrhea O
. O

However O
, O
the O
effectiveness O
of O
octreotide O
in O
preventing O
or O
controlling O
radiation- O
and O
chemoradiation-induced O
diarrhea O
is O
not O
known O
. O

A O
randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
was O
designed O
to O
determine O
the O
efficacy O
of O
long-acting O
octreotide O
acetate O
( O
LAO O
) O
in O
preventing O
the O
onset O
of O
acute O
diarrhea O
in O
patients O
undergoing O
chemoradiation O
therapy O
for O
rectal O
or O
anal O
cancer O
. O

Between O
4 O
and O
7 O
days O
before O
the O
start O
of O
radiation O
therapy O
, O
patients O
received O
a O
30-mg O
dose O
of O
LAO O
( O
109 O
patients O
) O
or O
placebo O
( O
106 O
patients O
) O
via O
intramuscular O
injection O
. O

A O
second O
dose O
was O
given O
on O
day O
22 O
( O
+/-3 O
days O
) O
of O
radiation O
treatment O
. O

A O
total O
of O
215 O
patients O
were O
included O
in O
the O
final O
analysis O
. O

The O
primary O
endpoint O
was O
the O
incidence O
of O
grade O
2-4 O
acute O
diarrhea O
; O
secondary O
endpoints O
included O
treatment O
compliance O
, O
medical O
resource O
utilization O
, O
patient-reported O
bowel O
function O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Statistical O
tests O
were O
one- O
or O
two-sided O
, O
as O
specified O
. O

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
9.64 I-Premise
months I-Premise
, I-Premise
incidence I-Premise
rates I-Premise
of I-Premise
grades I-Premise
2-4 I-Premise
acute I-Premise
diarrhea I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
( I-Premise
49 I-Premise
% I-Premise
placebo I-Premise
vs I-Premise
44 I-Premise
% I-Premise
LAO I-Premise
; I-Premise
P I-Premise
= I-Premise
.21 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
treatment I-Premise
differences I-Premise
in I-Premise
chemotherapy I-Premise
or I-Premise
radiation I-Premise
delivery I-Premise
, I-Premise
medical I-Premise
resource I-Premise
utilization I-Premise
, I-Premise
patient-reported I-Premise
bowel I-Premise
function I-Premise
, I-Premise
or I-Premise
QoL I-Premise
were I-Premise
observed I-Premise
. I-Premise

In B-Claim
this I-Claim
study I-Claim
, I-Claim
the I-Claim
prophylactic I-Claim
use I-Claim
of I-Claim
LAO I-Claim
did I-Claim
not I-Claim
prevent I-Claim
the I-Claim
incidence I-Claim
or I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
diarrhea I-Claim
and I-Claim
had I-Claim
no I-Claim
notable I-Claim
impact I-Claim
on I-Claim
patient-reported I-Claim
bowel I-Claim
function I-Claim
or I-Claim
QoL I-Claim
. I-Claim

A O
significant O
proportion O
of O
patients O
develop O
urinary O
incontinence O
early O
after O
radical O
prostatectomy O
. O

Posterior O
reconstruction O
of O
supporting O
tissues O
has O
been O
found O
to O
reduce O
incontinence O
in O
open O
and O
conventional O
laparoscopic O
prostatectomy O
series O
. O

To O
investigate O
whether O
our O
version O
of O
a O
posterior O
musculofascial O
reconstruction O
will O
reduce O
early O
incontinence O
and O
have O
a O
beneficial O
effect O
on O
patients O
' O
quality O
of O
life O
( O
QoL O
) O
. O

One O
hundred O
seven O
consecutive O
patients O
undergoing O
primary O
robot-assisted O
radical O
laparoscopic O
prostatectomy O
( O
RALP O
) O
performed O
by O
a O
single O
surgeon O
at O
one O
tertiary O
referral O
oncology O
institution O
were O
alternately O
assigned O
( O
not O
randomised O
) O
to O
intervention O
( O
n=53 O
) O
or O
control O
groups O
( O
n=54 O
) O
. O

RALP O
with O
median O
fibrous O
raphe O
reconstruction O
( O
MFRR O
) O
followed O
by O
formation O
of O
the O
urethrovesical O
anastomosis O
( O
intervention O
group O
) O
versus O
standard O
anastomosis O
without O
posterior O
reconstruction O
( O
control O
group O
) O
. O

Measurements O
included O
incontinence O
at O
baseline O
and O
3-mo O
intervals O
; O
QoL O
as O
measured O
by O
a O
simple O
questionnaire O
, O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life-Core O
30 O
( O
QLQ-C30 O
) O
, O
and O
Prostate O
Cancer O
Module O
( O
PR25 O
) O
questionnaires O
preoperatively O
and O
at O
6 O
mo O
postprocedure O
; O
tumour O
characteristics O
; O
operative O
time O
; O
fascial O
preservation O
score O
; O
duration O
of O
catheterisation O
; O
and O
anastomotic O
leakage O
on O
cystogram O
. O

For B-Premise
intervention I-Premise
and I-Premise
control I-Premise
groups I-Premise
respectively I-Premise
, I-Premise
mean I-Premise
catheter I-Premise
duration I-Premise
was I-Premise
11.74 I-Premise
d I-Premise
and I-Premise
12.74 I-Premise
d I-Premise
( I-Premise
p=0.451 I-Premise
) I-Premise
; I-Premise
leakage I-Premise
on I-Premise
cystogram I-Premise
was I-Premise
present I-Premise
in I-Premise
six I-Premise
and I-Premise
eight I-Premise
cases I-Premise
( I-Premise
p=0.28 I-Premise
) I-Premise
; I-Premise
and I-Premise
incontinence I-Premise
( I-Premise
any I-Premise
involuntary I-Premise
urine I-Premise
loss I-Premise
) I-Premise
at I-Premise
3 I-Premise
mo I-Premise
was I-Premise
75 I-Premise
% I-Premise
and I-Premise
69 I-Premise
% I-Premise
( I-Premise
p=0.391 I-Premise
) I-Premise
and I-Premise
at I-Premise
6 I-Premise
mo I-Premise
was I-Premise
51 I-Premise
% I-Premise
and I-Premise
43 I-Premise
% I-Premise
( I-Premise
p=0.686 I-Premise
) I-Premise
. I-Premise

Urinary B-Premise
retention I-Premise
occurred I-Premise
only I-Premise
in I-Premise
one I-Premise
case I-Premise
( I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

The B-Premise
percentage I-Premise
of I-Premise
cases I-Premise
returning I-Premise
to I-Premise
baseline I-Premise
in I-Premise
all I-Premise
QoL I-Premise
domains I-Premise
( I-Premise
except I-Premise
insomnia I-Premise
) I-Premise
was I-Premise
similar I-Premise
at I-Premise
6 I-Premise
mo I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Short B-Premise
follow-up I-Premise
, I-Premise
lack I-Premise
of I-Premise
blinding I-Premise
, I-Premise
and I-Premise
probable I-Premise
small I-Premise
differences I-Premise
in I-Premise
our I-Premise
method I-Premise
of I-Premise
MFRR I-Premise
performed I-Premise
compared I-Premise
with I-Premise
other I-Premise
studies I-Premise
were I-Premise
identified I-Premise
as I-Premise
significant I-Premise
limitations I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
analysed I-Premise
outcome I-Premise
measures I-Premise
was I-Premise
observed I-Premise
. I-Premise

Posterior B-Claim
reconstruction I-Claim
of I-Claim
the I-Claim
musculofascial I-Claim
complex I-Claim
does I-Claim
not I-Claim
appear I-Claim
to I-Claim
improve I-Claim
early I-Claim
urinary I-Claim
incontinence I-Claim
after I-Claim
RALP I-Claim
. I-Claim

In O
the O
Gynecologic O
Cancer O
Intergroup O
International O
Collaboration O
on O
Ovarian O
Neoplasms O
7 O
( O
ICON7 O
) O
trial O
, O
bevacizumab O
improved O
progression-free O
survival O
in O
patients O
with O
ovarian O
cancer O
when O
used O
in O
combination O
with O
first-line O
chemotherapy O
and O
as O
a O
single-drug O
continuation O
treatment O
for O
18 O
cycles O
. O

In O
a O
preliminary O
analysis O
of O
a O
high-risk O
subset O
of O
patients O
, O
there O
was O
also O
an O
improvement O
in O
overall O
survival O
. O

This O
study O
aims O
to O
describe O
the O
health-related O
quality-of-life O
( O
QoL O
) O
outcomes O
from O
ICON7 O
. O

ICON7 O
is O
a O
randomised O
, O
multicentre O
, O
open-label O
phase O
3 O
trial O
. O

Between O
Dec O
18 O
, O
2006 O
, O
and O
Feb O
16 O
, O
2009 O
, O
after O
a O
surgical O
procedure O
aiming O
to O
debulk O
the O
disease O
, O
women O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
( O
FIGO O
) O
high-risk O
stage O
I-IV O
epithelial O
ovarian O
cancer O
were O
randomly O
allocated O
( O
1:1 O
) O
by O
computer O
program O
and O
block O
randomisation O
to O
receive O
either O
six O
cycles O
of O
standard O
chemotherapy O
( O
total O
18 O
weeks O
) O
with O
carboplatin O
( O
area O
under O
the O
curve O
5 O
or O
6 O
) O
and O
paclitaxel O
( O
175 O
mg/m O
( O
2 O
) O
) O
alone O
or O
with O
bevacizumab O
( O
7·5 O
mg/kg O
) O
given O
intravenously O
with O
chemotherapy O
and O
continued O
as O
a O
single O
drug O
thereafter O
( O
total O
54 O
weeks O
) O
. O

The O
primary O
QoL O
endpoint O
was O
global O
QoL O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
quality-of-life O
questionnaire-core O
30 O
at O
week O
54 O
, O
analysed O
by O
ANOVA O
and O
adjusted O
for O
baseline O
score O
. O

Analyses O
were O
by O
intention O
to O
treat O
. O

The O
ICON7 O
trial O
has O
completed O
recruitment O
and O
remains O
in O
follow-up O
. O

This O
study O
is O
registered O
, O
number O
ISRCTN91273375 O
. O

764 O
women O
were O
randomly O
assigned O
to O
the O
standard O
chemotherapy O
group O
and O
764 O
to O
the O
bevacizumab O
group O
. O

At O
baseline O
, O
684 O
( O
90 O
% O
) O
of O
women O
in O
the O
standard O
chemotherapy O
group O
and O
691 O
( O
90 O
% O
) O
of O
those O
in O
the O
bevacizumab O
group O
had O
completed O
QoL O
questionnaires O
. O

At O
week O
54 O
, O
502 O
( O
66 O
% O
) O
women O
in O
the O
bevacizumab O
group O
and O
388 O
( O
51 O
% O
) O
women O
in O
the O
standard O
chemotherapy O
group O
provided O
QoL O
data O
. O

Overall B-Premise
, I-Premise
the I-Premise
mean I-Premise
global I-Premise
QoL I-Premise
score I-Premise
improved I-Premise
during I-Premise
chemotherapy I-Premise
by I-Premise
7·2 I-Premise
points I-Premise
( I-Premise
SD I-Premise
24·4 I-Premise
) I-Premise
when I-Premise
analysed I-Premise
for I-Premise
all I-Premise
women I-Premise
with I-Premise
data I-Premise
at I-Premise
baseline I-Premise
and I-Premise
week I-Premise
18 I-Premise
. I-Premise

The B-Premise
mean I-Premise
global I-Premise
QoL I-Premise
score I-Premise
at I-Premise
54 I-Premise
weeks I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
standard I-Premise
chemotherapy I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
( I-Premise
76·1 I-Premise
[ I-Premise
SD I-Premise
18·2 I-Premise
] I-Premise
vs I-Premise
69·7 I-Premise
[ I-Premise
19·1 I-Premise
] I-Premise
points I-Premise
; I-Premise
difference I-Premise
6·4 I-Premise
points I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3·7-9·0 I-Premise
, I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

Bevacizumab B-Claim
continuation I-Claim
treatment I-Claim
seems I-Claim
to I-Claim
be I-Claim
associated I-Claim
with I-Claim
a I-Claim
small I-Claim
but I-Claim
clinically I-Claim
significant I-Claim
decrement I-Claim
in I-Claim
QoL I-Claim
compared I-Claim
with I-Claim
standard I-Claim
treatment I-Claim
for I-Claim
women I-Claim
with I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

The O
trade-off O
between O
the O
prolongation O
of O
progression-free O
survival O
and O
the O
quality O
of O
that O
period O
of O
time O
needs O
to O
be O
considered O
in O
clinical O
practice O
when O
making O
treatment O
decisions O
. O

Mediating O
mechanisms O
of O
a O
12-week O
group-based O
exercise O
intervention O
on O
cancer O
survivors O
' O
quality O
of O
life O
( O
QoL O
) O
were O
examined O
to O
inform O
future O
exercise O
intervention O
development O
. O

Two O
hundred O
nine O
cancer O
survivors O
≥ O
3 O
months O
posttreatment O
( O
57 O
% O
breast O
cancer O
) O
aged O
49.5 O
( O
± O
10.4 O
) O
years O
were O
assigned O
to O
physical O
exercise O
( O
n O
= O
147 O
) O
or O
wait-list O
control O
( O
n O
= O
62 O
) O
. O

QoL O
, O
fatigue O
, O
emotional O
distress O
, O
physical O
activity O
, O
general O
self-efficacy O
and O
mastery O
were O
assessed O
at O
baseline O
and O
post-intervention O
using O
questionnaires O
. O

Path O
analysis O
was O
conducted O
using O
Mplus O
to O
explore O
whether O
improved O
physical O
activity O
, O
general O
self-efficacy O
and O
mastery O
mediated O
the O
effects O
of O
exercise O
on O
fatigue O
and O
distress O
and O
consequently O
QoL O
. O

The B-Premise
intervention I-Premise
was I-Premise
associated I-Premise
with I-Premise
increased I-Premise
physical I-Premise
activity I-Premise
( I-Premise
β I-Premise
= I-Premise
0.46 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
= I-Premise
0.14 I-Premise
; I-Premise
0.59 I-Premise
) I-Premise
, I-Premise
general I-Premise
self-efficacy I-Premise
( I-Premise
β I-Premise
= I-Premise
2.41 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.35 I-Premise
; I-Premise
4.73 I-Premise
) I-Premise
, I-Premise
and I-Premise
mastery I-Premise
( I-Premise
β I-Premise
= I-Premise
1.75 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.36 I-Premise
; I-Premise
2.78 I-Premise
) I-Premise
. I-Premise

Further O
, O
the B-Premise
intervention I-Premise
had I-Premise
both I-Premise
a I-Premise
direct I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
( I-Premise
β I-Premise
= I-Premise
-1.09 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-2.12 I-Premise
; I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
an I-Premise
indirect I-Premise
effect I-Premise
( I-Premise
β I-Premise
= I-Premise
-0.54 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.00 I-Premise
; I-Premise
-0.21 I-Premise
) I-Premise
via I-Premise
physical I-Premise
activity I-Premise
( I-Premise
β I-Premise
= I-Premise
-0.29 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.64 I-Premise
; I-Premise
-0.07 I-Premise
) I-Premise
and I-Premise
general I-Premise
self-efficacy I-Premise
( I-Premise
β I-Premise
= I-Premise
-0.25 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.61 I-Premise
; I-Premise
-0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
intervention I-Premise
had I-Premise
a I-Premise
borderline I-Premise
significant I-Premise
direct I-Premise
effect I-Premise
on I-Premise
reduced I-Premise
distress I-Premise
( I-Premise
β I-Premise
= I-Premise
-1.32 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-2.68 I-Premise
; I-Premise
0.11 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
significant I-Premise
indirect I-Premise
effect I-Premise
via I-Premise
increased I-Premise
general I-Premise
self-efficacy I-Premise
and I-Premise
mastery I-Premise
( I-Premise
β I-Premise
= I-Premise
-1.06 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.89 I-Premise
; I-Premise
-0.38 I-Premise
) I-Premise
. I-Premise

Reductions B-Premise
in I-Premise
fatigue I-Premise
( I-Premise
β I-Premise
= I-Premise
-1.33 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
=-1.85 I-Premise
; I-Premise
-0.83 I-Premise
) I-Premise
and I-Premise
distress I-Premise
( I-Premise
β I-Premise
= I-Premise
-0.86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.25 I-Premise
; I-Premise
-0.52 I-Premise
) I-Premise
were I-Premise
associated I-Premise
with I-Premise
improved I-Premise
QoL I-Premise
. I-Premise

Further O
, O
increased B-Premise
physical I-Premise
activity I-Premise
was I-Premise
directly I-Premise
associated I-Premise
with I-Premise
improved I-Premise
QoL I-Premise
( I-Premise
β I-Premise
= I-Premise
3.37 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.01 I-Premise
; I-Premise
5.54 I-Premise
) I-Premise
. I-Premise

The B-Claim
beneficial I-Claim
effect I-Claim
of I-Claim
group-based I-Claim
physical I-Claim
exercise I-Claim
on I-Claim
QoL I-Claim
was I-Claim
mediated I-Claim
by I-Claim
increased I-Claim
physical I-Claim
activity I-Claim
, I-Claim
general I-Claim
self-efficacy I-Claim
and I-Claim
mastery I-Claim
, I-Claim
and I-Claim
subsequent I-Claim
reductions I-Claim
in I-Claim
fatigue I-Claim
and I-Claim
distress I-Claim
. I-Claim

In B-Claim
addition I-Claim
to I-Claim
physical I-Claim
activity I-Claim
, I-Claim
future I-Claim
interventions I-Claim
should I-Claim
target I-Claim
self-efficacy I-Claim
and I-Claim
mastery I-Claim
. I-Claim

This B-Claim
may I-Claim
lead I-Claim
to I-Claim
reduced I-Claim
distress I-Claim
and I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
consequently I-Claim
improved I-Claim
QoL I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

To O
assess O
whether O
omission O
of O
post-operative O
radiotherapy O
( O
RT O
) O
in O
women O
with O
'low-risk O
' O
axillary O
node-negative O
breast O
cancer O
[ O
tumour O
size O
of O
less O
than O
5 O
cm O
( O
T0-2 O
) O
although O
the O
eligibility O
criteria O
further O
reduce O
the O
eligible O
size O
to O
a O
maximum O
of O
3 O
cm O
] O
treated O
by O
breast-conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost-effective O
. O

A O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphovascular O
invasion O
and O
preoperative O
endocrine O
therapy O
was O
performed O
. O

Breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
UK O
. O

Patients O
aged O
≥ O
65 O
years O
were O
eligible O
provided O
that O
their O
breast O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
they O
were O
suitable O
for O
breast O
conservation O
surgery O
, O
they O
were O
receiving O
endocrine O
therapy O
and O
they O
were O
willing O
and O
able O
to O
give O
informed O
consent O
. O

The O
standard O
treatment O
of O
post-operative O
whole O
breast O
irradiation O
or O
the O
omission O
of O
RT O
. O

Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost-effectiveness O
. O

Secondary O
outcome O
measures O
were O
recurrence O
rates O
and O
survival O
, O
and O
treatment-related O
morbidity O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
on O
four O
occasions O
over O
15 O
months O
, O
then O
by O
postal O
questionnaire O
at O
3 O
and O
5 O
years O
after O
surgery O
. O

The O
hypothesised O
improvement O
in O
overall O
quality O
of O
life O
with O
the O
omission O
of O
RT O
was O
not O
seen O
in O
the O
summary O
domains O
of O
the O
European O
Organisation O
for O
Research O
in O
the O
Treatment O
of O
Cancer O
( O
EORTC O
) O
scales O
. O

Some O
differences O
were O
apparent O
within O
subscales O
of O
the O
EORTC O
questionnaires O
, O
and O
insights O
into O
the O
impact O
of O
treatment O
were O
also O
provided O
by O
the O
qualitative O
data O
obtained O
by O
open-ended O
questions O
added O
by O
the O
trial O
team O
. O

Differences O
were O
most O
apparent O
shortly O
after O
the O
time O
of O
completion O
of O
RT O
. O

RT B-Premise
was I-Premise
then I-Premise
associated I-Premise
with I-Premise
increased I-Premise
breast I-Premise
symptoms I-Premise
and I-Premise
with I-Premise
greater I-Premise
( I-Premise
self-reported I-Premise
) I-Premise
fatigue I-Premise
, I-Premise
but I-Premise
with I-Premise
lower I-Premise
levels I-Premise
of I-Premise
insomnia I-Premise
and I-Premise
endocrine I-Premise
side I-Premise
effects I-Premise
. I-Premise

These B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
breast I-Premise
symptoms I-Premise
persisted I-Premise
for I-Premise
up I-Premise
to I-Premise
5 I-Premise
years I-Premise
after I-Premise
RT I-Premise
[ I-Premise
mean I-Premise
difference I-Premise
, I-Premise
RT I-Premise
was I-Premise
5.27 I-Premise
units I-Premise
greater I-Premise
than I-Premise
no I-Premise
RT I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
of I-Premise
1.46 I-Premise
to I-Premise
9.07 I-Premise
] I-Premise
, I-Premise
with I-Premise
similar I-Premise
, I-Premise
though I-Premise
non-significant I-Premise
, I-Premise
trends I-Premise
in I-Premise
insomnia I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
measure I-Premise
, I-Premise
with I-Premise
the I-Premise
no I-Premise
RT I-Premise
group I-Premise
having I-Premise
0.36 I-Premise
units I-Premise
greater I-Premise
quality I-Premise
of I-Premise
life I-Premise
than I-Premise
the I-Premise
RT I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-5.09 I-Premise
to I-Premise
5.81 I-Premise
) I-Premise
. I-Premise

Breast B-Claim
RT I-Claim
is I-Claim
tolerated I-Claim
well I-Claim
by I-Claim
most I-Claim
older I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
without I-Claim
impairing I-Claim
their I-Claim
overall I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQoL I-Claim
) I-Claim
. I-Claim

Although O
HRQoL O
should O
always O
be O
taken O
into O
account O
when O
determining O
treatment O
, O
our B-Claim
results I-Claim
show I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
RT I-Claim
does I-Claim
not I-Claim
impair I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Further B-Claim
economic I-Claim
modelling I-Claim
on I-Claim
the I-Claim
longer-term I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
RT I-Claim
is I-Claim
required I-Claim
. I-Claim